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Abstract 
Impaired skin healing is a significant and growing clinical concern, particularly in relation 
to diabetes, venous insufficiency and immobility. Previously, we developed electrospun 
scaffolds for the delivery of periostin (POSTN) and connective tissue growth factor 2 
(CCN2), matricellular proteins involved in the proliferative phase of healing. This study 
aimed to design and validate a novel electrosprayed coaxial microsphere for the 
encapsulation of fibroblast growth factor 9 (FGF9), as a component of the POSTN/CCN2 
scaffold, to promote angiogenic stability during wound healing. For the first time, we 
observed a pro-proliferative effect of FGF9 on human dermal fibroblasts (HDF) in vitro, 
indicating a potential cellular mechanism of action during wound healing. POSTN/CCN2 
scaffolds containing encapsulated FGF9 decreased wound diameter, with no negative or 
adverse effects at day 7, in a porcine model of acute cutaneous wound healing. Future work 
is required to investigate the effect of the POSTN/CCN2/FGF9 scaffold during impaired 
healing. 
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Chapter 1 
General Introduction 
1.1 – Wound Healing & Chronic Wounds – The Role of Fibroplasia and Angiogenesis 
1.1.1– The Skin – Anatomy & Physiology 
The skin is a complex, multifunctional organ tasked with protection, regulation and 
sensation. The barrier function of the skin protects the internal environment from harmful 
pathogens, inherent physiological mechanisms control thermoregulation, and various types 
of sensory neurons allow us to safely interact with our environment. These processes are 
guided by structures in the skin, organized into three major layers: the epidermis, dermis 
and subcutaneous hypodermis (Figure 1.1) [1].  
The epidermis consists of multiple sublayers and cell types. Ninety-five percent of the cells 
located in the epidermis are keratinocytes; defined by their ability to produce keratin which 
is composed of intermediate filaments and forms the internal cytoskeleton [2, 3]. The 
stratum germinativum, or basal cell layer, consists of a single layer of column-shaped, 
proliferating keratinocytes [4], which migrate through the stratums spinosum and 
granulosum towards the superficial layers of the epidermis while differentiating into flat, 
polyhedral, anucleated corneocytes. The thick, superficial layer of corneocytes forms the 
stratum corneum to provide mechanical protection, reduce water loss and inhibit the 
invasion of foreign substances [2, 4]. Pigment producing melanocytes, immunocompetent 
Langerhans cells, and sensory Merkel cells (located in hairless skin) also populate the 
epidermis [3].  
The dermal layer provides the skin its pliability, elasticity, and tensile strength with its 
diverse set of connective tissues, cell types, and structural components. Stress-resistant 
fibrillar collagens I and III synthesized by dermal fibroblasts are the major components of 
the extracellular matrix (ECM) and convey structural integrity to the skin. Other dermal 
components include: epidermally derived appendages, dermal dendrocytes, mast cells, 
histiocytes, blood vessels, nerves, lymphatics, sebaceous glands, apocrine glands, and 
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sweat glands [2]. The dermis is subdivided into upper papillary dermis and lower reticular 
dermis, defined by the structural and organizational differences of collagen and elastin 
fibers [4]. The dermal vasculature is organized into parallel superficial and subpapillary 
plexuses located near the base of papillary and reticular derma, respectively. Blood flow in 
the dermis provides nutrition to the skin and assists the body in thermoregulation [4]. Heat 
dissipation or conservation via vasodilation and vasoconstriction is controlled by 
intercommunication between superficial and subpapillary plexuses in response to external 
stimuli [4]. Thermoregulation is also controlled by hair follicles/arrector pili muscles and 
sweat glands. Piloerection traps air close to the skin for an additional layer of insulation 
when the body is cold and endothermic evaporation of sweat cools the surface of the skin 
[4, 5].  
The hypodermal subcutaneous layer of the skin consists primarily of fatty lipocytes but also 
contains connective tissue, nerves, and blood vessels [4]. This fatty underbelly insulates 
and cushions the body, provides buoyancy, and stores energy [4].  
The skin’s exposure to the external environment makes it vulnerable to damage. Cutaneous 
injury disrupts the skin’s ability to function properly and exposes the internal environment. 
Therefore, rapid and robust wound healing is essential for the maintenance of internal 
homeostasis and sterility. 
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Figure 1. 1 – Anatomy of the skin. A) Cross-sectional schematic illustration of the layers 
and structures composing human skin [5]. B) Masson’s Trichrome stained cryosection of 
porcine cutaneous tissue; porcine skin is very similar in structure and function to human 
skin. Connective tissues (collagen) are stained blue; muscle, erythrocytes and cytoplasm 
are stained red; and nuclei are stained black. The epidermis is divided into four sublayers 
(not shown due to scale): Stratum Corneum, Stratum Granulosum, Stratum Spinosum, and 
Stratum Basale (listed superficial to deep). Scale bar = 500µm. 
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1.1.2 – Cutaneous Wound Healing 
After injury, wound healing restores the cutaneous barrier, prevents infection, re-balances 
internal homeostasis, and minimizes fluid loss. The spatial and temporal sequence of events 
involved in normal wound healing are organized into four overlapping phases: haemostasis, 
inflammation, proliferation, and remodelling.  
Within one-hour post-injury, thrombin cleaves fibrinogen to create a polymerized fibrin 
matrix that captures circulating platelets to form a hemostatic plug. Aggregated platelets 
release cytokines and growth factors to recruit inflammatory cells and guide the initial 
stages of healing [6]. Inflammation begins one-hour after injury as inflammatory cytokines 
[interleukin (IL) -1α, IL-1β, IL-6, IL-8, tumour necrosis factor (TNF) -α, platelet derived 
growth factor (PDGF), transforming growth factor (TGF) -β] released by platelets, and 
leukocytes produce a chemotactic gradient that stimulates the migration of neutrophils, 
monocytes, smooth muscle cells (SMCs), and fibroblasts [7]. Neutrophils release reactive 
oxygen species to kill bacteria, secrete serine proteases and matrix metalloproteinases 
(MMPs) to debride nonviable tissue, and phagocytose dead bacteria and wound debris [7]. 
Monocytes responding to paracrine signals are converted into macrophages and resident 
and differentiated macrophages phagocytose debris and exhausted neutrophils and release 
another wave of signaling molecules [TGF-α, TGF-β, fibroblast growth factor (FGF) 
2/basic FGF (bFGF), PDGF, vascular endothelial growth factor (VEGF)] to recruit 
keratinocytes, fibroblasts and endothelial cells to initiate the next stage of healing [8].  
The proliferative stage is initiated three to four days post-injury and extends to four weeks. 
This period is dominated by fibroblast, endothelial cell, and keratinocyte proliferation, 
migration, and differentiation. Fibroplasia begins as fibroblasts, interacting with 
fibronectin, fibrinogen, and thrombin in the haemostatic clot proliferate and migrate into 
the wound bed [9, 10]. Migrating fibroblasts deposit collagen-rich ECM, gradually 
replacing the fibrin clot to increase structural integrity and provide a framework for 
neovascular growth [10]. Fibroplasia is regulated via a paracrine-mediated mechanism 
involving re-epithelializing keratinocytes. Keratinocytes upregulate anti-fibrotic 
urokinase-type plasminogen activator, MMP-1 and MMP-3, and downregulate pro-fibrotic 
connective tissue growth factor 2 (CCN2), collagen I and II, fibronectin, plasminogen 
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activator inhibitor-1, α-smooth muscle actin (α-SMA), and tissue inhibitor of matrix 
metalloproteinase (TIMP)-2/3 controlling catabolic fibroblast action on the ECM [11]. 
Granulation tissue, composed of the newly deposited collagen network and migrating 
endothelial cells and macrophages, functions as a structural and supportive matrix for 
angiogenesis and re-epithelialization [12].  
Angiogenesis is the process of vascular growth by endothelial cell migration, proliferation 
and tube formation [13]. In the healing wound, angiogenesis functions to re-establish 
normoxia and nutrient supply [8]. Tissue hypoxia post-injury promotes the release of 
inflammatory mediators that act on the wound periphery to increase vascular permeability 
and dilation. Extravasation occurs, and endothelial cells migrate into the wound bed [14, 
15]. Proteolysis reduces ECM density to facilitate endothelial migration, and angiogenic 
factors in the wound bed milieu (especially VEGF-A and FGF2/bFGF) promote endothelial 
cell proliferation and the formation of new capillary tubules in the developing granulation 
tissue [16-20]. Under hypoxic conditions in the early stages of wound healing, 
myofibroblasts mechanically support microvascular endothelial cells to facilitate 
neoangiogenesis [21]. Proliferating fibroblasts continue to deposit new ECM into the later 
stages of wound healing when normoxia has been re-established and as TGF-β levels 
continue to rise. Several studies have indicated angiogenesis as a key event in the wound-
healing process, and suppression of angiogenesis during conditions of delayed wound 
healing [22, 23]. 
It is very important that fibroplasia and angiogenesis work synergistically during wound 
healing. The control of ECM composition throughout the wound-healing process is closely 
related to specific endothelial cell behaviour and vessel organization. Proteolytic ECM 
remodelling decreases ECM density, exposes endothelial cell binding sites, and releases 
matrix-bound angiogenic factors to stimulate endothelial cell migration [24-30].  
Sequestration of angiogenic growth factors, cytokines, and ECM fragments by the ECM 
also promotes angiogenesis [31]. The influence of angiogenesis on fibroplasia is less clear 
however, proangiogenic factors have been linked to scar formation in adult wounds [32-
35]. 
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Re-epithelialization begins within hours of injury. Migrating fibroblasts and macrophages 
release FGF-2/7, TGF-α/β, TNF-α, and epidermal growth factor (EGF) stimulating 
keratinocyte migration and proliferation. Dissolution of desmosomal adhesions separates 
cell-cell and cell-substratum linkages allowing keratinocyte migration over the granulation 
tissue [36]. Proliferating and maturing keratinocytes behind the leading migratory edge 
restore the barrier function of the epithelium [37]. 
Remodeling begins two to three weeks after injury and can last for over a year [8, 37]. 
Fibroblasts, responding to increased collagen density, mechanical tension, and cytokines 
(especially TGF-β), transform into myofibroblasts with increased expression of α-SMA. 
These contractile myofibroblasts work to close the wound via integrin-ECM receptor 
mediated interaction [7]. Myofibroblast contractile phenotype is dependent on a positive 
feedback loop initiated by endogenous TGF-β and tensile forces that increase the density 
of α-SMA containing stress fibers, increase force production and tension development, and 
consequently upregulate TGF-β [38]. The granulation tissue is gradually replaced as 
fibroblasts upregulate expression of collagen I, and MMPs breakdown the old collagen III 
composed matrix [42, 43]. In the final stages of remodelling, apoptosis of most of the 
remaining endothelial cells, fibroblasts, myofibroblasts, and macrophages reduce the scar 
tissue to a relatively acellular mass of parallel collagen I fiber bundles [37, 39, 40]. The 
final scar tissue consists mainly of the few remaining fibroblasts and collagen I ECM that 
regains only ~80% of the mechanical properties of unwounded skin [37, 41, 42].  
1.1.3 – Chronic Wounds – Pathophysiology 
A chronic wound is defined as a tissue injury that has failed to proceed through the 
reparative process in a timely and organized fashion to establish a sustained anatomic and 
functional result within 3 months [43]. Chronic wounds are characterized by irregular 
proteolytic activity and chronic inflammation, heightened bacterial load, cellular 
senescence and inhibited mitogenic activity [42]. Activated keratinocytes, fibroblasts, 
endothelial cells, neutrophils, and macrophages increase expression of proteases in the 
wound bed [44]. Additionally, the over-production of reactive oxygen species from 
neutrophils directly damages the ECM and cell membrane leading to early cell senescence, 
and interferes with transcriptional pathways controlling pro-inflammatory signalling 
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molecules, up-regulating various MMPs and down-regulating antagonistic TIMPs [45, 46]. 
Studies examining biomarkers from the wound exudate of chronic wounds support this 
claim. In one study, biomarkers obtained from healthy and chronic wounds were compared 
[47]. Certain protease inhibitors (serine protease inhibitors and cystatins) were solely 
identified within wound exudate from healthy individuals. Additional evidence suggests 
that neutrophils and macrophages responsible for synthesizing proteolytic factors such as 
MMP-9, neutrophil elastase, and proteinase 3 were present at higher levels within the 
cellular infiltrate of chronic wounds. Further analysis revealed increased expression of 
these proteolytic products (MMP-9, neutrophil elastase, proteinase 3) [47], and serine 
proteases [48-51]. These results indicate a disturbed balance between proteases and their 
inhibitors within chronic wounds, which can lead to the excessive breakdown of matrix 
(hindering re-epithelialization and angiogenesis) and digestion of growth factors and their 
receptors. 
Activated neutrophils and macrophages release pro-inflammatory cytokines such as IL-1β 
and TNF-α that further contribute to imbalanced MMP expression and TIMP inhibition [7]. 
Regularly, wound-healing macrophages release soluble factors (such as TGF-β, PDGF-β 
and galectin 3) to counteract the degradation of extracellular matrix by MMPs. These small 
molecules increase the deposition of matrix and the release of TIMPs by myofibroblasts 
[52]. However, a pair of studies showed an increase of infiltrating neutrophils and 
proinflammatory macrophages, and a downregulation of anti-inflammatory factors 
responsible for the termination of inflammation and initiation of angiogenesis, matrix 
deposition, and remodelling within a population of chronic venous ulcers [53, 54]. 
Specifically, the expression of IL-1β and TNF-α is upregulated during pathological wound 
healing [36, 55, 56]. These cytokines promote the release of MMPs from macrophages and 
suppress the synthesis of ECM proteins and TIMPs resulting in inhibition of cellular 
migration due to the degradation of matrix, prolonging the wound-healing response [6, 36, 
55]. This unbalanced proteolytic activity results in the excessive degradation of ECM 
components, protease inhibitors, growth factors, and other wound repair mediators. These 
mechanisms produce a hostile environment that distorts the chemical and physical cues 
necessary for normal cellular action to take place, delaying the final stages of wound 
healing [57]. Without the resolution of inflammation and formation of the barrier function, 
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continued bacterial presence contributes to a feedforward mechanism which elevates the 
proinflammatory response. Additionally, the sustained bacterial load can result in the 
formation of a biofilm that physically impedes wound closure and blocks antibiotic 
treatments [47, 58-61].  
Angiogenesis and vasculogenesis are critical steps ensuring adequate nutrition and 
oxygenation during tissue healing. Within the diabetic chronic wound microenvironment, 
antiangiogenic factors (ex. myeloperoxidase) are upregulated while angiogenic stimulators 
(ex. extracellular superoxide dismutase, VEGF variants) are decreased [62]. This 
downregulation of angiogenic factors is due to proteolytic degradation which may account 
for the inadequate capillary growth witnessed in chronic venous leg ulcers [49, 63, 64]. 
Pathological angiogenesis may also contribute to the development of chronic wounds from 
pressure ulcers. Chemotaxis of endothelial cells during the proliferative stage of wound 
healing relies on chemokine ligand 9. However, expression of this proangiogenic factor is 
decreased in pressure ulcers resulting in abnormal angiogenesis [65].  
1.1.4 – Chronic Wounds – Classification & Prevalence 
Four main classes of chronic wounds exist, categorized based on underlying etiology – 
venous leg ulcers (VLUs), arterial ulcers, diabetic foot ulcers (DFUs) and pressure ulcers 
(PUs). VLUs caused by chronic venous insufficiency are the most common class of chronic 
wound affecting 1 to 2% of the adult population [7, 42]. Risk factors associated with 
chronic venous insufficiency and VLUs include: trauma, advanced age, obesity, pregnancy, 
phlebitis, deep vein thrombosis, congestive heart failure, and a history of previous ulcers. 
Arterial ulcers subsequent to arterial disease and inadequate blood supply to the skin 
account for up to 25% of leg ulcers [66]. Arterial disease is most commonly the 
manifestation of systemic atherosclerosis [67, 68]. DFUs are one common and serious 
complication of diabetes, affecting 4-10% of diabetics annually [42]. Risk factors 
associated with diabetes and DFUs include: neuropathy, hyperglycemia, and lower 
extremity arterial disease [68]. Peripheral neuropathy due to impaired nerve function 
caused by hyperglycemia reduces sensation, causes foot deformity, limits joint mobility, 
and structurally weakens affected areas. DFUs most commonly occur on the plantar region 
of the foot where a difficult viewing angle paired with an insensate foot increases the risk 
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of ulceration from repeated mechanical stress [7, 69]. PUs are localized areas of tissue 
necrosis that form after prolonged soft tissue compression causes localized hypoxia and 
ischemic-reperfusion injury [42, 70]. One to five percent of hospitalized patients and up to 
26% of nursing home patients presenting to the emergency department are affected by PUs 
[42]. Risk factors associated with PUs include: impaired mobility, decreased level of 
consciousness, diabetes mellitus, peripheral vascular disease, malnutrition, and 
fecal/urinary incontinence [71]. Patients with compromised sensation or mobility who are 
unaware or incapable of responding to the periodic need for repositioning are at greatest 
risk of developing PUs  [7, 45]. PUs most commonly occur over bony prominences, 
specifically on the heel (lateral malleolus) and sacrum (ischial tuberosity/greater 
trochanter) [42]. 
Currently in developed countries, the average person is at a 1-2% risk of developing a 
chronic wound in their lifetime. It is estimated that approximately 6.5 million people suffer 
from chronic wounds in the United States alone [72-75]. Amputation rate is increased 20-
fold in the diabetic population and 85% of diabetic related amputations are preceded by a 
foot ulcer [76, 77]. Furthermore, the five-year mortality rate associated with diabetic 
amputation is 45%, which is 25% greater for patients suffering from DFUs and ischemic 
ulcers than either pancreatic or breast cancer [78-81]. Chronic wounds treated with 
conventional therapy that are under 53% closed four weeks post-injury have a 9% chance 
of healing while 49% of DFUs never heal [81].  
Chronic wounds pose a significant burden on the health care system. Three billion dollars 
is spent per year in the US, $135 million per year in Canada (the average cost to treat a 
DFU in Canada is $39,000), and 2-4% of the total annual global health care expenditure is 
associated with chronic wounds and their comorbidities [73, 74, 82, 83]. The debilitating 
nature of these lesions limits function and quality of life, causes pain, incurs high costs of 
treatment, and causes emotional and physical distress to both patient and family. With an 
increasing prevalence of obesity, diabetes and atherosclerosis, as well as an aging 
population, the impact of these injuries on both the patient and system will continue to rise. 
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1.2 – Chronic Wound Care & Strategies Currently Under Investigation 
1.2.1 – Clinical Treatment of Chronic Wounds 
General measures – including glycemic control, normalization of blood pressure, 
management of dyslipidemia, smoking cessation, and an appropriate diet – can reduce the 
risk of ulcer development [41]. However, once an ulcer has formed, standard clinical 
wound care involves debridement of necrotic or devitalized tissue, management of 
infection, dressing to control exudate and moisture, mechanical off-loading to reduce shear 
forces and ulcer recurrence, and possible revascularization to restore blood flow to the 
affected tissue [84]. Adequate pressure off-loading, and revascularization provide the 
necessary support to allow optimal success of tissue engineering approaches [85, 86]. The 
application of advanced multidisciplinary wound care significantly improves rates of 
chronic wound healing [87].  
1.2.1.1 – Debridement  
Surgical, autolytic, enzymatic, and biosurgical debridement techniques involve the removal 
of hyperkeratotic epidermis (callus), necrotic tissue, foreign debris, and pathogens from the 
wound site to reduce the risk of infection and facilitate re-epithelialization by exposing 
underlying healthy tissue at the wound edge [41]. Surgical debridement is the gold-standard 
debridement technique, involving rapid and accurate removal of tissue with scissors and a 
scalpel however, it can be painful and may damage viable tissue. Autolytic debridement 
degrades nonviable tissue via the catabolic action of endogenous enzymes within a moist 
wound environment; autolytic debridement is slower but less painful than surgical 
debridement. Mulder et al. showed that DuoDerm, a clinically available hydrocolloid 
dressing with autolytic properties, successfully lysed fibrin cuffs thought to reduce tissue 
perfusion and lead to the development of venous disease and chronic venous ulcers [88]. 
Enzymatic debridement involves exogenous enzymes in topical ointments to degrade and 
remove necrotic material from the wound bed [89]. Collagenase is the only Federal Drug 
Association (FDA) approved enzymatic debriding agent and has been shown to increase 
endothelial cell and keratinocyte migration in vitro and in vivo via stimulation by degraded 
bioactive fragments within the wound bed [90]. Enzymatic debridement is faster than 
autolysis and easy to use. Biosurgical debridement involves the dissolution and ingestion 
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of necrotic tissue by enzymes in the saliva of medical grade maggots (e.g.,  Lucilia sericata, 
Phaenicia sericata, Lucilia cuprina). Biosurgical debridement rapidly and efficiently 
removes necrotic tissue and has been shown to stimulate fibroblast proliferation [89, 91-
93]. However, biosurgical debridement can be painful, may require patient coaching, and 
is rarely used due to reluctance by patients and care providers [92]. 
1.2.1.2 – Management of Infection  
Impaired healing and infection are secondary consequences of bacterial colonization in 
chronic wounds. Cleansing agents such as water, saline, or dilute vinegar (0.5% acetic 
acid), and topical antimicrobials such as low-concentration povidone iodine, cadexomer 
iodine gel beads, metronidazole gel, silver, and medical grade manuka honey, are effective 
at reducing bacterial load and wound size [89]. Without intervention, bacterial invasion 
into adjacent tissues can develop into necrotizing infection, gangrene, or deep abscesses 
with the need for surgical intervention to avoid amputation [94]. 
1.2.1.3 – Wound Dressing 
Wound dressings function to protect the wound from infection, provide a moist 
environment, absorb exudate, and promote tissue regeneration [41, 89]. Moisture-retentive 
wound dressings (MRWDs) maintain adequate moisture balance (moisture vapor 
transmission rate <35 g/m2/hr) to promote keratinocyte migration and wound healing. 
Chronic wound treatment with MRWDs have been shown to improve closure (up to 3.83-
fold) and reduce costs compared to conventional gauze dressings [95-97]. However, 
chronic wounds recur in up to 70% of patients [98]. The five basic categories of MRWDs 
are films, foams, hydrocolloids, alginates, and hydrogels [89]. Bioengineered skin 
substitutes may be considered a sixth category, as MRWDs with regenerative properties.  
1.2.1.3.1 – Films  
Films are comprised of thin, elastic layers of polyurethane applied mainly to the site of 
split-thickness skin grafts and acute surgical wounds. Films are permeable for gas 
exchange, transparent for visualization of the wound, and provide a barrier against bacteria. 
Disadvantages of films include poor drainage, and tissue damage upon removal. 
Commercially available films include Opsite®, Askina Derm®, and Bioclusive® [41, 89].  
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1.2.1.3.2 – Foams  
Foams are comprised of bilaminate hydrophobic polyurethane foam sheets with 
hydrophilic surfaces and are suitable for mild to moderately exudative wounds. Foams are 
absorbent, comfortable, and conformable but may require application of a secondary 
dressing to facilitate absorption, occlusion or drainage. Commercially available foams 
include Allevyn®, 3 M® Tegaderm®, and Askina® [41, 89, 99].  
1.2.1.3.3 – Hydrocolloids  
Hydrocolloid dressings combine a foam or polyurethane film backing with adhesive 
gelatin, pectin and carboxymethylcellulose matrix. Interaction between hydrocolloid 
matrix and wound exudate produces a gel that promotes autolytic debridement and 
stimulates granulation tissue formation. Hydrocolloids are conformable, waterproof, easily 
removed and are appropriate for wounds with mild to moderate levels of exudate. However, 
hydrocolloids are inappropriate for highly exudative and infected wounds, can be odorous, 
difficult to remove, and may cause skin maceration with highly exudative wounds. 
Commercially available hydrocolloids include Comfeel®, Tegasorb®, and DuoDERM® 
CGF [41, 89, 100]. A substantial body of evidence exists supporting the benefits of 
hydrocolloid dressings in chronic wound treatment [101, 102]. 
1.2.1.3.4 – Alginates  
Alginate dressings are composed of sodium and calcium salts of alginic acid (a 
polysaccharide from brown algae). Alginates have haemostatic properties, are highly 
absorbent, and are ideally suited for highly exudative wounds, but require secondary 
dressing changes when they become saturated. Alginates are inappropriate for dry wounds, 
potentially causing pain and tissue damage upon removal. Commercially available 
alginates include Sorbalgon®, Seasorb®, and Kaltostat® [41, 89, 99]. 
1.2.1.3.5 – Hydrogels  
Hydrogels contain insoluble methyl-acrylate polymers containing hydrophilic components 
and adhesive/absorbent methylcellulose, propylene glycol, pectins, and alginates. 
Hydrogels are highly absorbent, forming a gel after interaction with wound exudate which 
stimulates autolytic debridement. Hydrogels may be applied to a range of wounds from 
mildly to highly exudative. Skin maceration can occur with highly exudative wounds. 
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Commercially available hydrogels include Allevyn®, Aquacell®, and Exu-Dry® [41, 89, 
100]. 
1.2.1.3.6 – Bioengineered Skin Substitutes 
Like conventional MRWDs, bioengineered skin substitutes (BSSs) are protective dressings 
that preserve a moist wound environment and limit fluid loss. However, BSSs also actively 
stimulate healing. The design and structure of BSSs are tailored to the depth and remaining 
structural integrity of the wound being treated. BSSs for the replacement of the epidermis 
(e.g., for the donor site of large split-thickness grafts) are primarily autogenic keratinocyte 
expansions formulated into carrier dressings or suspensions that can be placed or sprayed 
onto the wound site. Currently, clinical autogenic epidermal BSSs include Epicel®, 
Epidex®, Myskin®, Bioseed®, and Cellspray® [103].   
Dermal BSSs are necessary when the native dermis has been removed. Dermal substitutes 
are designed as three-dimensional biomaterial matrices, similar in structural, elastic, and 
mechanical properties to the ECM, with or without a cellular component. Endogenous 
fibroblasts and endothelial cells repopulate acellular dermal BSSs (e.g., Oasis® and 
Alloderm®), gradually vascularizing and remodelling the skin substitute [103]. Acellular 
dermal BSSs are nonimmunogenic, mechanically robust, and can be used off the shelf. 
Cellular dermal BSSs are seeded with neonatal human foreskin fibroblasts and/or 
keratinocytes (e.g., Dermagraft® and Orcel®) and have been shown to regenerate skin at 
35 days post-wounding and improve wound healing with depressed myofibroblast activity 
in acute and chronic wounds (by reducing wound contractility to allow re-epithelialization 
to restore a more natural tissue barrier) [41, 104]. Dermagraft® was observed to stimulate 
cellular infiltration, angiogenesis, and re-epithelialization in chronic wounds [105]. 
Furthermore, in separate studies of murine and human models of diabetic and venous 
ulcers, Dermagraft® increased the rate of vascularization and wound closure compared to 
acellular dermal skin substitutes [106, 107].  
Bilayer skin substitutes are the most advanced class of BSSs consisting of both epidermal 
and dermal components. Apligraf® is a FDA-approved cellular bilayer skin substitute 
consisting of an epidermal layer of neonatal human foreskin keratinocytes and a dermal 
layer composed of type-I bovine-collagen fibrils seeded with neonatal human fetal 
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fibroblasts, and is intended for use in acute wounds, chronic skin ulcers, and burns [41, 89]. 
The keratinocyte and fibroblast populations contained in Apligraf® dressings are 
responsible for the production and delivery of cytokines [interferon (IF) -α, IF-β, IL-1/6/8], 
growth factors (e.g., PDGF) and ECM components to the wound bed [8]. In two studies of 
venous leg ulcers, application of Apligraf® with compression therapy was shown to 
significantly improve wound closure compared to compression therapy alone [106, 108]. 
However, high cost and limited shelf life are two major limitations of bilayer skin 
substitutes [106]. 
1.2.1.4 – Adjunctive Therapies  
There are currently several therapies used adjunctively with standard care to improve 
healing outcomes. Adjunct therapies increase closure rates, improve the quality of repaired 
tissue, decrease amputation rate and associated mortality, and lead to an overall reduction 
in the cost of care [41].    
1.2.1.4.1 – Negative Pressure Wound Therapy 
Negative-pressure wound therapy (NPWT) or vacuum-assisted closure therapy applies sub-
atmospheric pressure to a local area of tissue damage through a specialized pump connected 
to a foam dressing with an adhesive backing while a canister attached to the NPWT system 
collects wound exudate [109]. NPWT reduces tissue edema, improves circulation, 
promotes granulation tissue formation, and inhibits bacterial growth [110]. NPWT 
significantly improved rate of wound closure, time to complete closure and rate of 
granulation tissue formation after partial foot amputation in diabetic patients [109]. In one 
case study, NPWT accelerated wound healing of an infected chronic leg ulcer after 
reducing exudate and bacterial count [111]. After one week of treatment with NPWT, 
reduced inflammatory damage and improved perfusion was observed in three chronic 
wounds [112].   
The exact molecular mechanism of NPWT is unknown however, cytokine, chemokine, 
growth factor, and MMP expression is altered in response to NPWT [113]. TNF expression 
was downregulated [114] and proangiogenic factors IL-8, and VEGF were upregulated in 
human chronic wounds following NPWT [115]. Inflammatory mediators IL-1β and TNF-
α expression was reduced in skeletal muscle after NPWT [116]. Conflicting evidence has 
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been presented on MMP expression in response to NPWT. Expression of MMPs-1/2/9/13 
were reduced in two studies of human chronic wounds treated with NPWT [117, 118] 
however, a separate study of eight human chronic wounds found no difference in MMP-
2/3 and TIMP-1 expression following NPWT [114].  
1.2.1.4.2 – Hyperbaric Oxygen Therapy 
Hyperbaric oxygen therapy (HBOT) involves a patient breathing 100% oxygen for a 
specific period of time in a pressurized chamber (1-3 atmospheres) [119]. A standard 
treatment regimen involves 90-120-minutes of HBOT for 30 sessions [113]. HBOT is based 
on Henry’s law which states that the dissolution of gas in a liquid or tissue is proportional 
to the partial pressure of that gas in contact with the liquid or tissue [120]. Oxygen 
saturation of hemoglobin and dissolved oxygen in plasma both rise during HBOT. 
Hyperoxia stimulates the generation of ROS which disrupt bacterial metabolism and 
enhance the bactericidal oxygen-dependent leukocyte peroxidase system  [121]. Enhanced 
blood and tissue oxygenation by HBOT improves oxygen delivery to hypoxic tissues and 
vasoconstricts surrounding healthy tissue, alleviating edema and allowing natural host 
responses to infection and ischemia to proceed [122]. The resolution of edema stimulates 
angiogenesis, fibroblast proliferation and differentiation, and collagen formation and cross 
linking [123]. The mechanisms that produce the beneficial molecular effects of HBOT are 
unclear however, HBOT has been established as an effective adjunct to standard chronic 
wound care. HBOT improves wound closure, reduces rates of lower leg amputation., and 
reduces rates of amputation in diabetic patients with ischemic foot ulcers [41, 119, 124]. 
Additionally, HBOT possesses bactericidal capability; reducing cellular viability of 
biofilms in vitro, and bacterial load in vivo [125]. Disadvantages of HBOT include ear, 
sinus or lung damage, oxygen poisoning, and high costs and impracticality of the equipment 
involved [124]. Alternative techniques of enhanced oxygen delivery (e.g., topical oxygen 
delivery) can provide the benefits associated with HBOT and improve practicality, improve 
ease of use, and decrease costs [126].  
1.2.1.4.3 – Growth Factors 
Growth factors mediate cell division, migration and proliferation, and have a central role 
in each stage of the wound-healing process [127]. Topical growth factor formulations have 
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been used in chronic wound healing with beneficial results. Regranex®/Becaplermin is a 
recombinant human-derived PDGF gel, was the first growth factor to obtain FDA approval 
for use in DFUs and has also been shown effective in PUs. Application of 100 or 300µg/mL 
Becaplermin gel once per day significantly decreased wound size compared to placebo and 
standard care in PUs [128] and in DFUs [129]. However, the FDA has warned of the 
increased risk of cancer mortality associated with use of three or more tubes of Becaplermin 
[130]. Positive effects of other growth factors for the treatment of chronic wounds, such as 
bFGF/FGF2, recombinant human (rh) EGF, rhVEGF, and nerve growth factor, have been 
demonstrated [131-134]. Topical growth factor treatment is limited by rapid proteolytic 
degradation of the applied bioactive factor(s) in vivo [135]. 
1.2.2 – Strategies Currently Under Investigation 
Many of the current biological therapies focus on provision of a single bioactive factor 
targeted at a specific stage or mechanism. Many cutting-edge strategies still in the research 
phase are attempting to avoid this limitation by incorporating various active constituents 
and cellular components for more comprehensive chronic wound treatments. Three main 
areas have been focussed on: stem cell therapy, platelet-rich plasma, and gene therapies. 
Stem cell therapies for the treatment of chronic wounds supply adult stem and progenitor 
cells to the site of injury to recruit other cell types such as keratinocytes, macrophages and 
endothelial progenitor cells [136]. Platelet-rich plasma is autologous blood plasma 
containing a high concentration of platelets that release vital growth factors (PDGF, EGF, 
TGF-β, bFGF/FGF2, FGF9) to replenish the chronic wound environment upon application, 
and enhance cell migration, proliferation, angiogenesis, and matrix remodelling [137, 138]. 
Gene therapies involve the delivery of viral vectors containing genes encoding growth 
factors, and inflammatory mediators [139, 140].  
Bioengineered skin substitutes, topical growth-factor delivery, stem-cell therapies, platelet-
rich plasma, gene therapies, and the other adjunct treatment modalities use factors and 
equipment that are extremely expensive and impractical. Furthermore, scaling research of 
developing bioactive therapies is difficult due to the exorbitant cost, and a lack of animal 
models that accurately reflect the human condition [58].  
18 
 
 
 
1.3 – Electrohydrodynamic Atomization as a Fabricant of Wound-Healing Therapies 
1.3.1 – Scaffold Design for Tissue Regeneration 
Standard chronic wound care is limited by the passive nature of conventional dressings and 
rapid degradation of topical growth factors by proteolytic, acidic and heat sensitive 
mechanisms in vivo [141]. Biomaterial scaffolds act as delivery vehicles to protect and 
prolong the release of bioactive agents and confer mechanical or biological properties 
reminiscent of the natural granulation tissue or ECM. Biomaterial scaffolds interact with 
the wound microenvironment to physically promote cell adhesion, proliferation, 
differentiation, and migration, and to re-establish the normal cellular signaling gradients 
that have been disrupted by the pathological chronic wound microenvironment [142]. 
Biomaterial design involves the choice of appropriate fabrication methods, appropriate 
materials, and incorporation of the appropriate bioactive factors. The ideal biomaterial 
scaffold is biocompatible, structurally similar to the natural ECM (fiber diameter 50-500 
nm, 90% porosity, and average pore size of 100 µm), optimized to coordinate scaffold 
degradation with tissue repair, nonimmunogenic, and biodegradable [143-147]. Commonly 
utilized fabrication methods and materials for the design of biomaterial scaffolds, including 
three-dimensional porous scaffolds and core-shell spheres, are presented here.  
1.3.2 – Methods of Scaffold Fabrication 
1.3.2.1 – Three-Dimensional Porous Scaffolds 
1.3.2.1.1 – Self-Assembly 
Self-assembly involves spontaneous structural organization via covalent bonding of 
individual components. The most efficient self-assembling polymers are amphiphilic 
peptides. Amphiphilic peptide molecules, containing a peptide sequence and an alkyl ester 
lipid region, self assemble into three-dimensional triple-helical structures reminiscent of 
natural collagen’s secondary triple-helical structure by hydrophobic interaction of the 
lipophilic tail regions [148]. Amphiphilic peptides form triple helical fibers 5-8 nm in 
diameter in aqueous solution and are composed of 1) an alkyl tail, 2) four consecutive 
cysteine residues to form disulfide bridges and polymerize the molecules, 3) triple glycine 
residue hydrophilic head group, 4) a phosphorylated serine residue for interaction with 
calcium ions to direct mineralization, and 5) an arginine-glycine-aspartame (RGD) 
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sequence for cellular adhesion. Altering pH, solution concentration, and temperature can 
change self-assembly into structures such as gels, sheets, spheres, rods, disks, or channels 
[147]. Self-assembling amphiphilic peptides promote cell adhesion, cell proliferation, and 
angiogenesis [149], and fiber diameters coincide with the thinnest ECM collagen fibers (5-
8 nm). However, self-assembly only creates short fibers (<1 µm), has a low diversity of 
applicable polymers, and the complexity and low yield limits its scalability [148].  
1.3.2.1.2 – Phase-Separation 
Phase separation utilizes thermodynamic or water-based solvent extraction to separate 
polymer from the solvent component of a polymer solution to fabricate heterogeneously 
porous polymer scaffolds with diameters between 50-500 nm, similar to the natural ECM. 
Variation of temperature and polymer concentration, and addition of various porogens (e.g., 
sugar, salt) produce tunable microporous scaffold architecture [148]. Phase separation is a 
simple technique with adjustable mechanical properties, pore size, and pore 
interconnectivity (based on temperature and polymer concentration), and batch-batch 
uniformity. However, heterogeneity of the porous structure may negatively impact cellular 
infiltration, so the suitability of phase-separated scaffolds as wound-healing therapies is 
controversial [150]. Additionally, low yield, and low applicable polymer diversity are 
limitations associated with phase separation.  
1.3.2.1.3 – Lyophilization 
Lyophilization or freeze-drying involves vacuum sublimation of frozen hydrogels saturated 
with water. Evacuation of ice from within the hydrogels produces porous membranes, 
tunable by controlling the freezing temperature; decreasing temperature decreases final 
pore size [151]. Lyophilization is a simplistic method of producing a highly interconnected, 
three-dimensional, porous matrix, but thermoregulation is necessary to maintain structural 
integrity and inhibit collapse of the internal porous structure. The process is also limited by 
small, irregular pore sizing, long processing times, and expensive equipment [152].  
1.3.2.2 – Core-Shell Spheres 
1.3.2.2.1 – Solvent Evaporation/Emulsification-Evaporation 
Solvent evaporation or emulsification-evaporation involves solidification of particles 
during simultaneous solvent evaporation and polymer emulsification under high shear 
20 
 
 
 
stress to produce particles 200 nm to 2 µm in diameter. Solvent evaporation is a simple 
drug encapsulation process that is appropriate for scale-up however, toxicity of remaining 
organic solvents and an inverse relationship between drug content and particle diameter 
limit its use [153].  
1.3.2.2.2 – Emulsification-Diffusion 
Emulsification-diffusion involves dissolution of polymer and active constituent into a 
saturated solution of water and miscible organic solvent before stabilizers, surfactant, and 
sufficient water are added to induce solvent diffusion into the external aqueous phase,  thus 
aggregating residual polymer and active constituent into solid nanoparticles under 200 nm 
in diameter [154]. Emulsification-diffusion is reproducible, easy to scale-up, and allows 
incorporation of thermosensitive drugs. Encapsulation efficiency of lipophilic drugs is 
high, however, low encapsulation efficiency of hydrophilic drugs and long processing times 
are substantial drawbacks [155].  
1.3.2.2.3 – Spray Drying 
Spray drying atomizes a drug or polymer solution through fine pores into a drying chamber 
heated above the vaporization temperature of the solvent to produce spherical nano-scale 
droplets of polymer and drug. Spray drying is a single-step, scalable process capable of 
tunable particle size and drug encapsulation however, thermosensitive bioactive agents are 
incompatible with the elevated temperatures involved [156].  
1.3.2.2.4 – Nanoprecipitation 
Nanoprecipitation involves dissolution of active constituents and polymer into a water-
miscible organic solvent before addition of a non-polymer solvent aqueous solution. 
Nanoparticle precipitation occurs under moderate stirring due to rapid diffusion of organic 
solvent into the aqueous phase, similar to the emulsification-diffusion process [157]. 
Nanoprecipitation is simple, fast, reproducible, scalable, and capable of producing 
monodisperse particles. However, low polymer concentration in the organic phase and low 
loading efficiency of hydrophilic drugs, due to hydrophobicity of the nanoparticle matrix, 
are significant limitations [158].  
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1.3.2.2.5 – Electrohydrodynamic Atomization 
Finally, electrohydrodynamic atomization (EHDA) utilizes electromechanical and 
hydrodynamic forces to transform a polymer solution into either fibrous or spherical 
structures. Electrospinning and electrospraying are the two-main operative EHDA 
techniques, differing mainly in their processing conditions.   
1.3.3 – Electrospun Nanofibrous Scaffolds 
Studies have successfully utilized nanofibrous scaffolds or meshes for topical wound 
treatment [159, 160]. Blend electrospinning is an established method for the fabrication of 
nanofibrous meshes or scaffolds in which a bioactive agent is blended into the polymer 
solution that will eventually form the scaffold structure. Biomimetic scaffolds fabricated 
by blend electrospinning incorporate favourable qualities including biocompatibility, 
biodegradability, sterilizability, and important physical and mechanical properties 
reminiscent of the native ECM [161].   
A sufficiently high voltage (10 - 20 kV) is applied to a polymer solution [after blending 
with therapeutic agent(s)] that is actively pumped out of a syringe. Repulsive electrostatic 
forces eventually overcome surface tension of the liquid droplet (Taylor cone) at the 
spinneret tip, propelling a fine jet of electrically charged polymer solution towards a 
grounded collecting surface. As the stream travels, solvent evaporates, and the charge 
migrates to the surface of the polymer fiber. Bending of the travelling polymer due to 
electrostatic repulsion promotes elongation and thinning of the fiber until it is deposited on 
the grounded collecting surface. Depending on the polymer and solvent used, this process 
results in fibers of uniform diameter ranging from 50 nm to 10 μm (Figure 1.2B) [162].  
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Figure 1. 2 – Diagrammatic representation of simultaneous fabrication of an 
electrospun nanofibrous scaffold with electrosprayed coaxial microspheres. A) 
Electrospraying involves the appropriate combination of processing parameters (i.e., 
solution concentration, solution viscosity, flow rate, applied voltage, and collector distance) 
and a coaxial needle to form a compound Taylor Cone, elongating the solution meniscus 
until electrical repulsion overcomes surface tension to separate the solution into core-shell 
droplets that are deposited on a grounded collecting surface. B) Electrospinning utilizes a 
uniaxial needle and the same set of processing parameters to eject a thin fiber onto the 
collecting surface under the appropriate combination of processing parameters.  
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High protein loading (up to 100%), polymer diversity, ability to manipulate protein release, 
simplicity, cost efficiency, versatility, and the morphological resemblance of electrospun 
nanofibers to native ECM (including high surface area to volume ratio, interconnected 
porosity, and fiber diameter) are significant factors contributing to the utilization of 
electrospun nanofibrous scaffolds in tissue engineering applications [163, 164]. 
Additionally, the various parameters involved in the electrospinning process provide a 
means to customize scaffold characteristics [165]. Concentration and resultant viscosity of 
the polymer solution, solvent properties, distance from needle to collecting surface, applied 
voltage, flow rate, temperature, and humidity all contribute to the scaffold’s final 
morphology [166, 167].  
Perhaps the greatest advantage of blend electrospinning is that incorporation of bioactive 
factors into the polymer solution disperses bioactive molecules evenly throughout the 
scaffold, enabling a more controlled release compared to physical adsorption onto the 
surface of the fibers [168]. Electrospun scaffolds are highly interactive with the in vivo 
environment due to their high surface-area-to-volume ratio, nanoscale diameter, and highly 
porous structure. An initial burst release followed by sustained release of diffusing 
bioactive factors occurs during degradation of polymer fibers in vivo [169]. Bioactive 
factors that are present during normal healing, such as antimicrobial peptides, cytokines, 
and growth factors, are absent in chronic wounds [170]. Incorporation of EGF, bFGF, and 
antimicrobial peptide LL-37 into silk nanofibers by blend electrospinning re-established 
biological gradients of these bioactive factors in full-thickness excisional wounds on the 
dorsal surface of diabetic rabbits, accelerating wound healing, lowering MMP expression, 
regulating ECM secretion by fibroblasts, and eliminating biofilm or bacterial colonization 
[171].  
However, poor cellular infiltration and ingrowth due to small average pore radiuses [172], 
potential toxicity of residual solvents or cross-linking agents [173], and inefficient 
production [174, 175], are challenges involved with electrospinning in cutaneous wound-
healing applications. Pore size is proportional to fiber diameter. Decreasing the electrospun 
fiber diameter increases fiber-to-fiber contacts resulting in decreased average pore radius 
[176]. Small pore sizes combined with an inherently high degree of packing density 
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associated with the electrospinning process (due to overlying layers compressing fibers 
beneath) constrains the ability of cellular migration, limiting vascularization and tissue 
ingrowth in vivo [177]. Potential solutions to this problem include: increasing flow rate or 
increasing concentration of the polymer solution to produce thicker fibers, or selective and 
controlled heating of the electrospinning environment to facilitate solvent evaporation 
[161, 178, 179]. Larger fibers can counteract the limitation of pore size due to packing 
density however, increasing fiber diameter also inhibits cellular adhesion and migration 
[180]. The estimated ideal porosity of an electrospun scaffold to allow cellular infiltration 
is 100-500 µm [181]. Cytotoxicity of residual organic solvents or chemical cross-linking 
agents is a common concern associated with blend electrospinning due to the limited 
availability of biocompatible solvents and water-soluble polymers [173]. Alternative cross-
linking methods to increase stability while maintaining safety include enzymatic 
crosslinking, electrostatic crosslinking, or hydrogen bonding with sugars or polyphenols 
[165]. However, increased procedural difficulty and degradation of bioactive factors loaded 
into the scaffolds are concerns associated with these alternative cross-linking methods 
[165]. Inefficient production, due to insufficient insulation of the electrospinning chamber, 
impurities in the polymer solution, or the difficulty of achieving a stable Taylor cone,  
reduces encapsulation efficiency and future release of incorporated bioactive factors [182].   
Adjunct therapies have successfully enhanced the positive effects of electrospun scaffolds 
on wound healing. Electrospun poly-L-lactic acid nanofibrous scaffolds coated with aloe 
vera gel accelerated wound closure and improved inflammatory outcomes, reducing poly 
nuclear immune cell infiltration, increasing fibroblast maturation, re-epithelialization, and 
collagen deposition, compared to Vaseline-coated gauze [183]. Recent advances have 
enhanced the complexity and capability of EHDA. Coaxial needles fabricate core-shell 
structures to encapsulate bioactive factors instead of simple incorporation into fibrous or 
spherical structures, and the tunability of the electrospinning parameters allows for 
morphological variation to control release kinetics [184, 185]. For example, Shoba et al. 
designed a combinatorial multiphasic core-shell nanofiber delivery system with tailored 
release of bromelain (a debridement enzyme) and salvianolic acid B which consequently 
enhanced keratinocyte proliferation, endothelial cell migration, neovascularization, vessel 
density, and in vitro inhibition of bacterial colonization [186].    
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Electrospun nanofibers promote wound healing and skin regeneration [187].  Electrospun 
scaffolds share morphological similarities with the native ECM and offer the ability to 
incorporate bioactive molecules into nanofibers for targeted release within the wound 
microenvironment. However, the soluble nature of most biomolecules can cause a rapid 
initial burst release from the nanofibrous scaffolds, followed by degradation or aggregation 
due to the instability of these proteins against proteolysis, acidity, and heat in the wound 
microenvironment in vivo [188, 189]. The initial burst release of bioactive agents from 
electrospun protein fibers can be as rapid as 70% within 30 minutes of exposure to the 
biological environment [190]. Therefore, the success of an electrohydrodynamic tissue-
engineered treatment for chronic wounds may depend on an approach that combines the 
structural integrity of an electrospun scaffold with the ability to sustain prolonged and 
targeted release of functional bioactive factors throughout the wound-healing process [191, 
192].  
1.3.4 – Coaxial Electrospraying 
Polymeric core-shell microspheres are efficient vehicles for the delivery of therapeutic 
agents. The polymer shell protects the internalized (i.e. core) therapeutic agents, which 
gradually diffuse through the porous shell structure, thus sustaining release. Emulsion 
electrospraying is a cost-efficient, versatile technique capable of producing monodisperse 
core-shell microparticles [193]. 
Emulsion coaxial electrospraying is one technique capable of fabricating uniformly sized 
microspheres with an outer polymer shell and inner colloid core [194]. Coaxially 
electrospun microparticles and nanofibers have been shown to convey stability and 
sustained release of growth factors that may otherwise undergo rapid degradation in vivo 
[135]. Liao and Leong observed 10-14 day sustained release of VEGF-A and VEGF-C from 
core-shell polyurethane nanofibers [195]. An additional study showed maintenance of 
growth factor bioactivity after release from coaxial fibers or microparticles, when 
compared to fresh growth factor activity [196, 197].   
The basic concept of uniaxial electrospinning is preserved during coaxial electrospraying 
however, by varying parameters such as concentration of the polymer solutions, flow rate, 
and applied voltage, the charged stream can be divided into droplets [198, 199]. 
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Furthermore, the coaxial nozzle consists of two concentric but separate nozzles which are 
controlled by two individual syringe pumps. An electric field is introduced between the 
coaxial nozzle and a grounded collecting surface [200-203] and repulsive electric forces 
elongate the core and shell liquid menisci until a jet of multilayered liquid droplets is 
sprayed towards the grounded collecting surface, given the correct electrohydrodynamic 
forces are applied (Figure 1.2A) [204].  
Accurate control of the core-shell architecture, a high encapsulation rate (up to 100%), and 
protection of the contained therapeutic agents are the main advantages of coaxial 
electrospraying [200, 202]. Additionally, the utilization of separate solutions reduces the 
interaction of aqueous-based biological molecules with the organic solvents required to 
dissolve the shell-forming polymers, which can improve the functionality of the bioactive 
agent(s) [196].  
On the other hand, the thickness of the outer shell and size of the core solution must be 
tightly controlled since release of the therapeutic agent is highly dependent on diffusion 
through the polymeric shell [205]. The production of a functional microparticle with 
sufficient structural integrity, as well as the physical and chemical properties to allow 
sustained release via diffusion of the inner core material through to the biological 
environment, can be difficult to accomplish due to the multiple variables at play (e.g., flow 
rate, solution viscosity, applied voltage) and the different properties of core- and shell-
solutions. Imperfections in the shell structure due to mixing of core-shell solvents during 
electrospinning or defects in the core-shell structure can compromise sustained release and 
result in burst release of the bioactive agent from within the core [206]. Additionally, the 
thickness and composition of the shell layer is a major contributing factor to sustained 
release. Using hydrophobic poly(lactic acid) core and poly(3-hydroxy butyrate) shell, 
Wang et al. showed that hydrophobicity, as well as shell thickness, significantly effect the 
release profile of contained factors. Thin shells (~120 nm) exhibited 70% drug release 
within 11 days, while the same cumulative percent release required more than 30 days when 
the shell was ~230 nm thick [207].  
Hierarchically structured nanofiber and microsphere composite membranes have been 
fabricated with simultaneous electrospinning and electrospraying. Electrospun nanofibers 
28 
 
 
 
provide biomimetic mechanical properties of natural ECM, and electrospun core-shell 
microspheres re-establish signalling gradients that have been disrupted in the chronic 
wound microenvironment with protected and sustained release of bioactive factors. EHDA 
of nanofibers and microspheres from different source solutions onto a common collecting 
surface has been shown to produce uniform distribution of microspheres while maintaining 
porosity of the nanofibrous scaffold. Microsphere aggregation produces nonuniform 
distribution of the electrostatic field near the collecting surface resulting in uniform self-
organization of microsphere deposition [208]. Guo et al. electrosprayed bFGF 
encapsulating microspheres within electrospun poly-caprolactone (PCL) nanofibers to 
establish a chemotactic gradient to successfully enhance murine dermal fibroblast 
infiltration, and suggested accelerated angiogenic growth into the scaffolds [209]. 
1.3.5 – Scaffold Materials 
Choice of polymer composition is an important consideration in the design of electrospun 
nanofibrous scaffolds and electrosprayed core-shell microspheres. Both natural and 
synthetic polymers have been utilized [210]. Natural polymers (such as collagen, gelatin, 
silk, fibrinogen and chitin) are biocompatible, biodegradable and abundant in the natural 
environment. However, weak mechanical properties, processing difficulties, enzymatic 
degradation and potential immunogenicity limit their use. Due to the weak mechanical 
properties and rapid degradation of natural polymers in vivo, cross-linking is required to 
stabilize scaffold integrity. Chemical crosslinkers (e.g., glutaraldehyde, formaldehyde, 
polyether oxide, hexamethylene diisocyanate and polyurethane, acyl azide and 
carbodiimides, and glycerol) and physical crosslinkers (e.g., drying, heating, UV/gamma 
radiation) covalently bond amino acids on adjacent scaffold structures.  
Glutaraldehyde is a widely accepted chemical crosslinking agent of natural polymers; it is 
a five-carbon aliphatic molecule with a single aldehyde group at each terminus, it is easily 
accessible, inexpensive, and the vapour of a dilute solution effectively crosslinks collagen 
fibers within 24 hours [211]. Several functional groups (amine, thiol, phenol, and 
imidazole) and amino acids (lysine, tyrosine, tryptophan, phenylalanine, histidine, cysteine, 
proline, serine, glycine, glycylglycine, arginine) are reactive with glutaraldehyde [212, 
213]. However, crosslinking generally occurs between lysine ɛ-amino groups on adjacent 
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polypeptides [214]. Residual glutaraldehyde must be removed post-crosslinking due to the 
cytotoxicity of this chemical. Furthermore, depolymerization of glutaraldehyde crosslinks 
can release glutaraldehyde in vivo which may impair cellular function [211, 215, 216]. 
Synthetic polymers poly(lactic acid), poly(glycolic acid), poly(lactide-co-glycolide), and 
PCL provide efficient processing, flexible and tunable physical properties, resistance to 
enzymatic degradation, and stable mechanical properties. However, questionable 
biocompatibility and biodegradability, and high production costs are limiting factors [217]. 
Hydrophobicity of synthetic surfaces and a lack of cellular recognition sites (e.g., RGD 
sequences) limits cellular interaction with synthetic biomaterials [218].  
Alternatively, biomaterial composites aim to reduce the limitations associated with natural 
and synthetic polymers. Copolymers containing natural and synthetic components combine 
the physical, mechanical, and chemical properties of synthetic polymers with the 
biocompatibility, hydrophilicity, biodegradability, and important cellular recognition 
sequences contained in the polypeptide chains of natural polymers [218].  Incorporation of 
a synthetic polymer also eliminates the need for cytotoxic crosslinking [219]. The 
beneficial effects of copolymer materials were demonstrated in two studies investigating 
PCL/collagen and poly(L-lactic acid)-co-poly(ɛ-caprolactone)/gelatin scaffolds. The 
copolymer scaffolds significantly increased mechanical stability and cellular proliferation 
compared to scaffolds fabricated with the synthetic material alone [220, 221].  
1.3.5.1 – Gelatin 
Collagen I composes approximately 90% of the total collagen content in the skin [222]. 
Biomaterial scaffolds fabricated with collagen have been used extensively as a major 
component in dermal skin substitutes due to collagen’s high biocompatibility, 
biodegradability, and similar molecular composition to the natural ECM [223]. However, 
antigenicity of xenogeneic sources and high costs are two substantial limiting factors to the 
utilization of collagen in biomaterial scaffolds. Gelatin is a natural polymer alternative to 
collagen for use in biomaterial scaffolds [224]. Collagen denaturation via alkaline or acid 
processing produces gelatin with relatively low antigenicity and increased exposure of 
previously internalized cellular recognition sequences [225]. Type A gelatin is produced 
by acid pre-treatment of dermal porcine collagen, while type B gelatin is produced by 
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alkaline pre-treatment of dermal bovine hide [226]. Gelatin maintains the favourable 
biocompatibility and biodegradability of collagen, at a fraction of the cost [226]. Gelatin 
scaffolds have been shown to stimulate cellular adhesion, migration and proliferation, and 
accelerate wound healing [144, 227, 228]. 
1.3.5.2 – Poly(lactic-co-glycolic acid) 
Poly(lactic-co-glycolic acid) (PLGA) is a biocompatible and biodegradable copolymer of 
lactic and glycolic acid (LA and GA, respectively) capable of encapsulating hydrophilic 
and hydrophobic factors, is surface modifiable, and has been approved by both the 
European Medicines Agency and FDA for parenteral application [158]. LA to GA ratio, 
molecular weight, and acid or ester terminal end groups convey tunability of the 
physicochemical properties of PLGA, including: inherent viscosity, hydrophilicity, and 
degradability. Ester end groups improve resistance to hydrolytic degradation [229], and 
methyl groups on LA increase hydrophobicity (relative to GA), affecting solvent affinity, 
influencing interactions between polymer chains to affect viscosity of the PLGA solution, 
and reducing hydrolytic degradation of LA [230]. As the proportion of LA increases, PLGA 
resorption slows significantly from under 2 months at 50:50 LA:GA, to 12-16 months at 
85:15 LA:GA [229]. Bulk hydrolytic degradation reduces PLGA to monomeric lactate and 
glycolate which are metabolized naturally in vivo [231]. Initial hydrolytic ester cleavage is 
autocatalyzed by exposed carboxylic chain ends. Detached oligomers solubilize and are 
hydrolyzed further into individual LA/GA monomers before degradation by the body’s 
natural metabolic pathways to produce energy, carbon dioxide, and water [232]. However, 
acidification of the microenvironment can occur due to exposure of entrapped acidic 
carboxylic groups, perturbing protein structure and destabilizing encapsulated proteins 
[229]. The acidic destabilization of bioactive factors has been attenuated by incorporation 
of poorly water-soluble bases [233]. PLGA has been used extensively in targeted and 
controlled delivery of functional bioactive agents via electrosprayed core-shell 
microspheres with over 90% encapsulation efficiency and uniform sphere diameter ranging 
from 165 nm to 10 µm [202, 234]. 
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1.4 – Periostin, Connective Tissue Growth Factor 2 & Fibroblast Growth Factor 9 as 
Therapeutics for Chronic Wounds 
1.4.1 – Periostin & Connective Tissue Growth Factor 2 
The extracellular matrix (ECM) is a dynamic structure that displays multifunctional control 
over cellular behaviour. While its importance for structural integrity has been established 
[235], its functional role has also been recognized within the last two decades. Components 
of the ECM are targets for cell surface receptors controlling cell shape, survival, movement, 
and gene expression [236]. Further influence over cell behaviour is controlled through 
mechanotransduction, whereby the fluidity of the membrane conveys information to 
adhered cells [237]. Additionally, the ability of matrix proteins to serve as binding sites for 
diffusible growth factors and other proteins provides the ECM with control over the 
location and concentration of these factors to establish gradients and reservoirs for tissue 
morphogenesis and regeneration.  
Matricellular proteins are a class of non-structural proteins found within the ECM that 
modulate cell-matrix interactions to influence cell function [238]. These nonhomologous 
proteins are primarily expressed during development however, upregulation has also been 
described in response to tissue repair, remodelling, and disease [239]. Periostin (POSTN) 
is a 93.3 kDa N terminus-glycosylated matricellular protein containing four tandem 
fasciclin cell adhesion domains (Figure 1.3A) [240]. It was first observed as osteoblast 
specific factor 2, after Takeshita et al. discovered its secretion by murine osteoblasts in 
1993 [241]. Since then, POSTN has been witnessed in tissues, including skin [242] and 
bone [243], as well as pathological conditions, such as vascular injury [244], muscle injury 
[245], and myocardial infarction [246]. POSTN enhances keratinocyte proliferation and re-
epithelialization [247], interacts with αv-integrins to accelerate cutaneous wound repair via 
the phosphatidylinositol 3-kinase/Akt and MAP kinase pathways [247, 248], and modulates 
vascular SMC migration via focal adhesion kinase signalling [249]. In normal skin, POSTN 
is localized to the cells in the basal lamina [250]. However, during the remodelling phase 
of wound healing, it migrates to the extracellular compartment where it facilitates dermal 
fibroblast activation, differentiation, and contraction, contributing to dermal regeneration 
and wound closure [247, 248, 251]. 
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Connective tissue growth factor 2 (CCN2) is one of six members of the CCN family of 
matricellular proteins involved in the regulation of cell adhesion, migration, proliferation, 
differentiation, apoptosis, survival, senescence, and gene expression [252]. The acronym 
(CCN) comes from the first three members of the family to be described: CYR61 (cysteine-
rich 61/CCN1), CTGF (connective tissue growth factors/CCN2) and NOV 
(nephroblastoma overexpressed/CCN3) [253]. The structure of these proteins includes an 
N-terminal secretory peptide, four conserved modular domains (sequence homologies to 
insulin-like growth factor binding proteins, von Willebrand factor type C repeat and 
thrombospondin type I repeat, respectively), and a cysteine-knot motif containing carboxyl-
terminal domain (Figure 1.3B). Binding specificity to ECM and cell surface receptors is 
conferred by a protease-sensitive central hinge that bisects the proteins [252]. Throughout 
embryonic development, CCNs are widely expressed however, in the adult, these proteins 
are downregulated except during inflammation and repair [254, 255]. During wound 
healing, CCN2 is released by platelet α-granules and acts synergistically with TGF-β to 
promote ECM deposition and fibrogenesis by proliferating myofibroblasts [256]. 
Furthermore, CCN1-3 bind integrin αvβ3 and promote neovascular tubule formation 
through stimulation of endothelial cell proliferation and chemotaxis [257, 258]. CCN1-3 
proteins have also exhibited control of the expression and activities of other angiogenic 
factors (e.g., VEGF-A and VEGF-C) [259, 260]. Recent evidence suggests a role of these 
matricellular proteins in inflammation. CCN1 and CCN2, upregulated by extracellular 
signals released during inflammation (TNF-α, IL-1β, TGF-β, prostaglandins, nitric oxide, 
histamine, serotonin, ECM enzymes), serve to regulate the immune response by modulating 
the activity and expression of inflammatory markers [255]. The functions of POSTN and 
CCN2 during wound healing have been described previously in greater depth [261, 262].  
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Figure 1. 3 – Structural domains of human POSTN and CCN2. A) The first isoform of 
human POSTN contains a signal peptide region (SP), an EMI domain and four tandem 
fasciclin-like domains (FAS1). A Tryptophan (Trp-65) residue located within the EMI 
domain is responsible for fibronectin binding. The four FAS1 domains bind Tenascin-C, 
bone morphogenetic protein-1 (BMP1) and integrins. Together, the EMI and FAS1 
domains bind collagen I and collagen V, and mediate POSTN ligand binding interactions. 
Residues within the C-terminal region inhibit tenascin-C, fibronectin, collagen V, and 
POSTN ligand binding. B) Human CCN2 contains a signal peptide region and four domain 
structures with sequence homology to insulin-like growth factor binding proteins (IGFBP), 
von Willebrand factor-C (VWC), thrombospondin type 1 repeat (TSP1), and a C-terminal 
cysteine knot region. The IGFBP homologue is responsible for IGF-1/2 binding, the VWR 
domain is responsible for TGF-β, and BMP-2/4 binding, the TSP1 domain is responsible 
for VEGF, and low-density lipoprotein receptor-related protein-1 (LRP1), and the Cysteine 
Knot region is responsible for LRP-5/6, Wnt, heparin sulfate proteoglycan (HSPG), and 
fibronectin binding. Integrin binding is mediated by the VWC, TSP1, and Cysteine Knot 
domains. Amino acids 247-349 bind heparin. Proteolytic cleavage of the hinge region 
between residues 163 and 202 produces various splice variants. Numbers represent the 
ascending sequence of amino acid residues from N- to C-terminal regions.  
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1.4.2 – Fibroblast Growth Factor 9 
Previously labelled glia-activating factor, FGF9 was identified in 1993 as a 208 amino acid 
polypeptide after purification from the culture supernatant of a human glioma cell line 
[263]. FGF9 secretion occurs without a N-terminal signal peptide, indicating a different 
physiological role than other members of the FGF family [264]. It has been suggested that 
a co-translational pathway targets nascent FGF9 to the endoplasmic reticulum via N-
terminal and core-structure hydrophobic regions, without peptide cleavage, before FGF9 is 
glycosylated and subsequently secreted [265]. FGF9 maintains 30% sequence homology to 
prototypic FGF1/2. A β-trefoil fold (three copies of a four-stranded β-sheet) with peripheral 
N- and C- terminal segments composes FGF9 and drives protein dimerization (Figure 1.4). 
Unique β1-2 and β9-10 loop conformations within the β-trefoil core and ordered α-helical 
regions in the N- and C- terminal regions separate FGF9 structurally and functionally from 
other members of the FGF family. External interaction of αN/C-helices and internal 
interaction between β-trefoil β-1 and -12 strands, and the β8-9 loop are responsible for 
FGF9 dimerization and occlusion of important receptor binding sites, suggesting a 
biologically relevant autoinhibitory mechanism behind FGF9 dimerization [266].   
Fibroblast growth factor receptors (FGFRs) are single-pass transmembrane receptor 
tyrosine kinases with a single extracellular domain composed of three Ig-like domains and 
an intracellular split tyrosine kinase domain. Alternative splicing of the third Ig loop 
regulates FGFR ligand binding specificity [267]. FGF, HSPG, and FGFR complex 
formation results in receptor dimerization and transphosphorylation of intracellular 
tyrosine residues, activating downstream signal cascades. FGFRs initiate two main 
intracellular signalling pathways: FRS2 and PLCγ receptor substrate dependent 
upregulation of Ras-dependent MAPK and PI3K-Akt pathways [268]. High affinity FGF-
FGFR binding requires heparin sulfate proteoglycans (HSPGs); cell-surface or ECM 
glycoproteins known to bind many growth factors and regulate signal transduction 
pathways including: TGF-β, sonic hedgehog (SHH), Wnt, and FGFs [269]. HSPGs 
promote 2:2 FGF-FGFR complex formation and tissue-specific FGFR activation in vivo 
[270]. Furthermore, HSPGs stabilize FGFs to inhibit proteolytic degradation and reduce 
thermal denaturation, and restrict FGF diffusion to enhance local FGF action [270]. 
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FGF9 is involved in the mesenchymal development of the cerebellum, lung, heart and 
intestine [271-274]. While FGF9 is involved in the formation of neovasculature, it plays a 
limited role in tube formation [275]. Instead, the evidence suggests that this growth factor 
acts through upregulation of platelet-derived growth factor receptor-β via SHH signalling 
to promote mural cell (progenitors of SMCs and pericytes) layering around newly forming 
vasculature to improve the stability (enhancing flow) and vasoreactivity of the vessels 
[275]. FGF9 positively regulated murine mesenchymal SHH signalling [276] to promote 
VEGF-A mediated capillary plexus formation in early murine lung development [277]. 
Furthermore, FGF9 successfully reconfigured the microvasculature of murine renal tumors, 
reducing hypoxia and improving vasoreactivity of the tumors [278]. FGF9 has also been 
indicated as a mitogenic factor, stimulating neointimal SMC proliferation via activation of 
the extracellular signal-regulated kinase (ERK) 1/2 pathway in vitro [275, 279].  
The role of FGF9 in cutaneous wound healing has yet to be fully elucidated. FGF9 was 
found to be upregulated 2- to 33-fold post-wounding, relative to low or moderate 
expression in healthy dorsal skin of young and aged mice, during full-thickness excisional 
wound healing [280]. The same study found that, among the four FGFRs, only expression 
of FGFR1 was upregulated during healing [280]. Alternatively, a recent study showed that  
γδ T lymphocytes accumulating in the wound bed before reepithelization release FGF9 
which stimulates Wnt2 expression in dermal fibroblasts. Wnt2 expression causes activation 
of autocrine fibroblast Wnt signalling which induces FGF9 expression in Wnt-activated 
dermal fibroblasts. The authors found that wound closure occurs normally in mice lacking 
γδ T lymphocytes or T cells lacking FGF9 expression however, hair neogenesis was 
impaired in these animals. This work suggests FGF9 may have a regenerative role through 
the restoration of adnexal structures (due to activated Wnt2 signalling) which are usually 
lost in deep cutaneous wound healing [281]. Furthermore, Zheng et al. found FGF9 to be 
upregulated from days 3 to 21, peaking on day 7 through 10, and FGF9 mediated activation 
of FGF-Wnt/β-catenin signalling in mouse and human skin after laser ablation, and when 
rhFGF9 was cultured with normal human epidermal keratinocytes. These findings suggest 
an important role of FGF9 in the wound healing process through interaction with the FGF-
Wnt/β-catenin signalling pathway [282]. 
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Figure 1. 4 – Amino Acid Sequence Alignment of FGF9. FGF9 sequence alignment is 
based on crystal structure analysis performed using CLUSTALW [266]. Residues 
comprising terminal α-helices and the twelve β-strands are indicated above the sequence 
alignment. Residues associated with dimerization are colour coded blue, low and high 
affinity heparin binding sites are yellow, and peripheral and central heparin binding sites 
are green and brown, respectively. Low and high affinity heparin binding sites are well 
established in the literature [283], while the peripheral and central heparin binding sites 
presented here, were first reported by Plotnikov et al. [266]. 
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1.5 – Rationale, Hypothesis & Objectives 
1.5.1 – Rationale 
Chronic wounds present a significant burden on the healthcare system and on patients 
suffering from these afflictions. The passivity of dressings involved in standard care does 
little to correct the pathological microenvironment of chronic wounds. Tissue engineered 
approaches include electrohydrodynamic scaffolds and core-shell microspheres, which act 
as biomimetic granulation tissue to physically support vascular development, fibroplasia, 
re-epithelialization, and contraction, and serve as delivery vehicles of bioactive factors to 
re-establish the disturbed biochemical gradients within chronic wounds.  
Elliot et al. showed POSTN/CCN2 scaffolds significantly improve angiogenic growth in 
full-thickness cutaneous wounds on the dorsal surface of db/db mice when compared to 
control conditions (Hamilton lab, In Review, J Tissue Eng). However, vascular growth in 
response to POSTN and CCN2 was insufficient to recover wild-type wound closure 
(Hamilton lab, In Review, J Tissue Eng). Furthermore, microcomputed tomography 
(micro-CT) images indicated incomplete tubule formation and an immature vascular bed 
(Hamilton lab, In Review, J Tissue Eng). Therefore, POSTN/CCN2 scaffolds require a 
factor capable of supporting the pro-angiogenic effects of POSTN/CCN2 to improve 
wound-healing outcomes associated with this scaffold. 
FGF9 recruits mural cell populations and promotes endothelial tube wrapping to produce 
durable and vasoresponsive microvessels [275, 278, 284, 285]. The role of FGF9 in 
mesenchymal development (cerebellum, lung, heart, and intestine) and tissue repair outside 
of the skin has been well documented [271-274, 286, 287] but there is a lack of basic 
knowledge on the role of FGF9 within the cutaneous wound-healing environment. 
Therefore, FGF9 may serve adjunctively with POSTN/CCN2 scaffolds to stabilize 
angiogenesis and improve wound repair, however there is a need to further investigate the 
role of FGF9 in cutaneous wound healing.  
1.5.2 – Hypothesis 
It is hypothesized that the POSTN/CCN2 scaffold will serve as a granulation tissue mimetic 
to physically and functionally support re-epithelialization, fibroplasia, and angiogenesis. 
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POSTN/CCN2 released from gelatin electrospun scaffolds will facilitate angiogenesis, 
matrix deposition, and regulate myofibroblast phenotype during the inflammatory and 
proliferative stages of wound healing. Sustained FGF9 released from PLGA microspheres 
will support POSTN/CCN2 induced neoangiogenesis by promoting mural cell recruitment 
and wrapping around endothelial tubes to stabilize the neovasculature. The production of 
robust, functional vessels will increase nutrient and oxygen delivery to improve reparative 
processes and facilitate regeneration. 
1.5.3 – Objectives 
The specific objectives of this project were:  
1. To determine the influence of nanofibrous electrospun POSTN/CCN2 scaffolds on 
angiogenesis and wound repair 28 days post-wounding in a porcine model of 
cutaneous wound healing. 
2. To design and validate an electrospun POSTN/CCN2 scaffold with coaxially 
electrosprayed core-shell microspheres encapsulating FGF9, comprising the following 
sub-objectives: 
a. Assess in vitro effect of FGF9 on cellular populations involved in wound 
healing. 
b. Design and validate a novel POSTN/CCN2 scaffold with FGF9/PLGA 
microspheres using a new electrohydrodynamic system. 
c. Determine release kinetics and biological activity of FGF9 released from core-
shell PLGA microspheres. 
3. To determine the influence of nanofibrous electrospun POSTN/CCN2 scaffolds with 
FGF9/PLGA microspheres (POSTN/CCN2/FGF9 scaffold) on angiogenesis and 
wound repair 7 days post-wounding in a porcine model of cutaneous wound healing.  
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Chapter 2  
Influence of Nanofibrous Electrospun Periostin and Connective 
Tissue Growth Factor 2 Scaffolds on Angiogenesis and Wound 
Repair in a 28-Day Porcine Model 
2.1 – Introduction 
The skin is a functional barrier that protects and regulates the bodies internal environment. 
The two main anatomic layers of the skin, the epidermis and dermis, participate in 
thermoregulation, sensation, haemostasis, and wound healing [1]. Cutaneous wound 
healing involves four overlapping phases: hemostasis, inflammation, proliferation, and 
remodelling to collectively initiate repair, eliminate infection, and restore the barrier upon 
injury. However, under certain pathological conditions, wound closure does not occur [2]. 
Chronic wounds are cutaneous tissue defects characterized by a proinflammatory 
microenvironment, and excessive degradation of connective tissues and signalling 
molecules that disrupt the normal progression of reparative events, resulting in an open 
lesion that persists longer than 3 months. Chronic wounds are of significant and growing 
clinical concern, particularly in relation to diabetes, venous insufficiency and immobility. 
Chronic wounds are associated with increased rates of amputation, mortality, and pose a 
significant financial burden on the healthcare system; for instance, the average cost to treat 
a diabetic foot ulcer in Canada is $39,000 [3, 4].  
Conventional interventions remove necrotic or devitalized tissue, control infection, apply 
moisture retentive wound dressings, mechanically off-load the affected area, and if 
necessary, re-establish blood flow with revascularization procedures [5]. However, except 
for hydrocolloids that promote autolytic debridement, standard dressings are only capable 
of passive moisturization of the wound environment to facilitate healing and protecting the 
wound from external mechanical forces. Bioengineered skin substitutes, such as 
Dermagraft® and Apligraf®, are alternative dressings capable of providing bioactive 
factors and cell populations to the wound site. However, high costs and short shelf-life are 
major limitations associated with their use [6].  
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Granulation tissue-mimetic electrospun nanofibrous scaffolds are ideal for tissue 
regeneration as they provide tunable pore size, porosity, and fiber diameter, as well as a 
high surface area to volume ratio, thus closely mimicking the structure of the natural ECM. 
Furthermore, the electrospinning process is cost-efficient, scalable, compatible with a wide 
variety of available polymers, and can incorporate bioactive factors [7]. Gelatin is a natural 
alternative to collagen for the fabrication of electrospun scaffolds, retaining the 
biocompatibility and biodegradability of collagen, at a fraction of the cost [8].   
In addition to tunable architecture, incorporation of bioactive factors such as matricellular 
proteins enhances biocompatibility and bioactivity of electrospun scaffolds. Matricellular 
proteins are a class of non-structural ECM components that modulate cell-ECM interaction 
[9]. The matricellular protein POSTN enhances keratinocyte proliferation and re-
epithelialization [10], modulates vascular smooth muscle cell migration [11], facilitates 
dermal fibroblast activation and wound contraction, and accelerates acute cutaneous wound 
repair [12]. POSTN is upregulated on day 3 post-wounding and peaks at day 7, correlating 
with heightened myofibroblast differentiation [13]. The matricellular protein CCN2 is 
upregulated from day 3 to day 11 in acute wound healing, promoting ECM deposition and 
fibroplasia, endothelial cell proliferation and chemotaxis, and neovascular tubule 
formation, as well as regulating other angiogenic factors (e.g., vascular endothelial growth 
factor-A and -C (VEGF-A/C)) [14-18]. CCN2 modulates the activity and expression of 
certain inflammatory markers [19]. In previous research, we developed electrospun 
collagen-based scaffolds for the delivery of POSTN and CCN2. Addition of the scaffolds 
supported vascular growth and accelerated wound closure in db/db mice (Hamilton lab, In 
Review, J Tissue Eng).   
The aim of this study was to investigate the efficacy of POSTN/CCN2 electrospun gelatin 
scaffolds on tissue repair in a porcine model of cutaneous wound healing. Wound closure 
kinetics, angiogenic growth, and collagen deposition were evaluated and compared to 
scaffolds without POSTN/CCN2.  
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2.2 – Materials and Methods 
2.2.1 – 28-Day Porcine Study 
All animal procedures followed protocols approved by the University Council on Animal 
Care at Western University. An in vivo porcine model was used to determine the ability of 
POSTN/CCN2 and galectin 3 (GAL3) loaded gelatin biomaterial scaffolds to facilitate the 
cutaneous wound-healing process. Four circular, 2 cm diameter, full-thickness, excisional 
wounds were created on the dorsal surface of six age- and sex-matched healthy Yorkshire 
pigs, carried out by a veterinarian. In each animal, treatment groups were defined: 1) empty 
wound, 2) gelatin scaffold containing bovine serum albumin (BSA), 3) gelatin scaffold 
containing recombinant human (rh) GAL3, and 4) gelatin scaffold containing rhPOSTN 
(POSTN) and rhCCN2 (CCN2). Healthy pigs were anesthetized, circular full-thickness 
wounds were excised, and scaffolds (section 2.2.2) were placed (3 per wound) into the 
wound beds. Wound treatments were rotated clockwise in each pig to minimize positional 
effects. Euthanasia and tissue isolation occurred at day 28 post-wounding. Immediately 
after euthanasia, wounded and unwounded tissue samples were removed and prepared for 
analysis (Figure 2.1). Tissue samples for cryopreservation and paraffin embedding were 
immediately fixed in 10% neutral buffered formalin (Sigma-Aldrich) for 24 h at 4⁰C. After 
formalin fixation, tissues for cryopreservation were rinsed with PBS and transferred to 75 
mL 10% sucrose (Sigma-Aldrich) for 24 h at 4⁰C. Cryopreserved tissues were then 
transferred to 20% and 30% sucrose for 24 h each at 4⁰C. Tissue samples were then pre-
agitated with 1:1 clear frozen section compound (VWR) and 30% sucrose for 1h before 
excess hair was removed and the tissues were placed wound-down in a disposable base 
mold (Fisher Scientific). Tissues were covered with clear frozen-section compound, 
immediately frozen on dry ice, and stored at -20⁰C. Serial 8 µm samples were sectioned 
using a Leica CM1900 UV cryostat (Leica) and stored at -20⁰C. Tissue samples for paraffin 
embedding were transferred to 70% ethanol (Commercial Alcohols) after the 24 h formalin 
fixation, and paraffin embedded using a Leica RM2245 microtome (Leica). Serial 6 µm 
paraffin sections were cut and stored at room temperature. The final quarter of the wound 
tissues were divided into eighths and stored at -80⁰C in 2 mL microtubes for gene 
expression analysis and quantification of collagen content.   
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Figure 2. 1 – Division of porcine wounds for post-experimentation. One half and one 
quarter of each wound was cryopreserved, and paraffin-embedded, respectively, for future 
immunohistochemical staining. Cryopreserved and paraffin embedded tissues were divided 
based on proximity to the center of the wound (middle versus edge of the wound bed). One 
eighth of the wound tissue was taken for qRT-PCR and the final eighth for hydroxyproline 
quantification.  
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2.2.2 – Scaffold Preparation 
Stock solutions of BSA (Fisher Scientific), GAL3, POSTN, and CCN2 (all matricellular 
proteins were purchased from R&D) were diluted to 10 µg/mL in 21 wt% Type B gelatin 
from bovine skin (Sigma-Aldrich) dissolved in 40% v/v acetic acid (Thermo Fisher 
Scientific) in deionized water. The polymer solution was loaded into a plastic 1 cc syringe 
and a syringe pump (VWR) delivered the polymer solution through a 20-gauge blunt-tip 
stainless steel needle connected to a high voltage DC power supply (Gamma High Voltage 
Research). Rotation of the grounded stainless-steel mandrel was held constant at ~100 
RPM. A piece of aluminum foil was secured to the rotating mandrel with electrical tape 
and acted as the collecting surface. Scaffolds were electrospun for two hours using a flow 
rate of 0.3 mL/h, an applied voltage of 15 kV and a collector distance of 10 cm. After 
electrospinning, scaffolds were crosslinked for 48 hours by the vapours emitted from a 5 
mL solution of 1.5% v/v glutaraldehyde (50 wt% in H2O) (Sigma-Aldrich) in anhydrous 
ethyl alcohol (Commercial Alcohols), in a glass desiccator (VWR) containing drierite 
(W.A. Hammond Drierite Co. Ltd) that was vacuum sealed for 20 minutes [20].  Final 
processing of the scaffolds involved removal of residual glutaraldehyde with a one hour 
0.1 M glycine (Sigma-Aldrich) quench followed by three, 15-minute PBS rinses. Scaffolds 
were cut with a scalpel in circles, 2 cm in diameter, using the bottom of a 12-well plate as 
a stencil. The scaffolds, 2 cm in diameter, were separated from the tinfoil and rinsed with 
PBS followed by sterilization with ultra violet light while submerged in PBS for 30 minutes 
per side. Sterilized scaffolds were stored in 2 mL serum free Dulbecco’s Modified Eagle 
Medium (DMEM; high glucose; Thermo Fisher) at 4⁰C until use. Three scaffolds were 
layered into each wound during the porcine study. A representative image of the scaffolds 
utilized in the 28-day porcine study is presented in Figure 2.2.  
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Figure 2. 2 – Representative scanning electron microscopy image of an electrospun 
nanofibrous scaffold utilized in the 28-day porcine wound-healing study. 
Representative image of scaffolds fabricated using optimized parameters (section 3.2.2; 0.5 
mL/h, 17 kV, 8 cm) and a 21 wt% gelatin solution. Scale bar = 1 µm.  
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2.2.3 – Porcine Cutaneous Wound-Healing Outcomes 
2.2.3.1 – Wound Closure Kinetics 
Digital photography (Nikon Coolpix S3600) was used to image the wounds on the backs 
of the pigs at various timepoints throughout the 28-day study period. Wound photography 
occurred during bandage changes, the appropriate timing of which was determined by the 
veterinary staff. Variability in the timing of bandaging changes resulted in inconsistent 
imaging timepoints between pigs.  Imaging timepoints were as follows:  
Pig 1 – days 0, 8, 15, 21, 28 
Pig 2 – days 0, 8, 14, 21, 28 
Pig 3 – days 0, 12, 21, 28 
Pig 4 – days 0, 12, 21, 28 
Pig 5 – days 0, 8, 14, 22, 28 
Pig 6 – days 8, 14, 22, 28 
Pig 6 was not imaged at day 0, and therefore was removed from wound closure kinetic 
analysis. ImageJ analysis (National Institutes of Health) was used to measure wound area 
as perimeter of the epithelial border. A ruler included in the digital photographs ensured 
standardization of scale across images. Data analysis was conducted based on the 
assumption of minimal differences in wound closure between similar timepoints, allowing 
binning of data between the following timepoints: 1) day 8, 2) days 12, 14, and 15, 3) days 
21 and 22, and 4) day 28. All binned timepoints included data from 5 pigs (N=5), except 
the day 8 timepoint (N=3). One measurement was made per wound, per pig at each 
timepoint (n=1).  
Wound diameter was measured as the distance between the base of unwounded dermal 
tissue bordering the wound bed, parallel to the underlying hypodermal tissue using ImageJ 
software and tissue sections stained with Masson’s Trichrome. One Trichrome image (n=1) 
per condition, per pig (N=6) was analysed. Wound diameter measurement was used as a 
secondary measure of wound closure to avoid the measurement limitations associated with 
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digital photography and blocking of the wound border by the wound eschar. GraphPad 
Prism 6 (GraphPad Software) was used to conduct all statistical analysis in this thesis. 
2.2.3.2 – Angiogenesis 
Porcine tissue cryosections (section 2.2.1) were rinsed three times in PBS followed by a 
five-minute incubation in 1% sodium dodecyl sulfate (Bioshop Canada Inc.) in a 
humidified chamber at room temperature and rinsed a final three times in PBS. Sections 
were blocked using 10% horse serum (Thermo Fisher) in PBS for 30 minutes at room 
temperature in a humidified chamber followed by overnight incubation with Endoglin anti-
CD105 antibody (1:100, Invitrogen) and anti-CD146 (1:500, Abcam) diluted in 10% horse 
serum (a full list of antibodies used in this thesis is presented in Appendix T). Negative 
controls were left in 10% horse serum overnight. The next day, tissues were rinsed three 
times, consecutively, in PBS, incubated with secondary antibodies [Alexa Fluor (AF) 488 
GtαMs 1:100, AF 555 DkαRb 1:100, and Hoechst 33342 1:1000, Thermo Fisher] diluted 
in 10% horse serum for one hour at room temperature in a humidified chamber and then 
rinsed again three times in PBS. Coverslips were mounted using Immu-mount (Thermo 
Fisher) and sealed with CoverGrip Coverslip Sealant (Biotium). Mounted sections were 
stored at 4⁰C overnight in a dry container to allow the mounting medium to dry. Vascular 
structures were imaged using the appropriate filters of an Axio Observer Z.1 inverted 
microscope (Carl Zeiss). Blood-vessel density (number of blood vessels/mm2), percent 
wound tissue covered by vascular tissue, and average individual blood-vessel area were 
quantified with ImageJ color deconvolution and threshold particle analysis. Threshold 
values for the detection of fluorescence were set using negative control sections stained 
without primary antibodies (Appendix Q). One CD146+ immunofluorescent image (n=1) 
per condition, per pig (N=6) was analysed. 
2.2.3.3 – Collagen Deposition  
Extent of collagen deposition was visualized with Masson’s Trichrome staining of 
cryopreserved tissues (Molecular Pathology, Robarts Research Institute). A hydroxyproline 
assay kit (Sigma-Aldrich) was used to quantify collagen content. Hydroxyproline is a 
highly conserved amino acid in collagen and therefore can be used as an indicator of 
collagen content. A ~10 mg sample was taken from each tissue sample (per condition, per 
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pig; N=6) and weighed before and after lyophilization with a VirTis Benchtop K freeze 
dryer (VirTis). Dry tissues were used in the experiment, and dry weight was used to 
standardize the final calculations of hydroxyproline content. Dry samples were minced with 
a scalpel and degraded in 400 µL 6-M HCL at 120⁰C for three hours. After incubation, 
wounded and unwounded samples were diluted with 400 µL and 800 µL 6-M HCL, 
respectively. These dilutions were previously optimized in our lab to reduce the 
concentration of hydroxyproline from the collagen-dense tissues and enhance colorimetric 
differences in absorbance measurements between samples. Samples were centrifuged at 
13,000 g for two minutes and 2-µL supernatant (from samples and standards) was 
transferred in duplicate (n=2) to a 96 well transparent flat-bottom microplate. Wells were 
evaporated to dryness in a 60⁰C oven for one hour. 100 µL/well chloramine T/oxidation 
buffer mixture (6:94 v/v) was added to each well and incubated at room temperature for 
five minutes. 100 µL/well diluted DMAB reagent (DMAB concentrate: Perchloric 
Acid/Isopropanol, 1:1 v/v) was added and samples were incubated at 60⁰C for 90 minutes. 
Absorbance was measured using a Tecan2 Safire fluorescent/colorimetric microplate reader 
(Tecan) at a wavelength of 560 nm. The absorbance value was converted to hydroxyproline 
content using a standard curve (Appendix G), and the different dilutions used for wounded 
and unwounded tissues after degradation with the 6-M HCL was considered.  
2.3 – Results 
2.3.1 – Wound Closure Kinetics  
Representative images of the wounds from one pig for each treatment are shown at days 0, 
8, 14, 21, and 28 post-wounding (Figure 2.3). Wound closure was reduced in the presence 
of BSA scaffolds when compared to empty control wounds between days 8 and 15 (Figure 
2.4A). No differences were observed between any other treatment conditions. All wounds 
achieved over 94% closure by day 28. Individual 28-day wound closure kinetics for each 
pig are presented in Figure 2.5 as an indication of the variability in wound closure 
measurements between pigs. As a secondary measure of wound closure, day 28 wound 
diameter was measured as the distance between wound borders, parallel to the 
subcutaneous tissue (Figure 2.4B). No significant differences were observed in wound 
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diameter between scaffold conditions and empty wounds. Wound closure results including 
GAL3 data, are presented in Appendix A/B   
2.3.2 – Angiogenesis 
Our previous work has shown that POSTN/CCN2 electrospun scaffolds can rescue delayed 
healing in db/db mice and increase neovessel tubule formation. Further investigation of a 
POSTN/CCN2 scaffold in a 28-day healthy porcine model of cutaneous wound healing 
revealed no differences in angiogenic growth. CD146 (a cell surface glycoprotein used as 
a marker for the endothelial cell lineage) positive endothelial tissue was visualized with 
immunofluorescent staining. Representative cross-sectional images of the wound bed 
vasculature from one pig at day 28 post-wounding are shown with outlines indicative of 
blood-vessel measurements by ImageJ software (Figure 2.6). Blood-vessel density, percent 
wound-tissue area covered by vascular tissue, and the average area of individual blood 
vessels (blood-vessel area) were calculated with CD146 fluorescent images and ImageJ 
software (Figure 2.7A-C). No differences were observed in any of these measurements. 
Day 28 blood-vessel density, percent area, and individual area are analyzed independently 
per pig in Appendix N. Endoglin/CD105 (a type I membrane glycoprotein which is part of 
the TGF-β receptor complex, and is upregulated and expressed on the surface of endothelial 
cells after cutaneous tissue injury) positive endothelial tissue was also visualized with 
immunofluorescent staining (Figure 2.8) to demonstrate the vascular phenotype of porcine 
cutaneous wound tissue 28 days post-wounding. Angiogenic results including GAL3 data, 
are presented in Appendix C-E.   
2.3.3 – Collagen Deposition 
To determine extent of collagen deposition in porcine cutaneous wound tissue following 
full-thickness excisional wounding, wounded and unwounded sections were stained with 
Masson’s trichrome (Figure 2.9). At day 28, the wound margin is visible as termination of 
the pre-existing thick collagen fibers in the connective tissue of unwounded dermis. 
Masson’s Trichrome staining showed no distinction in collagen content between wounded 
and unwounded tissues. Hydroxyproline content quantified with a Hydroxyproline Assay 
Kit was used as an indicator of collagen deposition (Figure 2.10). No significant differences 
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were observed. Collagen deposition results including GAL3 data, are presented in 
Appendix F.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 3 – Representative images of wound closure from day 0 to day 28 in a porcine 
full-thickness cutaneous wound-healing model. Age/sex matched Yorkshire pigs (N=5) 
were subject to four full-thickness excisional wounds per animal (2 cm in diameter). 
Wounds received either no treatment, gelatin scaffold containing BSA, or gelatin scaffold 
containing POSTN and CCN2. Representative images of the four treatment conditions from 
one pig are shown at days 0, 8, 14, 21 and 28. Scale bar = 1 cm.  
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Figure 2. 4 – 28-day wound closure kinetics after full-thickness cutaneous wounding 
in a porcine model. Wound area was measured at each timepoint using ImageJ software 
to calculate closure kinetics. A) Data are presented as percent of original wound area closed. 
Wound closure was significantly slowed by BSA scaffolds when compared to empty control 
wounds from day 8 to day 15. N=3/5, n=1, two-way ANOVA, Tukey post-test for multiple 
comparisons, p<0.05. B) No differences in wound diameter were observed at day 28 post-
wounding. One-way ANOVA, Tukey post-test for multiple comparisons, * = p < 0.05, ** 
= p < 0.01, *** = p < 0.001. Data presented as mean ± SD. 
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Figure 2. 5 – Individual 28-day wound closure kinetics after full-thickness cutaneous 
wounding in a porcine model. Wound area was measured at each timepoint using ImageJ 
software to calculate closure kinetics. A-E) Data are presented as percent of original wound 
area closed. Individual closure kinetics data are presented for each individual pig to show 
the variability in wound area measurements due to inter-animal variability and limitations 
of the measurement method associated with wound eschar blocking the wound edge in 
digital images. Timepoints varied for each pig due to external control of experimental 
procedures by the UWO Animal Care and Veterinary Services team. Timepoints are 
outlined in section 2.2.3.1. n=1.  
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Figure 2. 6 – Representative images of vascular growth 28 days post-wounding in a 
porcine full-thickness cutaneous wound model. Representative cross-sectional images 
of the wound bed vasculature from one pig at day 28 post-wounding are shown. Endothelial 
tissue was visualized with CD146 immunofluorescent staining. Scale bar = 200 µm. 
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Figure 2. 7 – Effect of biomimetic scaffolds on angiogenesis 28 days post-wounding in 
a porcine full-thickness cutaneous wound-healing model. Using CD146 as a marker of 
endothelial tissue in porcine cryosections, blood-vessel density (A), percent wound-tissue 
area covered by vascular tissue (B), and individual blood-vessel area (C) were quantified 
with ImageJ’s colour deconvolution and threshold particle analysis tools. No differences 
were observed. N=6, n=1, one-way ANOVA, Tukey post-test for multiple comparisons, 
p<0.05. Data presented as mean ± SD. Angiogenic data are presented independently per 
pig in Appendix N. 
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Figure 2. 8 – Angiogenic phenotype in porcine wound tissue 28 days post-wounding. 
Fluorescent immunohistochemistry of porcine wound tissue 28 days post-wounding 
revealed angiogenic phenotype after staining for endothelial markers CD146 and 
CD105/endoglin. Representative images from one pig are shown. Each set of images 
include a section of epidermal and superficial dermal layers. CD146 (red), CD105/Endoglin 
(green) and an overlay including CD146, CD105 and Hoechst stained cellular nuclei (blue) 
are presented. Scale bar = 100 µm. 
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Figure 2. 9 – Effect of biomimetic scaffolds on collagen deposition 28 days post-
wounding in a porcine full-thickness cutaneous wound model. Representative cross-
sectional images of collagen deposition 28 days post-wounding visualized with Masson’s 
Trichrome staining. Connective tissues (collagen) are stained blue; muscle, erythrocytes 
and cytoplasm are stained red; and nuclei are stained black. Scale bar = 1 mm. 
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Figure 2. 10 – Hydroxyproline content as an indicator of collagen deposition 28 days 
post-wounding in a porcine full-thickness cutaneous wound model. Hydroxyproline 
content was quantified using a Hydroxyproline Assay Kit and normalized based on the dry 
weight of degraded tissue. No significant differences were observed. N=6, n=2, one-way 
ANOVA, Tukey post-test for multiple comparisons, p<0.05 Data presented as mean ± SD. 
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2.4 – Discussion  
Previous development of an electrospun POSTN/CCN2 collagen scaffold significantly 
improved angiogenesis and wound closure in db/db mice (Hamilton lab, In Review, J 
Tissue Eng). The present study aimed to investigate the angiogenic and reparative effects 
of POSTN/CCN2 scaffolds in a healthy porcine model of cutaneous wound healing.  
Wound closure was inhibited from day 8 to day 15 in BSA scaffold treated wounds, but not 
POSTN/CCN2 scaffold treated wounds compared to empty controls (Figure 2.4A). Gelatin 
has been shown to elicit a foreign body response against implanted biomaterials [21]. 
Delayed closure in response to the BSA scaffold treatments may be a result of the foreign 
body response against gelatin. Both POSTN and CCN2 promote ECM deposition, 
fibrogenesis, and contraction by proliferating myofibroblasts [10, 12, 14, 22] and POSTN 
has been shown to enhance keratinocyte proliferation and re-epithelialization [10]. 
Therefore, POSTN/CCN2 scaffolds may have enhanced the wound repair process 
following a foreign body response to the scaffold, resulting in no differences between 
POSTN/CCN2 scaffolds and empty wounds between days 8 to 15. Future work is required 
to characterize the cellular populations present at day 28 to determine the extent to which 
POSTN/CCN2 scaffolds may have contributed to wound contraction or re-epithelialization. 
POSTN has been associated with scar formation. Day 3 upregulation of POSTN following 
wounding has been shown to peak on day 7 and declines throughout early remodelling to 
mediate angiogenesis and fibroplasia throughout the wound-healing process in a mouse 
model [13]. However, overexpression of POSTN in hypertrophic and keloid scarring 
induces excessive fibroblast proliferation and contractility [23]. Therefore, future work 
should confirm the effect of POSTN/CCN2 scaffolds on wound closure in vivo and 
characterize the optimal POSTN/CCN2 concentration to balance fibroplasia with fibrosis. 
Wound closure of all conditions was equivalent by day 28 (all wounds were >94% closed) 
indicating no lasting negative effects of the scaffolds on the rate of wound closure. This 
effect demonstrates that in a porcine model, the scaffolds appear biocompatible, with no 
foreign body response evident in Masson’s Trichrome images at 28 days post-implantation. 
Individual 28-day wound closure kinetics for each pig are presented in Figure 2.5 as an 
indication of the variability in wound closure measurements, and the high variability in 
BSA and POSTN/CCN2 scaffold conditions at days 8 and 12/14/15. This variability can 
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be attributed to limitations associated with the porcine model, including wound eschar 
blocking the wound border and complicating wound area measurements (as can be seen at 
day 14 in Figure 2.3), and inter-animal variability.    
POSTN and CCN2 have been shown to stimulate vascular smooth muscle cell migration, 
endothelial cell proliferation and chemotaxis [11, 15, 16], as well as up-regulate pro-
angiogenic factors such as VEGF-A/C [17, 18] to promote neovascular tubule formation. 
Therefore, we anticipated POSTN/CCN2 scaffolds would enhance vascular growth. 
Vascular size and density in wounded tissues relative to unwounded tissues did not change. 
Quantification of blood-vessel density, percent wound area covered by vascular tissue, and 
individual blood-vessel area indicated no significant effects of BSA or POSTN/CCN2 
scaffolds. This result however, does not eliminate the possibility that scaffold treatments 
could have influenced angiogenic growth earlier in the healing process. During 
inflammation, hypoxia and cellular signalling initiate angiogenesis with robust endothelial 
cell proliferation, migration and nascent vessel formation [24]. Extensive sprouting and 
branching results in an immature and poorly perfused vascular network [25]. In the later 
stages of healing, vascular regression occurs as extraneous vessels are removed and mural 
cell coverage yields a stable, well-perfused vascular network [26]. Therefore, vascular 
regression may have reduced the impact of POSTN/CCN2 scaffolds on angiogenic growth 
observed at day 28. 
Elliott et al. demonstrated rescued wound closure and enhanced angiogenic growth in db/db 
murine wounds treated with POSTN/CCN2 collagen scaffolds (Hamilton lab, In Review, J 
Tissue Eng). However, our results indicate no effects on closure or angiogenesis by the 
POSTN/CCN2 scaffolds. This difference could be attributed to the acute state of wound 
healing in the healthy pigs used in this study. The rapid rate of healing in healthy individuals 
may reduce treatment effects observed in pathological situations [27]. In addition, normal 
expression levels of POSTN, CCN2, and other functional molecules in the porcine wounds 
may have reduced or eliminated the influence of the POSTN/CCN2 scaffold. The porcine 
model of cutaneous wound healing was chosen for this study because it is considered the 
gold-standard for cutaneous wound healing research due the physiological and anatomical 
similarities between human and pig skin [28]. Therefore, the lack of a physiologically 
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significant response may not eliminate the POSTN/CCN2 scaffold as an appropriate 
treatment for chronic wound healing. Instead, conflicting evidence presented by Elliot et 
al. and the 28-day porcine study presented here may highlight how cutaneous wound-
healing research conducted in murine models may not be easily translatable to large animal 
models. However, this does not eliminate the possibility that the scaffolds are effective in 
pathological situations as seen in the db/db mice, and may still function in human non-
healing wounds. 
The primary granulation tissue in cutaneous wounds is composed of fibronectin secreted 
by fibroblasts, which is later remodeled and replaced by fibrillar collagen I and III [29]. 
Assessment of collagen content in porcine cutaneous wounds at 28-days post-wounding 
showed similar results irrespective of scaffold treatment. Quantification of hydroxyproline 
content, as an indicator of collagen deposition, supported the qualitative findings by 
Masson’s trichrome that no differences in content between groups was observed (Figure 
2.10). Although the scaffolds contained gelatin, as the empty wounds showed similar 
hydroxyproline content, it is unlikely that the presence of gelatin influenced the results. 
Indeed, no scaffolds were evident in Masson’s Trichrome images indicating degradation or 
ejection by 28-days. In previous studies in db/db mice, the scaffolds were observed to be 
above the granulation tissue and were eventually shed with the eschar (Hamilton lab, In 
Review, J Tissue Eng).  
Finally, the effect of POSTN/CCN2 scaffolds on angiogenesis, collagen deposition, and 
other measures of wound repair (e.g., extent of re-epithelialization) may not be evident at 
28 days. Differences in the healing process could have occurred but were not evident in the 
wound tissues at 28 days post-wounding. Therefore, a follow-up study at an earlier 
timepoint was necessary to investigate the effect of POSTN/CCN2 scaffolds during the 
inflammatory and proliferative stages of wound healing. A separate porcine study involving 
6 different pigs, and a 7-day endpoint, was included in the original protocol for this study. 
However, complications associated with the pig’s size and health forced the 7-day 
timepoint to be removed. The 7-day follow-up study was conducted a year later and is 
presented in Chapter 3.   
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2.5 – Conclusions  
Wound closure kinetics, angiogenic growth, and collagen deposition in wounds treated with 
POSTN/CCN2 scaffolds indicate no negative effects of the electrospun scaffolds on the 
healing process at day 28 in a porcine model. Future research with a larger sample size and 
at earlier timepoint(s) is necessary to validate the current findings and to investigate the 
effect of POSTN/CCN2 scaffolds during inflammation and proliferation.  
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Chapter 3 
Design and Validation of a Matricellular Protein-Loaded 
Electrospun Scaffold Containing Encapsulated Fibroblast 
Growth Factor 9 in a Porcine Model of Cutaneous Wound 
Healing 
3.1 – Introduction  
In recent years, the use of electrospinning techniques has gained increasing interest for the 
fabrication of biomaterials. The advantage of electrospun scaffolds is that they exhibit 
morphological and size similarities to native extracellular matrix, with the potential to 
increase bioactivity through the incorporation of bioactive factors. The application of 
electrospinning has great potential to promote wound healing and skin regeneration through 
development of granulation tissue-mimetic scaffolds, which is the focus of this chapter [1]. 
However, with respect to growth-factor delivery, suitable release systems must be 
developed to overcome issues associated with incorporated bioactive factors released into 
a proteolytic in vivo environment where they are rapidly degraded [2-4].  Emulsion 
electrospraying can be used to fabricate core-shell microspheres with an outer polymer 
shell and inner colloid core. The polymer shell protects internalized bioactive factors that 
diffuse through the porous shell to provide sustained release of the factor temporally. 
Poly(lactic-co glycolic acid) (PLGA) is a biocompatible, biodegradable copolymer that has 
been used extensively in the development of electrosprayed core-shell microspheres for 
targeted drug delivery. The physicochemical properties of PLGA are tunable based on its 
chemical composition [2, 5]. In previous work, POSTN/CCN2 scaffolds rescued delayed 
healing and supported vascular growth in db/db mice. However, a full recovery of wild-
type wound-closure rates did not occur, and the vascular growth was composed of 
incomplete tubule formation and an immature vascular bed (Hamilton lab, In Review, J 
Tissue Eng). Therefore, although these results are promising, stabilization of developing 
vasculature could be improved. One candidate factor is fibroblast growth factor 9 (FGF9), 
which has been shown to promote mural cell layering around neovasculature and stimulate 
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neointimal smooth muscle cell (SMC) proliferation to improve vascular stability, 
vasoreactivity, and reduce tissue hypoxia in murine renal tumours [6-8].  
The aim of this study was to design and validate a novel electrohydrodynamic scaffold 
combining electrospun gelatin POSTN/CCN2 nanofibers with electrosprayed PLGA/FGF9 
microspheres. It is hypothesized that addition of encapsulated FGF9 core-shell 
microspheres (FGF9 microspheres) to the POSTN/CCN2 scaffold will protect and sustain 
the release of FGF9. Released FGF9 will recruit mural cell populations to support the 
development of neovasculature forming in response to POSTN/CCN2. Enhanced vascular 
stability in response to released FGF9 will enhance oxygen and nutrient supply to promote 
regeneration and wound closure. The effect of FGF9 on cell populations involved in wound 
healing was also investigated.   
3.2 – Materials and Methods 
3.2.1 - In Vitro Effect of FGF9 on Cell Populations Involved in Wound Healing 
3.2.1.1 – Isolation and Cell Culture of Primary Dermal Fibroblasts & NIH 3T3 Murine 
Embryonic Fibroblasts 
All procedures involving human tissue were approved by the University of Western Ontario 
Review Board for Health Sciences Research Involving Human Subjects and the Lawson 
Health Research Institute. All studies were performed in accordance with the Declaration 
of Helsinki. Written informed consent was received from participants prior to inclusion in 
the study. Healthy skin was isolated following lower extremity amputations and was 
immediately transferred to DMEM supplemented with 10% fetal bovine serum (FBS) and 
3% antimycotic-antibiotic (AA; Gibco). Hair was removed, and skin was divided into small 
sections with a scalpel before plating on cell culture plastic with DMEM (10% FBS; 3% 
AA). Skin was incubated at 37⁰C, 5% CO2 in a CO2 incubator (Sanyo Scientific) to allow 
fibroblasts to migrate and adhere to the culture surface. Primary dermal fibroblasts were 
frozen in liquid nitrogen at 80% confluence. NIH 3T3 murine embryonic fibroblasts and 
primary human dermal fibroblasts (HDFs) were cultured to American Type Culture 
Collection standard protocols. 
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HDFs and murine embryonic NIH 3T3 cells were cultured for two to three passages before 
use. Frozen cells were thawed and plated onto cell culture plastic with 10 mL DMEM [10% 
FBS; 1% AA, high serum media (HSM)] and incubated at 37⁰C with media changes every 
three days. During passaging and before experimental use, the cells were trypsinized 
(Trypsin-EDTA 0.5%; Gibco), counted with a Coulter Counter, and re-seeded.  
3.2.1.2 - Scratch Assay 
The migratory effect of FGF9 on HDFs was investigated using scratch assays. Primary 
HDFs from three different cell lines (M55H, F64H, M60H; N=3) were seeded in HSM at 
a concentration of 1.0x106 cells per well of a six-well plate and allowed to adhere during 
overnight incubation at 37⁰C. The following day, cells were incubated for two hours at 37⁰C 
with SFM supplemented with 10 µg/mL mitomycin-c (Sigma-Aldrich) to inhibit 
proliferation. After two PBS rinses, three parallel scratches were created with the end of a 
P10 pipet tip and cellular debris was washed away with another two PBS rinses. Media was 
changed with DMEM [2% FBS; 1% AA, low serum media (LSM)] ± 10 ng/mL FGF9 (Bio-
Techne) and the six-well plates were positioned on the stage of an Axio Observer Z.1 
inverted microscope. A temperature- and CO2-controlled incubation chamber maintained 
appropriate conditions for cell survival (37⁰C, 5% CO2). Phase-contrast images of 
migrating cells were captured in 20-minute intervals for 45 hours. ImageJ software was 
used to measure scratch area for percent scratch closure calculations at 3-, 6-, 9-, and 12-
hour timepoints, at which time the scratches were nearly closed. Each experiment was 
repeated five times (n=5), with a single replicate per cell line, per condition.   
3.2.1.3 - Chemotaxis Assay 
The chemotactic effect of FGF9 on HDFs (three primary HDF cell lines - M55H, F64H, 
M60H; N=3) and NIH3T3 cells was investigated using the Cultrex® Cell Migration Assay 
kit (Trevigen). Cells were cultured to 80% confluence and serum starved in DMEM [0% 
FBS; 1% AA, serum free media (SFM)] for 24 hours. After the 24-hour starvation, HDFs 
were seeded in quadruplicate (n=4) at 2.5 x 104 cells in 50 µL SFM and one NIH3T3 murine 
embryonic fibroblast cell line (N=1) was seeded in nonuplicate (n=9) at 5.0 x 104 cells in 
50 µL SFM per well of the 96 well chemotaxis migration plate. 150 µL of experimental 
media (SFM, HSM, or SFM + 1, 10, or 100 ng/mL FGF9) was added to the bottom culture 
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chamber. Cells were incubated and allowed to migrate through the 8 µm2 porous surface at 
37⁰C for four hours. Following incubation, media from top and bottom chambers was 
aspirated and both the insert and culture chambers were washed with PBS. 100-µL calcein-
AM dye in cell dissociation solution (1:833.3 v/v) was added to a black assay plate and the 
cell migration plate was assembled and allowed to incubate at 37⁰C for one hour. 
Fluorescence measurement was made by a fluorescence plate reader at a 485 nm excitation 
wavelength and a 520 nm emission wavelength. RFU was converted to cell number using 
standard curves (Appendix H/I) to determine migrated cell number.  
Standard curve measurement occurred during the four-hour experimental incubation. Cells 
were recounted, resuspended in cell detachment solution and 50 µL of 5 x 105 cells/mL 
NIH3T3 or 274.5 x 103 cells/mL HDF cell solution was added in duplicate to a Greiner 96 
well tissue-culture flat-bottom black plate. Cell solutions were serial diluted (0.5 dilution 
factor) and 50 µL was added in duplicate to an additional 10 wells. Two negative control 
wells were used with 50 µL cell dissociation solution and no cells. 50 µL cell dissociation 
solution and Calcein-AM dye (1:416.7 v/v) was added to each well and incubated at 37⁰C 
for 1 hour. Fluorescence measurement was made by a fluorescence plate reader at a 485 
nm excitation wavelength and a 520 nm emission wavelength.  
3.2.1.4 - Proliferation Assay 
The pro-proliferative effect of FGF9 on HDFs (three primary HDF cell lines - M55H, 
F64H, M60H; N=3) and NIH3T3 murine embryonic fibroblasts was investigated using the 
CyQUANT® proliferation assay kit (Molecular Probes). Cells were grown to 80% 
confluence before seeding in quadruplicate (n=4) at a density of 500 cells/well in a 96 well 
transparent flat bottom microplate. HDFs were incubated for 24 hours in 150 µL LSM 
followed by a 24-hour incubation in SFM at 37⁰C. After the 24-hour starvation period, the 
serum-free media was replaced with 150 µL treatment media: LSM/HSM ± 1 ng/mL; ± 10 
ng/mL; ± 100 ng/mL FGF9. HDFs were cultured in treatment media for 1, 3, 5, or 7 days 
at 37⁰C. Half-media changes (75 µL) were performed every two days, between 
experimental timepoints. On days 1, 3, 5, and 7, the experimental wells were rinsed twice 
with PBS and the 96 well plates were frozen at -80⁰C. Fluorescent analysis was completed 
after the day seven experimental endpoint.  
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CyQUANT® reagents and experimental plates were warmed to room temperature and were 
analyzed one at a time for consistency. Working buffer (225 µL cell-lysis buffer diluted 
20-fold and CyQUANT® GR dye diluted 400-fold, both in distilled water) was added to 
each well of the 96 well experimental plate and incubated for five minutes at room 
temperature, protected from light. 200 µL fluorescent working buffer was transferred to a 
Greiner 96 well tissue-culture flat black plate after the five-minute incubation and 
fluorescence was measured by a fluorescence plate reader at a 480 nm excitation 
wavelength and a 520 nm emission wavelength. RFU was converted to cell number using 
a standard curve (Appendix J).  
The standard curve was created from a cell pellet (5.0 x 105 cells) frozen on the first day of 
the experiment. The cell pellet was thawed and serially diluted (x10) in working buffer 
(dilution factor 0.67). After, 200 µL (2.5 x 105 cells/mL from 2 mL) was added in duplicate 
to a Greiner 96 well tissue culture flat black plate. Two negative control wells with no cells 
in the working buffer were included. Cells were incubated in working buffer for five 
minutes before fluorescence measurement. Fluorescence intensity was measured with a 
fluorescence plate reader at a 480 nm excitation wavelength and a 520nm emission 
wavelength.  
3.2.2 – Scaffold Fabrication, Design, and Validation 
3.2.2.1 Nanofiber Electrospinning 
Refer to section 2.2.2 for a description of the electrospinning protocol. For fiber diameter 
measurements, nanofibers were electrospun for five minutes and one 8 mm2 circular piece 
of scaffold was taken with a biopsy punch (Integra Multex) for each of the three trials per 
parameter combination (Table 1). Nanofiber morphological characterization was necessary 
due to the installation of a new electrospinning system (Figure 3.1).  
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Figure 3. 1 – Electrohydrodynamic Setup. The new electrohydrodynamic system was 
installed prior to the experimentation presented in Chapter 3. The high-voltage power 
supplies and syringe pumps were isolated from the main electrohydrodynamic fabrication 
chamber with plexiglass. A) Overview of the electrohydrodynamic system capable of 
simultaneous electrospinning and electrospraying. Individual components are labelled. B) 
Magnified view of the electrohydrodynamic fabrication chamber showing the 
electrospinning needle (B1) and the coaxial electrospraying needle (B2). 
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3.2.2.2 Scanning Electron Microscopy 
An 8 mm2 circular sample from each scaffold was taken using a biopsy punch and mounted 
on a 15 mm aluminum stub with adhesive carbon disc. Samples were osmium coated (OPC-
80T, Filgen) and imaged using a LEO 1530 scanning electron microscope (Carl Zeiss) at 
an accelerating voltage of 3 kV. Five different images were taken at 7500x magnification 
for fiber diameter measurements and one descriptive image was taken at 1500x 
magnification to visualize overall scaffold morphology. 
3.2.2.3 - Assessment of Fiber Morphology 
Three separate trials were conducted per parameter combination outlined in Table 1. 30 
fibers were measured from each of 5 SEM images per trial (n=150) using ImageJ software. 
Final analysis of fiber morphology combined the data collected for the 9 parameter 
combinations (N=9) with the variable in question held constant (e.g., rows 1-9 in Table 1 
for the 0.3 mL/h flow rate – Figure 3.6A). Therefore, 4050 individual fibers were measured 
per parameter analysed in Figure 3.6 (n=4050).    
The effect of polymer solution concentration (19 wt%, 21 wt% and 23 wt% gelatin solution) 
on scaffold morphology was also investigated, following the procedures described above, 
with the following exception: data analysis included the three separate trials (N=3) using 
the refined electrospinning parameters at each gelatin concentration tested. 30 fibers were 
measured for each of the 5 SEM images acquired per trial (n=150). 
Additional information recorded during electrospinning, imaging and fiber diameter 
measurements included: fiber dispersion on the collection surface (measured distance 
between dense edges of deposited fibers), fiber density on the collecting surface (relative 
scale of 1-3, low to high), percentage total structures resembling fibers versus non-fibrous 
structures (webbing/ribbons), relative fiber diameter variation (minimal, slight, moderate, 
high), and general notes involving observed trends and unusual scaffold appearance. 
Inclusion criteria for refining the scaffold parameters included: fiber percentage ≥99%, 
fiber distribution on the collecting surface ≥5 cm, fiber density on the collecting surface of 
3 (on a subjective scale of 1-3 indicating low to high fiber density), and fiber diameter 
distribution from scanning electron microscopy (SEM) images of minimal to slight. After 
exclusion of parameter combinations based on these criteria, the resultant parameters were 
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individually scored (flow rate, voltage and collector distance) and the parameters with the 
highest score were chosen for fabrication of the refined scaffold.  
Table 1 – Electrospinning Parameter Combinations. 
Gelatin 
Concentration 
(wt%) 
 
Flow Rate (mL/h) 
 
Voltage (kV) 
Collector Distance 
(cm) 
21 0.3 13 8 
21 0.3 13 10 
21 0.3 13 12 
21 0.3 15 8 
21 0.3 15 10 
21 0.3 15 12 
21 0.3 17 8 
21 0.3 17 10 
21 0.3 17 12 
21 0.5 13 8 
21 0.5 13 10 
21 0.5 13 12 
21 0.5 15 8 
21 0.5 15 10 
21 0.5 15 12 
21 0.5 17 8 
21 0.5 17 10 
21 0.5 17 12 
21 0.7 13 8 
21 0.7 13 10 
21 0.7 13 12 
21 0.7 15 8 
21 0.7 15 10 
21 0.7 15 12 
21 0.7 17 8 
21 0.7 17 10 
21 0.7 17 12 
19 0.5 17 8 
23 0.5 17 8 
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3.2.2.4 – Microsphere Coaxial Electrospraying 
Figure 1.2 outlines the process of dual-stream electrospinning and coaxial electrospraying 
of nanofibrous scaffolds containing core-shell microspheres as was the original intent for 
fabrication of the novel electrohydrodynamic scaffold incorporating coaxial microspheres 
containing FGF9. The shell solution, consisting of 50:50 poly(DL-lactide-co-glycolide) 
with carboxylate end group (nominal, PLGA) (LACTEL Absorbable Polymers), was 
dissolved in dichloromethane (methylene chloride/CH2Cl2, Sigma-Aldrich) and loaded into 
a glass 1 cc syringe. Overnight agitation at room temperature was necessary for complete 
dissolution of PLGA in dichloromethane. For morphological assessment, the core solution 
consisted of 0.5 wt% heparin sodium salt (Alfa Aesar), 1µg/mL BSA, and 0.5 wt% Type B 
Gelatin from bovine skin dissolved in PBS. Heparin was included to stabilize and protect 
FGF9 from denaturation, BSA to mimic the effects of FGF9 while limiting cost, and gelatin 
to increase solution viscosity to improve processability [9]. Microspheres electrosprayed 
for morphological assessment will be referred to as PLGA/BSA microspheres. Gelatin 
dissolution in PBS required 37⁰C overnight incubation. The core solution was loaded into 
a plastic 1 cc syringe. Both core and shell solutions were fed into the inner and outer needles 
of a pre-built type-304 stainless steel coaxial needle (Figure 3.2, 100-10-COAXIAL-2822, 
ramé-hart instrument co.) by separate syringe pumps, respectively. The coaxial needle was 
connected to a high-voltage DC power supply producing an electric potential between the 
tip of the needle and the grounded stainless-steel mandrel, rotating constantly at 100 RPM 
(Figure 3.1). A piece of aluminum foil was secured to the rotating mandrel with electrical 
tape to collect the electrosprayed microspheres. 
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Figure 3. 2 – Coaxial Needle dimensions. IID = inside needle inner diameter, IOD = inside 
needle outer diameter, OID = outside needle inner diameter, OOD = outside needle outer 
diameter. This figure is reproduced from: http://www.ramehart.com/pdf/coaxial_ 
prebuilt.pdf. 
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3.2.2.5 – Assessment of Microsphere Morphology 
Morphological characterization of BSA microspheres followed the parameter combinations 
outlined in Table 2. SEM imaging was performed as described in section 3.2.2.2. Three 
trials per parameter combination (N=3) were electrosprayed and five images were acquired 
at 1000x magnification for microsphere diameter measurements and one representational 
image was acquired at 400x magnification. ImageJ software was used to measure the 
diameter of 10 microspheres from each SEM image (n=50). Additional information 
recorded during electrospraying and imaging included: power supply micro-amperes, 
alternative material ejected onto tinfoil (e.g. droplets), material dispersion on the collecting 
surface (measured distance between dense edges of deposited material), material density 
on the collecting surface (relative scale 1-3, low to high), deposited microsphere density 
(relative scale 1-3, low to high), sphere to fiber ratio (relative scale 1-3, low to high), sphere 
diameter variability (relative scale 1-3, low to high), collapsed spheres (relative scale 1-3, 
low to high), large droplets or blotches on the collecting surface (relative scale 1-3, low to 
high), and general notes. 
Table 2 – Electrospraying Parameter Combinations. 
PLGA 
Concentration 
(wt%) 
OUTER 
Flow Rate 
(mL/h) 
INNER 
Flow Rate 
(mL/h) 
 
Voltage (kV) 
Collector 
Distance (cm) 
5 1.0 0.1 15 16 
5 1.0 0.1 15 18 
5 1.0 0.1 15 20 
5 1.0 0.1 17.5 20 
5 1.0 0.1 20 20 
5 1.0 0.1 22.5 20 
5 1.0 0.1 15 20 
5 1.0 0.2 15 20 
5 1.0 0.3 15 20 
5 0.3 0.1 15 20 
5 0.65 0.1 15 20 
5 1.0 0.1 15 20 
4 1.0 0.1 15 20 
5 1.0 0.1 15 20 
6 1.0 0.1 15 20 
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3.2.2.6 - Microsphere Core-Shell Morphology 
Rhodamine B Base (20 µg/mL, Sigma-Aldrich) was dissolved in the core solution 
immediately prior to electrospraying according to section 3.2.2.4. Microspheres were 
electrosprayed with 1.0 mL/h outer solution flow rate, 0.1mL/h inner solution flow rate, 5 
wt% PLGA concentration, 17.5 kV voltage, and 18 cm needle to collector distance, directly 
onto a stationary glass slide attached to the collecting mandrel with electrical tape. Post-
electrospraying sample preparation involved mounting and sealing coverslips with Immu-
mount and CoverGrip Coverslip Sealant, respectively. Core and shell structures were 
imaged with a Zeiss LSM 5 Duo Vario Confocal Microscope (Biotron Integrated 
Microscopy Facility, Western University). Rhodamine B Base (core structure) was 
visualized with a helium neon 543 laser and shell structures were visualized with 
reflectance confocal microscopy (Figure 3.12). 
3.2.3 – FGF9 Release Kinetics & Assessment of Biological Activity 
3.2.3.1 – Concurrent Release Kinetics Study & HDF Proliferation Assay 
To determine core-shell microsphere release kinetics and remaining biological activity of 
released rhFGF9 (bio-techne), a concurrent release kinetics study and HDF proliferation 
assay was developed. Initially, microspheres were electrosprayed for one hour, using four 
sets of conditions. PLGA concentration of the shell solution (5 wt%), gelatin concentration 
of the core solution (0.5 wt%), inner flow rate (0.1 mL/h), outer flow rate (1.0 mL/h), and 
collector distance (14 cm) were held constant. The protein content of the inner solution was 
varied between 100µg/mL BSA, 10 µg/mL FGF9, or 100 µg/mL FGF9. Applied voltage 
was held constant during the first three conditions but increased to 25 kV for fabrication of 
the final microsphere treatment (using 100 µg/mL FGF9).  
Tinfoil was weighed before and after electrospraying to normalize FGF9 release based on 
deposited microsphere mass. Tinfoil was attached to the collecting mandrel for microsphere 
collection and stored at -80⁰C after weighing. The microspheres were UV sterilized for two 
hours before starting the release kinetics study. After the sterilization period, the three 
sections of tinfoil per condition were curled and placed into individual 2 mL microtubes 
with microspheres facing inwards and 2 mL DMEM (10% heat-shock inactivated FBS; 3% 
AA) was added as release medium (FGF9 release media). Microspheres were submerged 
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in release media in triplicate per condition (N=3). Fresh release media supplemented with 
100 ng/mL FGF9 was included as a positive control condition. The release study was 
conducted at 37⁰C. Fresh release media was added 1, 3, 5, 7, and 14 days after the 
experimental start-point. At each timepoint, 300 µL release media was collected and 
combined from each conditional replicate and frozen at -80⁰C. A human FGF9 enzyme 
linked immunosorbent assay (ELISA) Kit (Thermo Fisher) was used to quantify cumulative 
FGF9 release over the 14-day study period using the 900 µL frozen release media. The 
remaining ~1.7 mL was combined per condition and stored at 4⁰C (separated by timepoint) 
for use in the concurrent HDF proliferation study.  
3.2.3.1.1 – Human FGF9 ELISA 
FGF9 release kinetics from the electrosprayed microspheres were measured using a human 
FGF9 ELISA Kit. Reagents and samples were prepared according to the assay protocol 
(EHFGF9, Human FGF-9 ELISA Kit Manual). All reagents and samples were brought to 
room temperature before use. 100 µL of each of the following solutions was added to the 
wells of an anti-human FGF9 precoated 96 well strip plate which were washed three times 
with 1x wash buffer between each of the following incubations. Each solution was 
incubated with gentle rocking at room temperature in the order and period indicated; 
standards and samples were run in duplicate (n=2) for 2.5 hours, 1x biotinylated antibody 
for 1 hour, streptavidin-HRP solution for 45 minutes, and TMB substrate for 30 minutes 
protected from light. Absorbance was measured using a fluorescent plate reader at a 
wavelength of 450 nm and 550 nm. Absorbance values measured at 550 nm were subtracted 
from values measured at 450 nm to correct for optical imperfections in the microplate. The 
standard curve is shown in Appendix L. 
3.2.3.1.2 – HDF Proliferation Assay 
Three primary HDF cell lines (M55H, F64H, M60H; N=3) were cultured to 80% 
confluence and seeded in quadruplicate (n=4) at a density of 500 cells/well in a 96 well 
transparent flat bottom microplate in 150 µL LSM for 24 hours at 37⁰C. A 5.0x105 cell 
pellet was frozen at -80⁰C for use as a standard curve during cell number quantification. 
After 24 hours, the growth media was changed to 150 µL SFM and the cells were incubated 
for an additional 24 hours at 37⁰C. The following day, coinciding with the day one 
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collection of release medium from the microsphere release kinetics study, HDF growth 
medium was changed to 150 µL release medium. Experimental plates were rinsed with 
PBS and stored at -80⁰C 1, 4, and 7 days after the addition of treatment media. At days 1, 
3, and 5, 150 µL fresh release media (collected from the release kinetics study on the same 
day) was added to the HDF proliferation experimental wells. After the study endpoint, HDF 
proliferation was assessed using the CyQUANT® proliferation assay kit according to the 
protocol outlined in section 3.2.1.4, with the exceptions mentioned above. The standard 
curve is shown in Appendix K. 
3.2.3.2 – EdU S-Phase DNA Incorporation  
To further confirm FGF9 activity, EdU incorporation during S-phase DNA replication in 
HDFs treated with FGF9 release media was measured using the Click-iT™ EdU Alexa 
Fluor™ 488 Imaging Kit (Thermo Fisher). Microsphere electrospraying and FGF9 release 
followed the protocol outlined in section 3.2.3.1, with the following exceptions. Conditions 
remained the same as in section 3.2.3.1 besides the 10 µg/mL FGF9 trial, which was 
removed. Microspheres were incubated for two days at 37⁰C in DMEM (2% FBS; 3% AA) 
release medium. 
HDF culture also remained the same as in the HDF proliferation assay in section 3.2.3.1.2 
(N=3), with the following exceptions: 3x103 cells were seeded in quadruplicate (n=4) per 
well of a 96 well plate, no standard curve was required for the EdU incorporation assay, 
and 200 µL release media was added to experimental wells at the beginning of the study 
(after the 2-day incubation period). HDFs were cultured in treatment media for 24 and 48 
hours. 
Reagents for the EdU incorporation assay were prepared according to the assay protocol 
(C10337, Click-iT® EdU Imaging Kit Manual). One-half experimental media (100 µL) 
was changed with SFM supplemented with 20 mM EdU to expose the cells to a final 
concentration of 10 mM EdU, incubated at 37⁰C for two hours. After the EdU incubation, 
growth media was removed, and the HDFs were fixed with 100 µL 4% paraformaldehyde 
(Sigma-Aldrich) in deionized H2O for five minutes at room temperature, followed by two 
1% BSA rinses. HDFs were incubated with 100 µL 0.1% Triton X-100 (Caledon) for 15 
minutes at room temperature for cell membrane permeabilization. Wells were washed twice 
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with 1% BSA and 100 µL Click-iT® Reaction Cocktail (C10337, Click-iT® EdU Imaging 
Kit Manual) containing azide conjugated AlexaFluor 488 fluorescent dye was added and 
incubated for 30 minutes at room temperature, protected from light. The wells were washed 
twice with 1% BSA and HDFs were counterstained with Hoechst 33342 in PBS (1:1000) 
for 30 minutes at room temperature, protected from light. Finally, the wells were washed 
twice with PBS and the cells were stored at 4⁰C in 200 µL PBS, wrapped in parafilm. 
Fluorescent images were captured on an Axio Observer Z.1 inverted microscope. ImageJ 
software was used to quantify EdU incorporation as the proportion of cells fluorescently 
labelled with AlexaFluor 488 versus the total number of cells counterstained with Hoechst 
33342.   
3.2.4 – 7-Day Porcine Study 
3.2.4.1 – Porcine Study 
Refer to section 2.2.1, with the following exceptions: three pigs were included in the study 
(Pig 7, 8, and 9 - continuously labelled from the previous 28-day porcine study; N=3), and 
treatment groups were comprised of: 1) an empty wound, 2) 10 µg/mL BSA scaffold, 3) 10 
µg/mL POSTN/CCN2 scaffold, 4) 10 µg/mL BSA + 9 µg/mL FGF9 microsphere scaffold 
(BSA/FGF9 scaffold), and 5) 10 µg/mL POSTN/CCN2 + 9 µg/mL FGF9 microsphere 
scaffold (POSTN/CCN2/FGF9 scaffold). Euthanasia and tissue isolation occurred at day 7 
post-wounding.  
3.2.4.2 – Scaffold Preparation  
Scaffold preparation followed the protocol in section 2.2.2, with the following exceptions: 
no galectin 3 treatment group was included, and a flow rate of 0.5 mL/h was used. Scaffolds 
were cut into circles, 2 cm in diameter, with a custom biopsy punch.  
Following the 0.1 M glycine quench and triple PBS rinses, BSA/FGF9 and 
POSTN/CCN2/FGF9 scaffolds were reattached to the rotating mandrel and FGF9 
microspheres were electrosprayed on the top surface as described in section 3.2.2.4. 
However, the core solution consisted of 9 µg/mL FGF9 instead of 1 µg/mL BSA. Scaffolds 
were UV sterilized (after being cut into circles 2 cm in diameter) for 30 minutes per side of 
each scaffold. BSA/FGF9 and POSTN/CCN2/FGF9 scaffolds were stored dry at 4⁰C. This 
adapted protocol was necessary to avoid hydrolytic reaction and breakdown of the PLGA 
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microsphere shell with aqueous 0.1 M glycine and PBS, before cutaneous insertion into the 
porcine wounds.  
3.2.4.3 – Porcine Cutaneous Wound-Healing Outcomes 
3.2.4.3.1 – Wound Closure Kinetics 
Refer to section 2.2.3.1, with the following exception: wound images were acquired on 
days 0, 3 and 7, wound closure kinetic measurements included one image (n=1) per 
condition, per pig (N=3), and wound diameter measurements included two Masson’s 
Trichome images (n=2) per pig. 
3.2.4.3.2 – Angiogenesis 
Refer to section 2.2.3.2. Two CD146+ immunofluorescent image (n=2) per condition, per 
pig (N=3) were analysed. No primary antibody negative control CD146/CD105 
immunofluorescent images from the day 7 porcine study are shown in Appendix R.  
3.2.4.3.3 – Collagen Deposition 
Refer to section 2.2.3.3, with the following exceptions: 400 µL and 1200 µL 6-M HCL was 
used for tissue degradation, and 4 µL and 2 µL degraded tissue supernatant was transferred 
to the 96 well plate for drying, for wounded and unwounded samples, respectively. A ~10 
mg sample was taken from each tissue sample per condition, per pig (N=3) and measured 
in duplicate (n=2). 
3.3 – Results 
3.3.1 – In Vitro Effect of FGF9 on Cell Populations involved in Wound Healing  
3.3.1.1 – Effect of FGF9 on HDF Migration  
A preliminary set of experiments were conducted to assess the effect of FGF9 on HDFs, 
which has not been previously described. A series of scratch assays were conducted to 
determine the effect of FGF9 on HDF migration. LSM supplemented with 10 ng/mL FGF9 
(LSM + 10 ng/mL FGF9) did not affect the migration rate of HDFs (Figure 3.3B). 
Representative phase contrast images at 0, 9, and 18 hours post-scratching are shown in 
Figure 3.3A. Only HSM significantly increased HDF chemotaxis. No differences were 
observed between FGF9 treatments and SFM.   
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3.3.1.2 – Effect of FGF9 on HDF Chemotaxis 
A set of modified Boyden Chamber assays were conducted to determine the effect of FGF9 
on HDF and NIH 3T3 chemotaxis. SFM + 100ng/mL FGF9 significantly increased HDF 
chemotaxis compared to SFM without FGF9 (p<0.05). Chemotaxis of HDFs treated with 
HSM significantly increased compared to other conditions except SFM + 100 ng/mL FGF9 
(Figure 3.4A). FGF9 had no effect on NIH 3T3 chemotaxis (Figure 3.4B).   
3.3.1.3 – Effect of FGF9 on HDF Proliferation  
To determine the effect of FGF9 on HDF proliferation, proliferation rate of HDFs exposed 
to LSM or HSM ± 1, 10, or 100 ng/mL FGF9 was assessed. At day 7, LSM + 10 ng/mL 
and +100 ng/mL FGF9 significantly increased HDF proliferation compared to LSM 
without FGF9 (Figure 3.5A). Between FGF9 treatment conditions, 10 ng/mL FGF9 
significantly increased HDF proliferation compared to 1 ng/mL and 100 ng/mL FGF9. 
HSM enhanced the proliferative effect of FGF9 observed in the proliferation assay 
conducted with LSM (Figure 3.5B). At day 5, HSM + 10 ng/mL and + 100 ng/mL FGF9 
significantly increased HDF proliferation compared to negative controls. All FGF9 
conditions significantly increased HDF proliferation at day 7 with a positive linear 
relationship as FGF9 concentration increased. HSM + 10 ng/mL and HSM + 100ng/mL 
significantly increased HDF proliferation compared to HSM + 1 ng/mL FGF9 at day 7. 
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Figure 3. 3 – Effect of FGF9 on HDF migration. Human dermal fibroblasts were seeded 
1x106 cells per well of a 6 well plate and allowed to adhere overnight. After overnight 
incubation, three parallel scratches were created with a P10 pipet tip in the confluent cell 
layer. Growth media was changed to LSM ± 10 ng/mL FGF9 and time lapse microscopy 
captured images sequentially every 20 minutes for 48 hours. A) Representative images of 
scratch wound closure for one cell line are shown at three timepoints. Scale bar = 100 µm. 
B) Migration was measured as average cumulative area closed. No differences at any 
timepoint were observed. N=3, n=5, t-test, p<0.05. Data presented as mean ± SD.  
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Figure 3. 4 – Effect of FGF9 on HDF chemotaxis. The Cultrex® Cell Migration Assay 
Kit was used to investigate the chemotactic effect of FGF9 on HDFs (three primary HDF 
cell lines - M55H, F64H, M60H) and NIH3T3 murine embryonic fibroblasts using 
modified Boyden Chamber assays. Experimental media included: SFM, HSM, or SFM + 1 
ng/mL, + 10 ng/mL or + 100 ng/mL FGF9. Cells migrated at 37⁰C through an 8 µm2 porous 
surface for 4 hours before migrated cell number was quantified with Calcein-AM 
fluorometric staining. A) HDF chemotaxis significantly increased in response to HSM 
versus SFM, SFM + 1 ng/mL FGF9 and + 10 ng/mL FGF9. HDF chemotaxis significantly 
increased in response to DMEM (0% FBS) + 100 ng/mL FGF9 compared to SFM. N=3, 
n=4, two-way ANOVA, Tukey post-test for multiple comparisons, * = p < 0.05, ** = p < 
0.01, **** = p < 0.0001. B) Chemotactic migration of NIH3T3 cells significantly increased 
in response to HSM versus all other treatments. No differences were observed between 
SFM and any FGF9 treatment. N=1, n=9, one-way ANOVA, Tukey post-test for multiple 
comparisons, **** = p < 0.0001. Data presented as mean ± SD. 
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Figure 3. 5 – Effect of FGF9 on HDF proliferation. Human dermal fibroblasts (three 
primary HDF cell lines - M55H, F64H, M60H) were cultured on tissue culture plastic for 
7 days with LSM or HSM ± 1 ng/mL, ± 10 ng/mL or ± 100 ng/mL FGF9. At study endpoint, 
cells from each timepoint were stained with CyQUANT® GR dye and fluorescent intensity 
was converted to cell number at days 1, 4, and 7 using a standard curve. A) Cell number 
significantly increased at day 7 in response to LSM + 10 ng/mL and + 100 ng/mL compared 
to LSM. Media supplemented with 10 ng/mL FGF9 increased HDF proliferation 
significantly more than all other treatment groups. No differences were observed on days 
1, 3, or 5. N=3, n=4, two-way ANOVA, Tukey post-test for multiple comparisons, * = p < 
0.05, **** = p < 0.0001. B) HSM + 10 ng/mL FGF9 and + 100 ng/mL FGF9 significantly 
increased HDF proliferation compared to controls at day 5. Proliferation increased in 
response to FGF9 at all three concentrations at day 7. Proliferation was significantly greater 
for cells in media supplemented with 10 ng/mL FGF9 and 100 ng/mL FGF9 versus those 
in media supplemented with 1 ng/mL FGF9 at day 7. No differences were observed on days 
1 or 3. N=3, n=4, two-way ANOVA, Tukey post-test for multiple comparisons, * = p < 
0.05, **** = p < 0.0001. Data presented as mean ± SD. 
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3.3.2 – Scaffold Fabrication, Design, and Validation 
3.3.2.1 – Assessment of Fiber Diameter 
To determine the effect of varying electrospinning parameters on gelatin fibre morphology, 
diameter of nanofibers electrospun using 27 parameter combinations (Table 1) were 
quantified. Increasing solution flow rate and applied voltage significantly decreased fiber 
diameter (Figure 3.6A/B, respectively). Increasing distance above 8 cm significantly 
increased fiber diameter however, no difference in fiber diameter was observed between 
10 cm and 12 cm (Figure 3.6C).  
To determine the effect of gelatin concentration on scaffold morphology, diameter of 
nanofibers electrospun using 19 wt%, 21 wt%, and 23 wt% gelatin solutions were 
quantified. Gelatin concentration had no substantial visible effect on scaffold morphology 
(Figure 3.7A-F). However, quantification of fiber diameter showed that increasing gelatin 
concentration significantly increased fiber diameter (Figure 3.7J). Frequency and Gaussian 
distribution plots, mean, and standard deviation of fiber diameters are presented in Figures 
3.7G-I.  
A set of refined electrospinning parameters were chosen based on data recorded during the 
fiber diameter quantification process. The final optimized parameters produced a 
nanofibrous scaffold with the lowest average fiber diameter and second lowest standard 
deviation to produce ECM biomimetic scaffolds with highly homogeneous fiber 
morphology (Figure 3.8).   
3.3.2.2 – Assessment of Microsphere Diameter 
To determine the effect of varied electrospraying parameters on PLGA/BSA microsphere 
morphology, diameter of spheres electrosprayed using 15 parameter combinations (Table 
2) were quantified. Significant or observable trends did not exist for applied voltages, 
PLGA concentrations, inner flow rates, or collector distances however, there were 
differences between individual parameters. An applied voltage of 20 kV produced spheres 
with significantly lower diameter than at 17.5 kV and 22.5 kV, and an applied voltage of 
22.5 kV produced spheres with significantly higher diameter than at 17.5 kV and 20 kV 
(Figure 3.9B). Sphere diameter significantly increased when electrosprayed with 6 wt % 
PLGA solution and 0.3 mL/h inner flow rate compared to 5 wt% and 0.2 mL/h, respectively 
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(Figure 3.9C/D). Despite these differences, no significant trends were observed except with 
variation of outer flow rate. Sphere diameter significantly increased when outer flow rate 
was raised above 0.3 mL/h (Figure 3.9A). No other differences were observed. 
Representative images of PLGA/BSA microspheres electrosprayed at the various 
parameter combinations are presented in Figure 3.10.  
To determine the effect of potential extraneous variable(s) on the outcome of 
electrosprayed BSA/PLGA microsphere morphology, a separate analysis was conducted 
based on trials with the highest and lowest sphere diameter variability. Representative 
images (Figure 3.11B/C) indicate the significant decrease in sphere diameter with increased 
diameter variability (Figure 3.11A). BSA/PLGA sphere diameter measurements follow a 
normal distribution in trials with monodisperse spheres compared to a right screwed 
distribution of trials with high diameter variability. The spread of diameter measurements 
is wider when variability is higher (0.55-19.42 µm versus 0.84-13.64 µm) (Figure 
3.11D/E). 
3.3.2.3 – Microsphere Core-Shell Morphology 
PLGA/BSA microsphere core and shell structures were visualized with immunofluorescent 
staining and confocal microscopy. Representative images of PLGA shell and protein core 
structures are independently presented in Figure 3.12A/B. Magnification of one 
representative sphere shows the distinction between core and shell structures and the 
localization of the fluorescently labelled protein solution within the core of the microsphere 
(Figure 3.12D). 
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Figure 3. 6 – Effect of flow rate, distance and voltage on electrospun fiber diameter. 
Fiber diameter was measured using ImageJ software and SEM images of scaffolds 
electrospun using the 27 parameter combinations outlined in Table 1. Concentration of 
gelatin solution was held constant at 21 wt%. A-C represent combined data of the nine 
parameter combinations at each flow rate, voltage and collector distance. A) Fiber diameter 
significantly decreased with increasing flow rate. B) Fiber diameter significantly decreased 
from 13 kV to 17 kV and significantly increased between 15 kV and 17 kV. C) Increasing 
collector distance significantly increased fiber diameter at each distance. The Y-axes have 
been adjusted to enhance visualization of the observed relationships.  N=9, n=4050, one-
way ANOVA, Tukey post-test for multiple comparisons, * = p < 0.05, ** = p < 0.01, **** 
= p < 0.0001. Data presented as mean ± SD. 
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Figure 3. 7 – Effect of varied gelatin solution concentration on fiber diameter. Fiber 
diameter measurements were calculated using ImageJ software and SEM images of 
scaffolds electrospun using three different gelatin concentrations (19 wt%, 21 wt% and 23 
wt%). Optimized parameters were held constant: 0.5 mL/h flow rate, 17 kV voltage, 8 cm 
collector distance. A-F) Representative images of scaffolds 7500x magnification (A-C 
scale bar = 1 µm) and 1500x magnification (D-F scale bar = 10 µm). G-I) Frequency and 
Gaussian distributions at each gelatin concentration showing percentage of fiber diameters 
within each bin range relative to the total number of measurements. N=3, n=150, bin size: 
G-I=20 nm. J) Fiber diameter significantly increased with increasing gelatin concentration. 
N=3, n=150, one-way ANOVA, Tukey post-test for multiple comparisons, **** = p < 
0.0001. Data presented as mean ± SD. 
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Figure 3. 8 – Refined scaffold morphology. Quantitative and qualitative information 
recorded during the electrospinning, imaging, and quantification of fiber diameter was used 
to make the final decision of an optimized scaffold parameter combination. The final 
optimized scaffold parameters were: 0.5 mL/h flow rate, 17 kV applied voltage and 8cm 
collector distance. This combination produced attractive results (regarding the quantitative 
and qualitative observations measured) in all categories of all three experimental trials, had 
the lowest average fiber diameter and second lowest standard deviation among all 
parameter combinations. A) Representative image of scaffolds fabricated using the 
optimized parameters (0.5 mL/h, 17 kV, 8 cm) and a 21 wt% gelatin solution. Scale bar = 
1 µm. B) Frequency and Gaussian distribution of fiber diameters electrospun with the 
optimized parameters. Percentage fibers within each bin range are shown relative to the 
total number of measurements. N=3, n=150, bin size=20 nm.  
 
 
 
 
 
 
124 
 
 
 
 
125 
 
 
 
 
 
 
 
 
 
 
Figure 3. 9 – Effect of electrospraying parameter variation on microsphere diameter. 
Microspheres were electosprayed using the conditions outlined in Table 2, with varied outer 
solution flow rate (0.3 mL/h, 0.65 mL/h, 1.0 mL/h), applied voltage (17.5 kV, 20 kV, 22.5 
kV), PLGA concentration of the outer solution (4 wt%, 5 wt%, 6 wt%), inner solution flow 
rate (0.1 mL/h, 0.2 mL/h, 0.3 mL/h), and distance from tip of the coaxial needle to 
collecting surface (16 cm, 18 cm, 20 cm). Concentration of gelatin in the inner solution was 
held constant at 0.5 wt%. 8 mm2 circular sections were osmium coated (OPC-80T, Filgen) 
for SEM imaging and ImageJ software was used to measure microsphere diameter in 
response to the varied experimental parameters. A) Microsphere diameter significantly 
increased with increasing outer flow rate. B-E) Differences existed between certain 
conditions for the remaining parameters however, no consistent trends were observed. N=3, 
n=50, one-way ANOVA, Tukey post-test for multiple comparisons, * = p < 0.05, ** = p < 
0.01, *** = p < 0.001, **** = p < 0.0001. Data presented as mean ± SD. 
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Figure 3. 10 – Representative images of microspheres electrosprayed at each 
parameter combination. Parameters not under investigation were held constant at: 1.0 
mL/h outer flow rate, 0.1 mL/h inner flow rate, 5 wt% PLGA concentration, 15 kV voltage, 
and 20 cm collector distance. Scale bar = 20 µm. 
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Figure 3. 11 – Potential confounding effect of extraneous variables on microsphere 
diameter measurements. A separate analysis was conducted to determine the effect of 
potential extraneous variables on the results presented in Figure 3.9. Within the three 
samples measured for each condition, trials with the highest and lowest microsphere 
diameter standard deviation where chosen for analysis, corresponding to “high” and “low” 
variability, respectively. A) Microsphere diameter significantly decreased when variability 
in microsphere diameter was high. 50 microspheres (n=50) were measured for each of the 
15 individual parameter combination trials included (N=15), Mann-Whitney test, **** = p 
< 0.0001. Data presented as mean ± SD. B-C) Representative SEM images of low and high 
variability trials. Scale bar = 5 µm. D-E) Frequency distributions of low and high variability 
microsphere diameter, and the Gaussian distribution of the low variability condition, 
showing percentage of microsphere diameters within each bin range relative to the total 
number of measurements. N=15, n=50, bin size = 1 µm. 
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Figure 3. 12 – Confocal imaging shows core-shell structure of electrosprayed 
microspheres. The core and shell structures of electrosprayed microspheres were 
visualized with a Zeiss LSM 5 Duo Vario Confocal Microscope. Microspheres were 
electrosprayed at 1.0 mL/h outer solution flow rate, 0.1 mL/h inner solution flow rate, 5 
wt% PLGA concentration, 17.5 kV voltage, and 18 cm needle to collector distance. A) 
Confocal reflectance microscopy was used to visualize microsphere shell structure. B) 
Rhodamine B Base (20 µg/mL) was dissolved in the inner solution and a helium neon 543 
laser was used to fluorescently visualize the microsphere core. C) Combined core-shell 
microspheres (A-C Scale bar = 20 µm). D) Magnified core-shell structure of an 
electrosprayed microsphere. Scale bar = 5 µm. 
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3.3.3 – FGF9 Release Kinetics & Assessment of Biological Activity 
3.3.3.1 – FGF9 Release Kinetics & Effect on HDF Proliferation 
To determine the release profile and bioactivity of FGF9 released from the microspheres, 
a solid-phase sandwich ELISA and concurrent HDF proliferation assay were conducted to 
assess release kinetics and biological activity of FGF9, respectively. Significantly more 
FGF9 was detected in the release media of microspheres electrosprayed at 17.5 kV and 25 
kV with an inner solution concentration of 100 µg/mL FGF9 than an inner solution 
concentration of 10 µg/mL FGF9, or negative control BSA microspheres. Microspheres 
electrosprayed with an applied voltage of 25 kV released significantly more FGF9 than 
microspheres electrosprayed at 17.5 kV (Figure 3.13A). However, media containing FGF9 
had no effect on HDF proliferation (Figure 3.13B).  
3.3.3.2 – Effect of Released FGF9 on HDF EdU S-Phase DNA Incorporation  
Due to the initial complete burst release of FGF9 from the microspheres, it was determined 
that cellular exposure to FGF9 would have been limited to the first day of the experiment 
before the first complete media change on day 2. Therefore, a 48-hour 5-ethynyl-2’-
deoxyuridine (EdU) S-phase incorporation assay was designed as a follow-up measure of 
HDF proliferation in response to FGF9 released for 2 days from PLGA microspheres. 
Proportion of HDF S-phase transition was determined by immunofluorescent staining of 
cellular nuclei labelled with Alexa Fluor 488 azide dye or counter-stained with Hoechst 
33342. No differences were observed between treatment groups at the 24-hour timepoint 
(Figure 3.14A). At 48 hours, FGF9 microspheres electrospun with 100 µg/mL FGF9 at 
17.5 kV and 25 kV released bioactive FGF9 which induced a significant proliferative 
response from the HDFs (Figure 3.14B). At 24 and 48 hours, positive control media 
supplemented with 100 ng/mL FGF9 significantly increased HDF EdU incorporation 
compared to all other conditions (Figure 3.14A/B). Immunofluorescent images revealed 
the positive relationship of FGF9 release media on HDF proliferation at 48 hours (Figure 
3.14C/D). EdU incorporation data are presented independently per cell line in Appendix O. 
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Figure 3. 13 – Release kinetics and biological activity of encapsulated rhFGF9. A) 
FGF9 released from the microspheres was measured with a solid-phase sandwich ELISA. 
A majority of the encapsulated FGF9 was released in an initial burst during the first day of 
the study. There was significantly more FGF9 released from microspheres electrosprayed 
with 100 µg/mL FGF9 (at 17.5 kV and 25 kV) than with 10 µg/mL FGF9. Released FGF9 
was prolonged until day three in the 100 µg/mL FGF9 trial (17.5 kV). N=3, n=2, two-way 
ANOVA, Tukey post-test for multiple comparisons, *** = p < 0.001, **** = p < 0.0001. 
Data presented as mean ± SD. B) Human dermal fibroblasts were cultured on tissue culture 
plastic for 7 days with DMEM (10% heat-inactivated FBS; 3% AA) BSA/FGF9 release 
medium or DMEM (10% heat-inactivated FBS; 3% AA)) + 100 ng/mL FGF9. After the 
study endpoint, cells were stained with CyQUANT® GR dye and fluorescent intensity was 
converted to cell number at days 1, 4, and 7 using a standard curve. No differences were 
observed on days 1 or 4. Cell number significantly increased at day 7 in response to DMEM 
(10% heath-inactivated FBS) + 100 ng/mL FGF9 compared to all other conditions. No 
differences existed between the negative control, or FGF9 microsphere treatments at day 
7. N=3, n=4, two-way ANOVA, Tukey post-test for multiple comparisons, **** = p < 
0.0001. Data presented as mean ± SD. 
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Figure 3. 14 – Edu incorporation during S-phase DNA replication as an indicator of 
HDF proliferation and biological activity of released FGF9. Microspheres 
electrosprayed with core solutions containing 100 µg/mL BSA or FGF9 were submerged 
in DMEM (2% FBS; 3% AA) release medium. Three primary HDF cell line were seeded 
3000 cells/well in quadruplicate into a 96 well plate. Cells were treated with 200 µL release 
media from each condition or DMEM (2% FBS; 3% AA) supplemented with fresh 100 
ng/mL FGF9. HDFs were incubated with treatment media for 24 or 48 hours before 
fibroblast nuclei were fluorescently labelled for incorporated EdU (pink) and 
counterstained with Hoechst 33342 (blue). EdU incorporation into DNA during S-phase 
replication indicated the proportion of proliferating cells relative to HDFs presenting only 
Hoechst staining. A) FGF9 released from electrosprayed coaxial microspheres had no 
effect on HDF proliferation after 24 hours. HDFs cultured with DMEM (2% FBS; 3% AA) 
supplemented with 100 ng/mL fresh FGF9 significantly increased proliferation at 24 hours. 
N=3, n=4, two-way ANOVA, Tukey post-test for multiple comparisons, **** = p < 0.0001. 
Data presented as mean ± SD. B) Released FGF9 significantly increased HDF proliferation 
after 48 hours compared to negative controls. Media supplemented with 100 ng/mL FGF9 
significantly increased fibroblast proliferation compared to all other treatments. N=3, n=4, 
two-way ANOVA, Tukey post-test for multiple comparisons, * = p < 0.05, **** = p < 
0.0001. Data presented as mean ± SD. C-D) Representative images of EdU and Hoechst 
nuclear staining 24 and 48 hours after treatment with DMEM release medium containing 
microspheres with 100 µg/mL encapsulated BSA or FGF9 and a positive control containing 
100 ng/mL fresh FGF9. Scale bar = 100 µm. EdU incorporation data are presented 
independently per cell line in Appendix O. 
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3.3.4 – 7-Day Porcine Study 
3.3.4.1 – Wound Closure Kinetics 
To determine the effect of POSTN/CCN2 scaffolds and gelatin/PLGA scaffolds with and 
without FGF9 microspheres on the proliferative stage of healing, a 7-day porcine wound-
healing study was conducted. Full-thickness, excisional wounds, 2 cm in diameter, were 
created bilaterally on the dorsal surface of three healthy pigs. Representative images of the 
wounds from one pig for each treatment are shown at days 0, 3, and 7 post-wounding 
(Figure 3.15). Figure 3.16A/B show a representative image and magnified view of 
BSA/FGF9 and POSTN/CCN2/FGF9 scaffolds. Wound closure was quantified, and no 
significant differences were observed between treatments at 3 or 7 days post-wounding 
(Figure 3.17A). Individual 7-day wound closure kinetics for each pig are presented in 
Figure 3.18 as an indication of the variability in wound closure measurements between 
pigs. Wound diameter was measured as the distance between wound borders, parallel to the 
subcutaneous tissue from Masson’s Trichrome stained sections (Figure 3.17C). Wound 
diameter measurement at day 7 was used as a secondary measure of wound closure to avoid 
the measurement limitations associated with digital photography and blocking of the wound 
border by the wound eschar. BSA/FGF9 and POSTN/CCN2/FGF9 scaffolds significantly 
reduced wound diameter at day 7 compared to empty wounds (16.85 mm and 16.16 mm 
versus 18.42 mm, respectively).  
3.3.4.2 – Angiogenesis 
To determine the effect of POSTN/CCN2 and POSTN/CCN2/FGF9 scaffolds on 
angiogenesis during the proliferative stage of healing, CD146 positive endothelial tissue 
was visualized with immunofluorescent staining. Representative cross-sectional images of 
the wound bed vasculature from one pig at day 7 post-wounding are shown with outlines 
indicative of blood-vessel measurements by ImageJ software (Figure 3.19). Blood-vessel 
density and percent wound area covered by vascular tissue significantly increased in 
wounded tissues compared to unwounded tissues (Figure 3.20A/B). Individual blood vessel 
area significantly increased in empty and POSTN/CCN2/FGF9 scaffold conditions 
compared to unwounded tissues (Figure 3.20C). Day 7 blood-vessel density, percent area, 
and individual area are analyzed independently per pig in Appendix P. Endoglin/CD105 
positive endothelial tissue was also visualized with immunofluorescent staining (Figure 
139 
 
 
 
3.21) to demonstrate the vascular phenotype of porcine cutaneous wound tissue 7 days post-
wounding.   
3.3.4.3 – Collagen Deposition 
Collagen deposition in sections of cutaneous wound tissue following full-thickness 
excisional wounding, and in unwounded tissues, was visualized with Masson’s Trichrome 
staining (Figure 3.22). 7-day wound margins are visible as termination of the pre-existing 
thick collagen fibers in the connective tissue of unwounded dermis. Hydroxyproline 
content was quantified as a measure of collagen deposition (Figure 3.23). Wounded tissues 
contained significantly less hydroxyproline than unwounded tissue. BSA scaffolds 
significantly increased wound bed hydroxyproline content compared to empty control 
wounds (0.2570 and 0.1632 µg/µL/mg, respectively). 
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Figure 3. 15 – Representative images of wound closure from day 0 to day 7 in a porcine 
full-thickness cutaneous wound model. Age/sex matched Yorkshire pigs (N=3) were 
subject to five full-thickness excisional wounds per animal (2 cm in diameter). 
Experimental conditions included: 1) empty wound, 2) BSA gelatin scaffold, 3) 
POSTN/CCN2 gelatin scaffold, 4) BSA gelatin scaffold + FGF9/PLGA microspheres, and 
5) POSTN/CCN2 gelatin scaffold + FGF9/PLGA microspheres. Representative images of 
the wounds from one pig are shown at days 0, 3, and 7. Scale bar = 1 cm. 
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Figure 3. 16 – Representative image of POSTN/CCN2/FGF9 scaffolds used in the 7-
day porcine full-thickness cutaneous wound study. None of the electrospun fibers are 
visible beneath the layer of aggregated microspheres. A) 400x magnification of overall 
scaffold morphology. Scale bar = 10 µm. B) 1500x magnification of porous microspheres. 
Scale bar = 10 µm. 
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Figure 3. 17 – 7-day wound closure kinetics after full-thickness porcine cutaneous 
wounding. Wound closure kinetics were calculated from wound areas measured at each 
timepoint using digital photography and ImageJ software. A-B) Data are presented as 
percent of original wound area closed. Average wound closure is separated based on 
timepoint (A) and condition (B), each bar corresponding to day 3 or 7, respectively. No 
differences in wound closure existed. N=3, n=1, two-way ANOVA, Tukey post-test for 
multiple comparisons, p<0.05. C) Using ImageJ software, day 7 wound diameter was 
measured as the distance between the base of unwounded dermis bordering the wound bed, 
parallel to the underlying hypodermal tissue, in Masson’s Trichrome stained sections. BSA 
and POSTN/CCN2 gelatin scaffolds with FGF9/PLGA microspheres significantly reduced 
wound diameter at day 7 compared to controls. N=3, n=2, one-way ANOVA, Tukey post-
test for multiple comparisons, * = p < 0.05. Data presented as mean ± SD. 
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Figure 3. 18 – Individual 7-day wound closure kinetics after full-thickness cutaneous 
wounding in a porcine model. Wound area was measured at each timepoint using ImageJ 
software to calculate closure kinetics. A-C) Data are presented as percent of original wound 
area closed. Individual closure kinetics data are presented for each individual pig to show 
the variability in wound area measurements due to inter-animal variability and limitations 
of the measurement method associated with wound eschar blocking the wound edge in 
digital images. One image (n=1) was measured per condition, per pig (N=1).   
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Figure 3. 19 – Representative images of vascular growth 7 days post-wounding in a 
porcine full-thickness cutaneous wound model. Endothelial tissue was visualized with 
CD146 immunofluorescent staining. Representative cross-sectional images of the wound 
bed vasculature from one pig at day 7 post-wounding are shown. Original CD146 
fluorescent images and corresponding images after colour thresholding and vessel 
measurement are shown. Scale bar = 250 µm. 
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Figure 3. 20 – Effect of biomimetic scaffolds on angiogenesis 7 days post-wounding in 
a porcine full-thickness cutaneous wound model. Using CD146 as a marker of 
endothelial tissue in porcine cryosections, blood-vessel density (A), percent wound-tissue 
area covered by vascular tissue (B), and individual blood-vessel area (C) were quantified 
with ImageJ’s color deconvolution and threshold particle analysis tools. No differences, in 
any angiogenic outcome, existed between treatment conditions. A) Blood-vessel density 
significantly increased in wounded tissue. No differences in blood-vessel density existed 
between treatment conditions. B) The proportion of wound area covered by vascular tissue 
was significantly greater for all treatment conditions compared to controls, except the BSA 
+ FGF9 treatment. C) Average individual vessel area was significantly greater in empty 
and POSTN/CCN2 + FGF9 scaffold treated conditions compared to controls. No other 
differences were observed. N=3, n=2, one-way ANOVA, Tukey post-test for multiple 
comparisons, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. Data 
presented as mean ± SD. Angiogenic data are presented independently per pig in Appendix 
P.  
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Figure 3. 21 – Angiogenic phenotype in porcine wound tissue 7 days post-wounding. 
Fluorescent immunohistochemistry of porcine wound tissue 28 days post-wounding 
revealed angiogenic phenotype after staining for endothelial markers CD146 and 
CD105/endoglin. Representative images from one pig are shown. Each set of images 
include a section of epidermal and superficial dermal wound tissue. CD146 (red), 
CD105/Endoglin (green), and an overlay including CD146, CD105 and Hoechst stained 
cellular nuclei (blue) are presented. Scale bar = 50 µm.  
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Figure 3. 22 – Effect of biomimetic scaffolds on collagen deposition 7 days post-
wounding in a porcine full-thickness cutaneous wound model. Representative cross-
sectional images of wound bed collagen deposition 7 days post-wounding, visualized with 
Masson’s Trichrome staining. Connective tissues (collagen) are stained blue; muscle, 
erythrocytes and cytoplasm are stained red; and nuclei are stained black. Scale bar = 2 mm.  
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Figure 3. 23 – Hydroxyproline content as an indicator of collagen deposition 7 days 
post-wounding in a porcine full-thickness cutaneous wound model. Hydroxyproline 
content was quantified using a Hydroxyproline Assay Kit and normalized based on the dry 
weight of degraded tissue. Hydroxyproline content was significantly reduced in wounded 
tissues compared to unwounded tissues. Hydroxyproline content was significantly 
increased in the BSA scaffold condition compared to empty control wounds. N=3, n=2, 
one-way ANOVA, Tukey post-test for multiple comparisons, * = p < 0.05, **** = p < 
0.0001. Data presented as mean ± SD. 
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3.4 – Discussion  
It has been previously shown that POSTN/CCN2 collagen scaffolds enhance angiogenesis 
in full-thickness, excisional, cutaneous wound in db/db mice (Hamilton lab, In Review, J 
Tissue Eng). However, incomplete tubule formation and an immature vascular bed likely 
contributed to the inability of the murine wounds to recover to wild-type rates of wound 
closure. The series of experiments described in this chapter aimed to design and validate a 
novel electrohydrodynamic scaffold composed of POSTN/CCN2 electrospun nanofibers 
and FGF9 electrosprayed core-shell microspheres. Preliminary investigations aimed to 
reveal the effect of FGF9 on migratory and proliferative actions of HDFs and NIH3T3 
murine embryonic fibroblasts to elucidate potential mechanisms of action of FGF9 during 
wound healing, and as potential indicators of FGF9 activity after release from 
electrosprayed microspheres. Morphological characterization of electrospun nanofibers 
and electrosprayed core-shell microspheres was investigated during manipulation of 
electrohydrodynamic parameters, and in vitro release kinetics and biological activity of 
FGF9 microspheres were assessed to determine microsphere impact. Finally, the efficacy 
of POSTN/CCN2 scaffolds and FGF9 microspheres in wound repair was investigated in a 
7-day porcine model of cutaneous wound healing. Wound closure kinetics, angiogenic 
growth, and collagen deposition were evaluated and compared to scaffolds without 
POSTN/CCN2 and FGF9 microspheres.  
3.4.1 – In Vitro Effects of FGF9 on Cell Populations Involved in Wound Healing 
The delivery of FGF9 as a therapeutic wound-healing agent has not been investigated yet. 
Preliminary experiments aimed to reveal potential cellular effects of FGF9 to elucidate 
potential mechanisms of action and to serve as indicators of bioactivity after FGF9 release 
from the microspheres. Dermal fibroblasts are an important cellular component in wound 
healing. Fibroblasts degrade the fibrin clot, secrete collagen III, fibronectin and hyaluronic 
acid to compose the granulation tissue’s structural matrix, and participate in wound 
contraction after differentiation into α-smooth muscle actin expressing, contractile 
myofibroblasts [10]. The effects of FGF9 on migration, chemotaxis, and proliferation of 
HDFs and of NIH 3T3 mouse embryonic fibroblast chemotaxis were assessed. FGF9 had 
no effect on HDF migration or NIH 3T3 chemotaxis but significantly increased HDF 
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chemotaxis and proliferation. Information regarding FGF9’s role during wound healing and 
its effect on dermal fibroblasts is limited however, certain evidence such as induction of 
hair neogenesis by FGF-Wnt/β-catenin activation of dermal fibroblasts in mice, illustrates 
the multifaceted role of FGF9 during wound healing [11]. Future work is necessary to 
elucidate the molecular mechanisms responsible for the chemotactic and proliferative 
effects of FGF9 on HDFs. 
3.4.2 – Scaffold Fabrication, Design, and Validation 
The materials and methods utilized to fabricate the novel electrohydrodynamic scaffold 
presented here were chosen based on cost-efficiency, scalability, and stability of the 
incorporated bioactive factors. Gelatin is a cost-efficient natural alternative to collagen 
[12], capable of dissolution in acetic acid to reduce protein denaturation compared to 
harsher organic solvents [13]. Organic solvents disrupt secondary and tertiary protein 
structure, reducing bioactivity of the incorporated factors [13]. Benign solvents such as low 
concentration acetic acid have been used to produce electrospun collagen fibers of 100-
200nm thickness [14, 15]. Furthermore, gelatin was observed to increase average pore size 
relative to electrospun collagen scaffolds (2000 to 6000 nm2 and 1500-4000 nm2, 
respectively) [16]. Gelatin was chosen as the electrospinning polymer because it maintains 
the biocompatibility and biodegradability of collagen, at a fraction of the cost, without 
potential antigenicity, and has been shown to stimulate cellular adhesion, migration and 
proliferation, and accelerate wound healing in vivo [17-20]. 
The release profile of bioactive factors from uniaxial fibers is similar to core-shell 
microspheres (an initial burst followed by sustained release) however, 30 day cumulative 
release of bioactive factors from electrospun fibers is substantially lower than from core-
shell microspheres (<70% and >80%, respectively) [21-24]. Electrospun fibers were chosen 
for the delivery of POSTN/CCN2 because the release profile of bioactive factors from 
uniaxial electrospun fibers correlates with POSTN/CCN2 upregulation on day 3 during 
wound healing [25]. Both electrospun fibers and electrosprayed microspheres sustain 
release of bioactive factors and improve bioactivity compared to topical application of 
bioactive factors [26, 27]. Concurrent release of FGF9 and FGF2 from electrospun fibers 
directed SMC migration to stabilize endothelial cell/SMC tube formation [21]. FGF9 
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released alone from electrospun PEA fibers recruited mural cells and enhanced vascular 
maturation via upregulation of platelet derived growth factor receptor-β [22]. Release of 
FGF9 from the PEA scaffolds retained bioactivity with limited burst release however, 30-
day cumulative FGF9 release only reached 18% and 10% for blend and emulsion 
electrospinning, respectively. Sustained release of vascular endothelial growth factor-A 
and -C from core-shell polyurethane nanofibers was achieved by Liao and Leong [28]. 
Core-shell microspheres have not been used for the delivery of FGF9. To maximize release, 
improve control over release, and enhance protection of encapsulated bioactive factors, 
electrosprayed core-shell microspheres were chosen for the delivery of FGF9. Physical 
separation of immiscible core and shell solutions ensure FGF9 stability during processing, 
and control of shell thickness and porosity by parameter variation and polymer composition 
enhance FGF9 stability and release in vivo [29]. PLGA was chosen as the shell polymer 
because it is a European Medicines Agency and Federal Drug Association approved, 
biocompatible, and biodegradable copolymer extensively used in electrohydrodynamic 
fabrication of wound-healing constructs due to its tunable physicochemical properties [30]. 
Heparin sodium salt was added to the core solution to increase the stability of FGF9 and 
FGF9-FGFR binding [31].  
Our initial intent was to produce a co-structural scaffold containing evenly dispersed 
microspheres throughout the nanofiber mesh by simultaneously electrospinning nanofibers 
and electrospraying microspheres (Figure 1.2). Fabrication of a 3D angiogenic growth 
factor gradient using this method successfully guided angiogenesis in a murine model [9]. 
However, an alternative protocol was adopted due to risk of premature hydrolytic 
degradation during glycine quenching and storage. Therefore, scaffolds and microspheres 
were fabricated separately with an intermediate glycine quench to block unreacted aldehyde 
groups after lysin/hydroxylysine crosslinking by glutaraldehyde [32, 33]. 
For scaffold design, we first characterized electrospun fiber diameter to determine the basis 
for future manipulation of scaffold morphology. Increasing flow rate and applied voltage 
decreased fiber diameter whereas increasing collector distance and gelatin concentration 
increased fiber diameter (Figure 3.6A-C, Figure 3.7J). Parameter variation had no 
observable effects on fiber orientation.  
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Several studies support the effect of polymer solution concentration on fiber diameter [34-
37]. The interplay between viscosity, surface tension and coulombic repulsion of the 
polymer solution as it travels towards the collecting surface determines the final fiber 
diameter with varied solution concentration [38]. At low solution concentrations, the 
repulsive electrical forces will overcome the surface tension of the polymer solution as 
solvent evaporates and charge density on the surface of the polymer increases, forming 
droplets [39]. As solution concentration increases, viscosity increases until the electrical 
force is no longer strong enough to dissipate the polymer ejection into droplets due to 
surface tension acting to reduce surface area to mass, instead forming a chain of disjointed 
beads [35]. Increasing solution concentration enhances the effect of viscoelastic forces, 
which eventually overcome the influence of surface tension and form smooth fibers. As the 
solution concentration and viscosity increase further, strengthening viscoelastic forces 
allow thicker fibers to form [34].   
Decreased fiber diameter in response to increased applied voltage is also supported in the 
literature [34, 40]. At higher applied voltage, the surface charge and field strength of the 
ejected polymer solution are elevated, increasing coulombic repulsion of the polymer 
solution to elongate and thin the polymer fiber [34]. Conflicting evidence suggests applied 
voltage either increases or decreases fiber diameter due to altered mass of polymer ejected, 
and variation in jet morphology (i.e., the number of ejections) [37]. 
Flow rate has not been shown to influence fiber diameter [37, 41]. However, increased 
accumulation of solution at needle tip with increasing flow rate reduces the charge ratio of 
the solution and decreases the amount of ejected solution due to interference by uncharged 
particles. Lowering the volume of solution ejected decreases viscoelastic forces as solvent 
evaporation occurs, which may account for the decreased fiber diameter in response to 
increasing flow rate [40, 41]. 
Lengthening the collector distance alters deposition time, evaporation rate, and whipping 
interval [42]. If the collector distance is too short, inadequate evaporation produces wet 
fibers, increasing diameter. Limited evidence exists to explain the phenomenon witnessed 
in this study. Dissipation of electrical forces during transit may reduce the strength of 
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coulombic repulsion, allowing aggregation of the polymer fiber before deposition, 
increasing fiber diameter. 
The refined scaffold parameters produced a scaffold with the lowest average fiber diameter, 
low diameter variation, high fiber dispersion on the collection surface, high deposition 
density, and minimal alternative structures (such as webbing, ribbons, and beads). The 
lowest fiber diameter was chosen because it most accurately mimicked the fiber diameter 
of the natural ECM, reportedly between 50-500 nm or 30-130 nm [43, 44], and decreased 
cell adhesion has been observed as fiber diameter increases [45]. The collector distance 
was changed to 10 cm in subsequent studies to improve fiber dispersion which was very 
narrow at 8 cm.  
We next assessed the effect of electrospraying parameter variation on microsphere 
diameter. Maintaining homogeneity in the size, shape and porosity of fabricated 
microspheres can dictate their performance in vivo [37]. Any factor thickening the initial 
jet diameter will produce spheres of greater diameter after atomization. Increased outer and 
inner liquid flow rate provide more material to the tip of the needle, increasing the diameter 
of the coaxial jet which increases sphere diameter [29, 46]. As applied voltage increases, 
electrical stress elongates the ejected fiber promoting the break-up of the coaxial jet into 
particles of reduced size [29]. Obvious trends were not observed in response to varied 
voltage, PLGA concentration, inner flow rate, or collector distance. This result may be due 
to extraneous confounding variable(s). Solution properties (viscosity, polymer 
concentration, molecular weight of polymer, electrical conductivity, elasticity, surface 
tension), processing conditions (applied voltage, collector distance, solution flow rate, 
needle diameter), and ambient conditions (temperature, humidity, and atmospheric 
pressure) contribute to the final morphology of electrosprayed microspheres [37]. 
Electrospraying occurred in a laboratory without tight environmental regulation. Therefore, 
variation in the ambient conditions between trials may account for the variability in sphere 
morphology (Figure 3.11), compounded by the complexity of coaxial electrospraying with 
the interaction of multiple proteins and solvents. Impurities in the outer solution may have 
become lodged in the thin space (diameter = 0.0508 mm) between inner and outer needles, 
disturbing the flow of the outer solution. The high variability between trials may be 
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attributable to the inability to achieve a stable Taylor cone. Between the inner and outer 
solutions, the driving liquid is the solution effecting the electrostatic force of the applied 
voltage, transferring the electrical stress and fluid motion to the other solution via viscosity 
[47]. The driving solution is defined as the solution with the lower electrical relaxation 
time: 
te = ɛrɛO/K  
Where ɛr is the relative electrical permittivity (capacitance of an electric field in a particular 
medium), K is the electrical conductivity of the liquid, and ɛO is the vacuum permittivity 
constant (8.85 x 10-12 F/m) [47]. BSA was described as the driving liquid in an 
electrospraying system with outer solution PLGA dissolved in dichloromethane and inner 
solution BSA dissolved in water, due to the high electrical conductivity of BSA [5, 48]. 
Microspheres electrosprayed with BSA and PLGA in these studies corroborated our 
findings of the proportional effect of PLGA concentration on particle size [5, 48]. However, 
electrospraying with an inner solution as the driving liquid decreases stability of the Taylor 
cone [49]. The inner BSA solution during electrospraying in the diameter measurement 
study may account for the inability to achieve a stable Taylor cone and the variability 
between the trials. Future work is required to electrospray using a needle with a larger inner 
to outer needle diameter, enhanced environmental control, and a solution combination that 
produces an outer driving solution to enhance formation and stability of the Taylor cone 
The core and shell structures of electrosprayed microspheres were visualized with confocal 
microscopy. Almost all electrosprayed microspheres contained fluorescent dye, indicating 
a high encapsulation rate. Future work is necessary to quantify microsphere core-shell 
morphology, including porosity, core to shell ratio, and thickness in response to varied 
processing parameters. Quantification of average shell and core diameter in response to 
varied process parameters such as PLGA concentration, PLGA LA:GA ratio, alternative 
polymers and solvents, and manipulation of electrospraying parameters should be 
conducted in the future with release kinetics studies and SEM imaging to determine the 
effect on microsphere porosity and release. Release of encapsulated bioactive factors is 
highly dependent on diffusion through the polymer shell relative to porosity and thickness 
[50]. Increasing shell thickness from 120 nm to 230 nm increased time to 70% drug release 
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from 11 to 30 days [51]. Increasing outer flow rate, outer solution concentration, and the 
molecular weight of the outer solution polymer are three methods of thickening the shell 
structure [37, 52, 53]. Alternatively, introduction of porogens into the shell solution 
increase porosity to accelerate diffusion of encapsulated factors [54]. The final optimized 
microsphere will sustain FGF9 release throughout POSTN/CCN2 induced angiogenesis, 
stabilizing tubule formation and improving the maturity of the vasculature to enhance 
oxygen and nutrient delivery and promote regeneration.  
3.4.3 – FGF9 Release Kinetics & Assessment of Biological Activity 
The chosen set of refined electrospraying parameters from the sphere diameter study 
consistently produced monodisperse microspheres. To determine FGF9 release and 
bioactivity from the refined microspheres, a concurrent release kinetics study and HDF 
proliferation assay were conducted. Over 94% of the final concentration of FGF9 in the 
release media was released on the first day of the study. This burst release may be 
attributable to high porosity resulting from solvent evaporation during the electrospraying 
process or shell thickness which may have been thin enough for bulk hydrolytic degradation 
to fully degrade the shell structure of the microspheres within 24 hours [55]. Decreasing 
porosity and increasing shell thickness would extend the burst release and promote 
sustained release from the microspheres. Outer flow rate and shell polymer concentration 
proportionally control shell thickness, attributable to elevated material density and chain 
entanglements, and to higher viscosity and surface tension, respectively [52]. Alternatively, 
increasing voltage has been shown to decrease shell thickness from 119 nm at 3.4 kV to 53 
nm at 4.6 kV, accounting for enhanced FGF9 release from microspheres electrosprayed at 
25 kV [52].  
Differential solvent evaporation between the shell and core solutions solidifies the polymer 
shell before the core solvent has completely evaporated. Vapour pressure eventually 
overcomes the structural integrity of the solidified shell, producing pores in the shell 
structure as the evaporated gas escapes [56]. Time to solidification of the shell structure 
has been delayed by raising polymer concentration to increase viscosity and surface tension 
which directly counteract the escape of pore forming gas, and by utilizing solvents with 
elevated boiling points/vapour pressure to reduce evaporation of the shell solution, 
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prolonging the ability of evaporating gas to escape from the core [52, 57]. Alternatively, 
blocking pores with dimethyl sulfoxide successfully improved protein entrapment and 
produced linear release without significant denaturation of the encapsulated protein [58]. 
Future characterization of FGF9 release at earlier timepoints (e.g., 6, 12, and 18 hours) may 
enhance our understanding of the mechanisms of release resulting in the 24-hour burst 
release.  
Microspheres electrosprayed with an applied voltage of 25 kV released significantly more 
FGF9 on the first day. Observations presented here and evidence in the literature suggest 
that surface charge and field strength increase with elevated voltage, increasing coulombic 
repulsion and elongating the ejected fiber [29, 34]. Elongation of the coaxial polymer fiber 
produces core-shell microspheres with reduced diameter [29, 46]. Reducing the diameter 
of the coaxial polymer ejection subsequently reduces the amount of encapsulated protein 
after atomization of the jet into core-shell microspheres [59]. Concentration of electrical 
charge may elongate the outer solution liquid relative to the inner solution, thinning the 
shell structure and increasing core to shell volume ratio [29]. A thinner shell and larger core 
may have increased the amount of FGF9 released. Alternatively, increased voltage may 
improve the stability of the core-shell ejection to increase encapsulation efficiency and the 
amount of FGF9 available for release without changing the core to shell volume [59].  
The HDF proliferation assay began 24 hours after the start of the release kinetics study. 
Quantification of FGF9 release kinetics indicated that over 94% of the encapsulated FGF9 
was released on the first day of the study. HDFs were exposed to 9.01 ng/mL or 8.07 ng/mL 
FGF9 in the 100 µg/mL FGF9 and 100µg/mL FGF9 – 25 kV trials, respectively. The HDF 
proliferation assay involved a complete media change on the second day of the study. 
Therefore, exposure of HDFs to FGF9 was effectively terminated on the second day of the 
experiment and released FGF9 was observed to have no effect on HDF proliferation. A 
follow-up study was designed to test the bioactivity of FGF9 released in 48 hours. HDFs 
were exposed to release media or media supplemented with 100 ng/mL fresh FGF9. The 
proportion of cells entering S-phase at 24 and 48 hours was quantified by fluorescent EdU 
incorporation. A significant increase in HDF proliferation in response to FGF9 release 
media was observed at 48-hours, indicating that the biological activity of released FGF9 
166 
 
 
 
was maintained. Future work is required to optimize the release kinetics of FGF9 
microspheres to prolong its release.  
3.4.4 – 7-Day Porcine Study  
Based on the evidence suggesting that FGF9 released from the microspheres was bioactive, 
the influence of the novel POSTN/CCN2/FGF9 scaffold on angiogenesis and wound repair 
was investigated in a 7-day porcine model. Representative images of the FGF9 scaffolds 
are presented in Figure 3.16. The underlying nanofibrous scaffold is not visible due to 
aggregation of microspheres, PLGA fibers, and larger collapsed droplets.  
No differences were observed in percent wound closure at day 3 or 7. Individual 7-day 
wound closure kinetics for each pig are presented in Figure 3.18 as an indication of the 
variability in wound closure measurements between pigs. This variability can be attributed 
to limitations associated with the porcine model, including wound eschar blocking the 
wound border (as can be seen at day 7 in Figure 3.15), and inter-animal variability. Wound 
diameter significantly decreased in response to BSA/FGF9 and POSTN/CCN2/FGF9 
scaffolds compared to empty wounds at day 7. Hydroxyproline content significantly 
decreased in wounded tissues compared to unwounded tissue. POSTN and CCN2 have 
been shown to facilitate myofibroblast differentiation and promote ECM deposition and 
fibrogenesis by proliferating fibroblasts during cutaneous wound healing [60-62]. In 
addition, application of rhCCN2 to a rhesus-monkey burn wound model increased wound 
closure, fibroblast migration into the wound bed and collagen deposition, and accelerated 
re-epithelialization [63]. However, BSA/FGF9 scaffolds also significantly decreased 
wound diameter compared to empty wounds, indicating that FGF9, and not POSTN/CCN2, 
may have contributed to reduced wound diameter at day 7. Based on our findings that FGF9 
increases HDF chemotaxis and proliferation, FGF9 released from the scaffolds may have 
recruited dermal fibroblasts to the site of injury, enhancing granulation tissue formation 
and subsequent myofibroblast presence, increasing contraction of the wound bed and 
reducing wound diameter. Additional work is required to quantify cellular populations in 
the wound bed tissue to determine potential mechanisms of action of FGF9 that would 
account for the reduction in wound diameter in the treatment conditions with FGF9 
microspheres.  
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We have observed for the first-time chemotactic and pro-proliferative effects of FGF9 on 
HDFs in vitro. FGF9 action on HDFs in vivo has not been investigated however, based on 
these results, we suggest that reduced wound diameter at day 7, in response to BSA/FGF9 
and POSTN/CCN2/FGF9 scaffold treatments, may be a result of FGF9 action on HDF 
proliferation and chemotaxis. Future work is required to determine the role of FGF9 during 
wound healing in vivo. In Masson’s Trichrome stained sections, collagen bundle formation 
appears to be occurring at the level of the subcutaneous tissue, deep within the wound bed. 
Scaffolds are still visible in the wound eschar or within the granulation tissue. 
3.5 – Conclusions 
Preliminary experimentation revealed proliferative and chemotactic effects of FGF9 on 
HDFs. A novel electrohydrodynamic scaffold was designed and validated in vitro and in 
vivo. Processing control over fiber diameter was presented however, extraneous variables 
inhibited a clear observation of the effect of process parameters on microsphere diameter. 
Refined microspheres exhibited complete 24-72 hour burst release of encapsulated FGF9 
that retained its bioactivity. Scaffolds containing FGF9 microspheres significantly 
decreased wound diameter compared to empty wounds in a 7-day porcine cutaneous 
wound-healing model.  No other differences between treatment conditions were observed, 
which may be due to the acute state of the wound healing model. Future work is required 
to characterize the proportion of cell populations (fibroblasts, myofibroblasts, M1 and M2 
macrophages) in the wound bed to evaluate scaffold influence on wound closure. 
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Chapter 4 
General Discussion 
4.1 – Summary & Final Conclusions 
4.1.1 – Objective 1. To determine the influence of nanofibrous electrospun 
POSTN/CCN2 scaffolds on angiogenesis and wound repair 28 days post-
wounding in a porcine model of cutaneous wound healing. 
BSA scaffolds significantly delayed wound closure between days 8 and 15. No differences 
were observed in wound diameter between scaffold treated wounds and empty control 
wounds at day 28. No significant differences were observed in angiogenesis or collagen 
deposition.  
4.1.2 – Objective 2. To design and validate an electrospun POSTN/CCN2 scaffold with 
coaxially electrosprayed core-shell microspheres encapsulating FGF9. 
a.  Assess in vitro effect of FGF9 on cellular populations involved in wound healing. 
FGF9 significantly increased HDF proliferation and chemotaxis in a dose-dependent 
manner. No differences of FGF9 treatment on HDF 2-D migration or NIH 3T3 chemotaxis 
were observed.  
b.  Design and validate a POSTN/CCN2 scaffold with FGF9/PLGA microspheres using a 
new electrohydrodynamic system. 
For scaffold optimization, we first characterized the effect of varying processing 
parameters on electrospun fiber diameter. Increasing flow rate and the applied voltage 
resulted in decreasing fiber diameter whereas increasing collector distance and gelatin 
concentration increased fiber diameter, consistent with previous findings [1-3]. Refined 
electrospinning parameters produced a scaffold with the lowest fiber diameter, within the 
range of dermal ECM collagen fibers [4, 5]. Processing parameters of the refined scaffold 
included: 0.5 mL/h flow rate, 17 kV applied voltage, and 8 cm collector distance. Increasing 
outer flow rate increased the diameter of microspheres. Lack of control over ambient 
conditions, clogging of the coaxial needle, or an inner driving liquid may have contributed 
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to high variability between electrospraying trials, resulting in no clear effects of applied 
voltage, PLGA concentration, inner flow rate, or collector distance on microsphere 
diameter. Confocal microscopy indicated a high encapsulation rate and a clear core-shell 
structure of electrosprayed microspheres.  
c. Determine biological activity and release kinetics of encapsulated FGF9/PLGA 
microspheres. 
Initial experimentation indicated a 24-hour burst release of FGF9 from the microspheres 
with no effect on HDF proliferation, indicating loss of bioactivity. However, a follow-up 
study with a revised protocol tailored to the burst release kinetics showed that FGF9 
released from the microspheres significantly increased HDF proliferation at 48 hours.    
4.1.3 – Objective 3. To determine the influence of nanofibrous electrospun 
POSTN/CCN2 scaffolds with FGF9/PLGA microspheres on angiogenesis and 
wound repair 7 days post-wounding in a porcine model of cutaneous wound 
healing.  
Wound closure rates were similar between all conditions 7 days post-wounding. However, 
wound diameter was significantly reduced in BSA/FGF9 and POSTN/CCN2/FGF9 
scaffold treated wounds compared to empty control wounds. Angiogenesis significantly 
increased in all wounds irrespective of treatment. Visualization of the vascular bed 
indicates a branching vascular network in POSTN/CCN2/FGF9 sections relative to the 
linear parallel vessels observed in empty wound sections. Hydroxyproline content was 
significantly reduced in all wounded tissues relative to unwounded tissues at day 7 post-
wounding. BSA scaffolds significantly increased hydroxyproline content compared to 
empty wounds. No evidence was found of any of the scaffold treatments resulting in a 
foreign body response 7 days post-wounding.  
4.2 – Contributions to the Current State of Knowledge 
4.2.1 – General Significance 
Chronic wounds are characterized by a pro-inflammatory microenvironment, enhanced 
proteolytic activity, and excessive degradation of matrix components and signalling 
molecules [6]. Cellular senescence, reduced mitogenic activity, and heightened bacterial 
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load disrupt fibrogenesis, angiogenesis, re-epithelialization, matrix deposition, and wound 
contraction producing the pathophysiology indicative of chronic wounds [7]. Pathological 
angiogenesis has been indicated as a key contributor to the development of chronic wounds, 
but no wound care based strategy to influence this has been developed [8]. Standard chronic 
wound therapies manage infection, establish moisture balance with moisture retentive 
wound dressings, remove necrotic tissue, and support the healing process with pressure 
offloading and revascularization procedures [9]. However, these methods are suboptimal, 
leading to ulcer recurrence in up to 70% of patients due to the inability of conventional 
dressings to properly address the underlying pathological mechanisms acting within the 
chronic wound environment resulting in fibrotic repair [10]. Conventional dressings reduce 
bacterial burden and provide moisture control but do very little to actively re-establish the 
native wound microenvironment to promote tissue regeneration. Furthermore, current 
bioactive alternatives such as bioengineered skin substitutes (e.g., Dermagraft®) and 
growth factor therapies have low clinical efficacy and are limited by high costs, short shelf 
life (under 5 days), fragility, and rapid degradation of bioactive factors upon release in vivo 
[11, 12].  
Angiogenesis is impaired in all chronic wounds, contributing to further tissue damage 
through chronic hypoxia, impaired nutrient delivery, and defective granulation tissue 
formation [13]. Previous work in our laboratory showed that POSTN was significantly 
suppressed at the edge of human chronic wounds and that blood vessels do not grow into 
the wound bed [14]. However, POSTN/CCN2 scaffolds rescued delayed healing and 
supported vascular growth in db/db mice (Hamilton lab, In Review, J Tissue Eng), although 
micro-CT angiography showed the blood vessels formed were leaky and mural cell 
recruitment and stabilization was required. Electrohydrodynamic atomization is a cost-
efficient, simple, scalable alternative to conventional methods of biomaterial scaffold 
fabrication. We have designed and validated a novel electrohydrodynamic granulation 
tissue-mimetic biomaterial scaffold as a delivery vehicle of POSTN, CCN2, and FGF9 to 
re-establish the presence of these bioactive factors within the proteolytic chronic wound 
microenvironment and to promote and stabilize new vascular growth. FGF9 has been 
shown to enhance mural cell wrapping during endothelial tubule formation to stabilize 
vasculature and improve vasoreactivity of the vessels [15]. Therefore, the aim of the novel 
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POSTN/CCN2/FGF9 scaffold was to re-establish POSTN and CCN2 to promote 
angiogenesis within the inflammatory chronic wound microenvironment, and to support 
that vascular growth via FGF9 mediated mural cell layering to facilitate oxygen and 
nutrient delivery, and to promote inflammatory to proliferative transition in chronic wounds 
[13].  
4.2.2 – POSTN/CCN2/FGF9 Scaffolds for Tissue Repair 
POSTN and CCN2 are matricellular proteins upregulated during the proliferative phase of 
wound healing. POSTN facilitates dermal fibroblast activation, differentiation and 
contraction, contributing to dermal regeneration and wound closure [16-18]. CCN2 
promotes myofibroblast ECM deposition and fibrogenesis, stimulates endothelial cell 
proliferation and chemotaxis for neovascular tubule formation, and regulates expression of 
angiogenic factors such as vascular endothelial growth factor-A and -C [19-23]. FGF9 
promotes mural cell wrapping of nascent vasculature to improve stability and vasoreactivity 
of the vessels [15]. With clinical translation in mind, the overall aim of this thesis was to 
develop cost-efficient methods for the delivery of POSTN, CCN2, and FGF9 for wound-
healing purposes.  
We utilized electrospinning, which is an excellent method for reproducibly fabricating 
biomimetic nanofibrous scaffolds from a wide variety of natural and synthetic polymers 
with biologically relevant features [24]. Various studies have electrospun nanofibrous 
scaffolds with structural mimicry to the dermal ECM (fiber diameters of 30 to 500nm) [4, 
5, 25-28] indicating a decrease in cell adhesion and growth kinetics as fiber diameter 
increases [29]. Therefore, we chose the electrospinning combination that produced the 
lowest average fiber diameter while maintaining uniform fibers. However, the bioactive 
potential of uniaxial electrospun nanofibers is limited by increased protein denaturation due 
to direct solvent exposure during blending of the polymer electrospinning solution, and 
rapid degradation of bioactive factors on the surface of the fibers exposed to the proteolytic 
in vivo microenvironment [6]. Electrosprayed core-shell microspheres reduce protein-
solvent interaction and physically protect encapsulated bioactive factors from proteolytic 
degradation. POSTN/CCN2 collagen scaffolds previously enhanced angiogenic growth 
and wound closure in db/db mice (Hamilton lab, In Review, J Tissue Eng). In this study, 
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the collagen scaffold was redesigned using gelatin as the electrospinning polymer to reduce 
costs while maintaining the functional and mechanical properties of the original scaffold. 
FGF9 electrosprayed microspheres were designed as an additional component of the 
POSTN/CCN2 scaffold, to protect and sustain release of FGF9 throughout POSTN/CCN2 
action during wound healing, with the goal of promoting the stabilization of POSTN/CCN2 
induced vascular formation via mural cell wrapping [15]. 
The influence of POSTN/CCN2 and the novel POSTN/CCN2/FGF9 scaffolds on 
angiogenesis and wound repair was investigated during the proliferative and remodelling 
stages of wound healing in two porcine studies. To our knowledge, this was the first 
investigation of FGF9 in a porcine model of cutaneous wound healing.  
Gelatin biomaterials have been shown to elicit a foreign body response in mice [30], which 
may account for delayed wound closure in BSA scaffolds treated wounds compared to 
empty control wounds between days 8 and 15 in the 28-day porcine study. Based on their 
defined roles in healing [19-21, 31], the POSTN/CCN2 scaffold may have stimulated 
fibroblast migration, proliferation, deposition of fibronectin and collagen, and 
differentiation into myofibroblasts to begin contraction, accounting for the lack of a 
significant difference in wound closure between POSTN/CCN2 scaffolds and empty 
wound conditions. Day 7 wound diameter was significantly reduced in BSA/FGF9 and 
POSTN/CCN2/FGF9 scaffold treated wounds compared to empty wounds, indicating a 
potential role of encapsulated FGF9, and not POSTN and CCN2, on wound closure. Further 
work is necessary to characterize the cellular populations within the wound bed at day 28 
to determine potential cellular effects of FGF9 on wound closure in vivo.   
Day-7 angiogenic measures indicated significant increases in blood-vessel density, percent 
wound area covered by vascular tissue, and individual vessel size in wounded tissues 
compared to unwounded tissue. Furthermore, vessel phenotype changes between wounded 
conditions. Linear, elongated vasculature forming in empty wounds branches into a more 
randomized vascular bed in response to scaffold treated wounds, especially BSA/FGF9 and 
POSTN/CCN2/FGF9 scaffolds. FGF9 is known to enhance vascular stability and 
vasoreactivity via mural cell wrapping of developing vasculature [15]. Therefore, enhanced 
branching observed in the fluorescent images of the vascular bed may be indicative of 
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improved vessel stability by released FGF9. However, proteolytic, acidic and temperature-
related mechanisms present within the healthy wound microenvironment quickly degrade 
bioactive factors in vivo [32]. In the acute porcine wounds, burst released FGF9 during the 
first 24 hours of the study was likely degraded. Therefore, FGF9 is most likely not the cause 
of enhanced vascular growth. Future work is required to increase shell thickness and reduce 
porosity to improve sustained release and protect FGF9 from the enhanced proteolytic 
mechanisms in the chronic wound microenvironment [6]. 
POSTN promotes migration and tube formation of human umbilical vein endothelial cells 
via extracellular signal-regulated kinase (ERK) -1/2 and focal adhesion kinase signalling 
[33], and CCN2 stimulates endothelial cell proliferation and chemotaxis to promote 
neovascular tubule formation [21]. No differences were observed between angiogenic 
measures of POSTN/CCN2 and BSA scaffolds in the 28-day porcine study, suggesting the 
POSNT/CCN2 scaffold did not influence angiogenic processes despite previous evidence 
indicating an influence of POSTN and CCN2 on endothelial cell migration, proliferation, 
and tube formation [33, 34]. This may be due to the acute nature of the wound healing 
model masking the effects of POSTN and CCN2 released into the wound bed. Healthy 
wound healing mechanisms and a normal balance of wound healing mediators may have 
reduced the observable effect of exogenous POSTN and CCN2 [35]. 
Between days 7 and 28, blood-vessel density (204.91 vessels/mm2 versus 180.96 
vessels/mm2, respectively), percent wound area covered by vascular tissue (4.27% versus 
9.14%, respectively), and individual blood-vessel area (462.22 µm2 versus 155.11 µm2, 
respectively) significantly decreased (Appendix S). Decreased vessel density and size at 
day 28 are indicative of vascular regression as the preliminary vascular network is 
remodelled and stabilized in the later stages of healing [36-38]. The natural reduction of 
vascular tissue may explain the lack of differences in blood-vessel density between 
wounded and unwounded tissues during the 28-day porcine study.  
POSTN and CCN2 have been indicated in fibroblast activation, differentiation, and ECM 
deposition [16, 17, 19, 39]. POSTN/CCN2 scaffolds did not elicit increased collagen 
deposition in the porcine wounds at day 7 or day 28, contradictory to previous descriptions 
of the action of these matricellular proteins during wound healing. The rapid rate of healing 
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and normal expression of POSTN, CCN2, and FGF9 in the healthy pigs may have reduced 
the influence of the POSTN/CCN2 and POSTN/CCN2/FGF9 scaffolds at days 7 and 28, 
respectively [35]. 
In this thesis, we have presented for the first time the influence of a novel 
POSTN/CCN2/FGF9 electrohydrodynamic granulation tissue biomimetic scaffold on 
wound healing in the gold standard pre-clinical model of cutaneous wound-healing 
research. No adverse or negative effects of the POSTN/CCN2/FGF9 scaffold were 
observed. The absence of significant effects, relative to reduced wound closure and 
enhanced angiogenic growth in db/db mice observed by Elliot et al., may be due to the 
healthy state of the porcine model (Hamilton lab, In Review, J Tissue Eng), indicating the 
need for future work to investigate the effects of the POSTN/CCN2/FGF9 scaffold on 
angiogenesis and wound repair in pathological wound healing.   
Preclinical trials assess nonhuman efficacy and toxicity. Once a substantial body of 
evidence exists supporting the efficacy and absence of toxicity in applicable animal models, 
a phase I clinical trial can begin. The phase I clinical trial evaluates safety and adverse 
effects related to administration of the biomaterial [40]. Human chronic wounds are 
characterized by a lack of vascular ingrowth, ECM deposition, and cellular infiltration [14]. 
Scaffolds containing FGF9 microspheres decreased wound diameter at day 7 compared to 
empty wounds in the 7-day porcine model, without causing any adverse events, indicating 
the potential efficacy of the novel scaffold in human chronic wound healing. Therefore, 
this work may support the use of the novel POSTN/CCN2/FGF9 scaffold in a phase I 
human clinical trial to determine efficacy and toxicity of the scaffold in human wound 
healing [40]. 
4.2.3 – Therapeutic Efficacy of Fibroblast Growth Factor 9  
FGF9 promotes mural cell layering around newly forming vasculature to improve the 
stability and vasoreactivity of neovessels [15]. In addition, FGF9 stimulates neointimal 
smooth muscle cell proliferation via the ERK1/2 pathway in vitro [15, 34]. For the first 
time, we have shown that FGF9 stimulates primary HDF proliferation and chemotaxis, 
although whether this effect is ERK1/2 mediated has yet to be investigated. Future work is 
required to determine the FGF9 concentration which optimizes HDF proliferation and 
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chemotaxis. This information would be valuable as a target for FGF9 release kinetics from 
the FGF9 microspheres. Furthermore, the effect of FGF9 on HDFs in vivo and during 
wound healing is largely unknown. FGF9 was upregulated 2- to 33-fold between days 2 
and 21 (peaking on days 7 through 10) during full-thickness cutaneous murine wound 
healing [41], suggesting FGF9 may actively participate in the late stages of inflammation 
and throughout the proliferative stage of wound healing. In addition, FGF9 stimulates 
Wnt/β-catenin signalling when cultured with human epidermal keratinocytes [42] and 
FGF9 expression has been linked to autocrine dermal fibroblast Wnt signalling and hair 
neogenesis in mice cutaneous wounds [43]. These results suggest a multifaceted, 
regenerative role of FGF9 during wound healing, which has yet to be fully elucidated.  
Future work should investigate effects of the POSTN/CCN2/FGF9 scaffold with and 
without incorporated POSTN/CCN2, and with topical application of FGF9 to elucidate the 
role of this growth factor during wound healing. Our findings of the proliferative and 
chemotactic effects of FGF9 on primary HDFs suggest that sustained release of FGF9 from 
optimized microspheres may serve a secondary role besides stabilization of the developing 
vasculature in a human chronic wound. However, burst release of FGF9 in the initial 24 
hours post-implantation during the 7-day porcine study may have reduced the potential 
effects of FGF9 due to rapid proteolytic degradation. To accurately measure the therapeutic 
efficacy of FGF9 for chronic wound healing, future animal models are required with 
application of the POSTN/CCN2/FGF9 scaffold after microsphere optimization to improve 
sustained FGF9 release.  
4.2.4 – The Porcine Model for Chronic Wound-Healing Research  
The porcine model is considered the gold-standard for wound-healing research due to the 
structural and functional similarities between pig and human skin [44]. However, 
significant limitations are associated with the porcine model. Pigs are difficult to work with 
due to their large size, species-specific reagents are not readily available, they are extremely 
expensive to house and maintain, and transgenic disease models are less prevalent and more 
difficult to produce than other species [45]. Alternatively, the feasibility of murine models 
is much higher: costs are low, they are easy to work with due their small size, they are much 
more cost-efficient, and many species-specific reagents and applicable transgenic models 
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exist [45]. However, the structure and function of the skin in murine models differs 
substantially from the human skin, limiting the translatability of murine outcomes to the 
human condition [45, 46].  
Porcine diabetic and chronic non-healing wound models have yet to recapitulate human 
chronic wounds as healing returns to normal within 3 weeks, inconsistent with the human 
condition [47-50]. Therefore, delayed wounding in the pig can not be considered chronic 
wounding. However, this problem persists among small animal models. The rabbit-ear 
ulcer model generates an ischemic wound after suturing of blood flow to the ear however, 
this model does not accurately replicate hypoxia in human chronic wounds [51, 52]. 
Magnetic ischemia-reperfusion wounds in rats reproduce the cellular and molecular 
mechanisms underlying human pressure ulcers however, they are limited in applicability 
to chronic non-healing wounds [53]. Genetically induced diabetes in db/db mice is a 
popular model in chronic wound-healing research however, the diabetic condition and 
healing deficiencies observed in db/db mice are not equivalent to the human condition [54]. 
Animal models mirror pathological conditions observed in human chronic wounds 
however, discrepancies in molecular mechanisms distinguish chronic wounding in animals 
from humans [55].  
We have learned many lessons during the two porcine studies conducted in this thesis, 
which may benefit other groups who utilize the porcine model. We can attest to the 
impracticality of the porcine model, as well as the high cost. During the 28-day porcine 
study, the adolescent pigs were housed from 4 to 5 months of age, at which time they had 
grown from 40 kg to 83 kg. Multiple members of the veterinary and research teams were 
required to move the pigs before and after surgery. Imaging of the wounds was completed 
while the pigs were awake, making clear photography with an accurately placed ruler very 
difficult and time consuming to accomplish. Furthermore, large variability between animals 
was a limiting factor to the results of this research. Our experience suggests health related 
complications involved in porcine models that have not been described elsewhere. One pig 
died under anaesthetic during the surgical procedure in the 28-day study, and the original 
7-day study was cancelled due to the death of one pig with myocardial encephalopathy. 
These outcomes demonstrate some of the potential health risks involved with the porcine 
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model, even with animals that are considered healthy at the onset of the study. Development 
of porcine models of impaired healing may exacerbate the health-related risks that we 
observed, further decreasing the feasibility of the porcine model. 
The porcine model is considered the gold standard for pre-clinical wound-healing research 
due to the structural and functional similarities between human and pig skin [44]. However, 
our results did not correlate with the enhanced angiogenesis and wound closure kinetics 
observed by Elliot et al. in db/db mice (Hamilton lab, In Review, J Tissue Eng), indicating 
a disconnect between wound-healing research in pathological and acute wounding. 
Comparison of chronic wound treatments in the porcine model, alternative animal models 
of impaired healing, and in the human condition is necessary to determine the validity of 
the porcine model as the gold standard for human wound-healing research. 
4.3 – Limitations  
4.3.1 – Microsphere Fabrication 
A set of electrospraying conditions capable of consistently producing a stable Taylor cone 
was not discovered during the morphological characterization of microsphere diameter. 
The accumulation of solution on the tip of the coaxial needle occasionally produced 
microspheres with high size variability, confounding measurement of microsphere 
diameter in response to varying electrospraying parameters. Ambient conditions, an inner 
driving liquid, or clogging of the needle due to impurities in the outer solution may be 
responsible for this outcome. The lack of control over microsphere morphology and core-
shell structure contributed to the complete release of FGF9 within 3 days, which may have 
limited effects of the POSTN/CCN2/FGF9 scaffold on angiogenesis and wound repair in 
the 7-day porcine study. 
4.3.2 – Acute Porcine Wound-Healing Model 
Animal models have yet to recapitulate the complex, multifactorial nature of human chronic 
wounds [52]. Healthy Yorkshire pigs were selected as the wound-healing model for this 
research. The rapid rate of healing and normal expression of bioactive factors in the acute 
wounds created on the dorsal surface of the healthy pigs may have reduced the influence 
of POSTN/CCN/FGF9 scaffolds [35]. Wound area measurement was limited by the wound 
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eschar. The eschar was not removed to avoid disrupting the underlying granulation tissue. 
Wounds with occlusive eschar were measured based on visible area of the wound border, 
increasing variability in wound measurements. Furthermore, the porcine studies were 
limited by small samples sizes due to the logistical considerations and high costs associated 
with the porcine model (day 28 N = 6, day 7 N = 3).  
4.4 – Future Directions 
4.4.1 – Animal Wound Models 
Despite the similarities between pig and human skin, the cellular and molecular 
mechanisms involved in acute and chronic wounding greatly differ [50]. Accelerated 
healing and normal expression of signalling molecules relative to the pathological condition 
may have reduced or eliminated the influence of scaffold treatments in these studies. 
Follow-up studies are required in impaired pig models to investigate the effect of the 
scaffolds in a model that better simulates chronic wounding. Follow-up studies in the acute 
porcine wound-healing model are required to increase sample size and statistical power to 
elucidate effects that were not observed here. To evaluate the efficacy of FGF9 in chronic 
wound-healing, the effect of POSTN/CCN2/FGF9 scaffolds on vascular stability in db/db 
mice should be conducted and compared with previous work by Elliot et al. (Hamilton lab, 
In Review, J Tissue Eng).  
4.4.2 – Co-Structural Scaffold Development 
Originally, the POSTN/CCN2/FGF9 scaffold was meant to be fabricated by simultaneous 
electrospraying of FGF9 microspheres for even dispersion within electrospun 
POSTN/CCN2 nanofibers (Figure 1.2). However, hydrolytic degradation of the PLGA 
shell was a concern during glycine quenching and storage. Therefore, POSTN/CCN2 
scaffolds were electrospun, crosslinked, and neutralized before a secondary electrospraying 
step deposited the FGF9 microspheres in a layer on top of the nanofibrous scaffold (Figure 
3.16). Future scaffold development may utilize PLGA with a higher concentration of lactic 
acid to reduce the hydrolytic degradation rate of the core-shell microspheres, and increase 
the feasibility of the original protocol for the fabrication of the co-structural 
POSTN/CCN2/FGF9 scaffold [56]. Microspheres evenly dispersed throughout the scaffold 
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will improve control over the sustained release of FGF9 [57]. In addition, biological effects 
of FGF9 may have been inhibited due to initial burst release and rapid proteolytic 
degradation. Future microsphere optimization is required to thicken the PLGA shell and 
reduce porosity to improve sustained release in vivo. Quantification of shell thickness in 
response to varying process parameters will contribute to control over release kinetics. 
Finally, optimization of coaxial electrospraying requires a consistent, stable Taylor cone. 
Future work should control ambient conditions (stable environmental control, drierite 
under the collecting mandrel to absorb excess moisture in the air), electrospray with an 
outer driving liquid [58], and utilize needles of different dimensions, to increase the 
consistency and stability of the Taylor cone.  
4.5 – Final Summary  
The results presented in this thesis demonstrate successful encapsulation of FGF9 within 
core-shell PLGA microspheres fabricated by coaxial electrospraying. Sustained release of 
FGF9 was not achieved however, bioactivity was retained. For the first time, FGF9 was 
observed to increase HDF proliferation and chemotaxis, indicating a potential cellular 
mechanism of action during wound healing. Scaffold conditions containing encapsulated 
FGF9 decreased wound diameter at day 7 in a porcine model of wound healing. Normative 
collagen deposition and blood-vessel density in scaffold treated wounds without a foreign 
body response, adverse events, or negative results support further investigation of the novel 
POSTN/CCN2/FGF9 scaffold in animal models of impaired wound healing. Future work 
is required to optimize microsphere morphology to sustain release of encapsulated 
bioactive factors and investigate the role of the POSTN/CCN2/FGF9 scaffold in a more 
applicable model of chronic wound healing.  
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Appendices 
Appendix A: GAL3 results included in representative wound images from the day 28 
porcine cutaneous wound-healing study. 
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Appendix B: GAL3 results included in wound closure kinetics data from the day 28 
porcine cutaneous wound-healing study. 
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Appendix C: GAL3 results included in angiogenic outcomes from the day 28 porcine 
cutaneous wound-healing study. 
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Appendix D: GAL3 results included in representative CD146 immunofluorescent 
images of the wound bed vasculature from the day 28 porcine cutaneous wound-
healing study.  
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Appendix E: GAL3 results included in representative CD146/CD105 
immunofluorescent images of the wound bed vasculature from the day 28 porcine 
cutaneous wound-healing study. 
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Appendix F: GAL3 results included in Masson’s Trichrome images and 
hydroxyproline content from the day 28 porcine cutaneous wound-healing study. 
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Appendix G: Standard curve for the quantification of hydroxyproline content in 28-
day porcine tissues using a Hydroxyproline Assay Kit.    
Appendix H: Standard curve for the quantification of NIH3T3 cell number using 
the Cultrex® Cell Migration Assay Kit. 
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Appendix I: Standard curve for the quantification of HDF cell number using the 
Cultrex® Cell Migration Assay Kit. 
 
Appendix J: Standard curve for the quantification of HDF cell number using the 
CyQUANT® Proliferation Assay Kit. 
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Appendix K: Standard curve for the quantification of HDF cell number using the 
CyQUANT® Proliferation Assay Kit. 
Appendix L: Standard curve for the quantification of released FGF9 from 
electrosprayed PLGA microspheres using the Human FGF9 ELISA Kit. 
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Appendix M: Standard curve for the quantification of hydroxyproline content in 7-
day porcine tissues using a Hydroxyproline Assay Kit.    
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Appendix N: Angiogenic outcomes of the 28-day porcine wound-healing study 
presented per pig. 
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Appendix O: S-phase EdU incorporation at 48 hours in response to elevated levels of 
FGF9 released from core-shell microspheres presented per cell line. 
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Appendix P: Angiogenic outcomes of the 7-day porcine wound-healing study 
presented per pig. 
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Appendix Q: No primary antibody negative control images of CD146/CD105 
(Endoglin) immunofluorescent staining in the 28-day porcine study (scale bar = 200 
µm). 
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Appendix R: No primary antibody negative control images of CD146/CD105 
(Endoglin) immunofluorescent staining in the day 7 porcine study (scale bar = 250 
µm). 
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Appendix S: Porcine cutaneous wound-healing angiogenic outcomes on day 7 
compared to day 28 (** = p < 0.01, *** = p < 0.001). 
204 
 
 
 
Appendix T: List of Antibodies 
 
1⁰  Mouse monoclonal anti-CD105 endoglin antibody (Invitrogen)  
Rabbit monoclonal anti-CD146 (Abcam)  
 
2⁰  AF 488 goat anti-mouse IgG (Thermo Fisher) 
AF 555 donkey anti-rabbit IgG (Thermo Fisher) 
Hoechst 33342 (Thermo Fisher) 
Rhodamine B Base (Sigma) 
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